


# Tuesday – Saturday, November 16-20, 2021



# Symposium Chairman **Frank J. Veith, MD**

Symposium Co-Chairmen Enrico Ascher, MD Kenneth Ouriel, MD, MBA Sean P. Lyden, MD

Sponsored by
Cleveland Clinic



# www.VEITHsymposium.org

# **PROGRAM OUTLINE AT A GLANCE**

# **TUESDAY PROGRAMS**

Program A: (Sessions 1-8) 6:45 A.M. – 3:21 P.M.
Progress In Transcatheter Heart Valves And Thoracic And Abdominal Aortic Disease
(Sessions 9 and 10) 3:22 PM – 6:15 PM)
Management of Pulmonary Embolism
Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

Program B: (Sessions 11-22) 6:50 A.M. – 6:10 P.M.

Progress In Vascular Robotics, Guidance Systems, Simulation And Laparoscopy; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; Hot New Topics In Lower Extremity Occlusive Disease Treatment; New Technology, New Concepts And Artificial Intelligence (AI); Vascular Surgery Recognition, Identity And Independence; Updates On Open And Hybrid Vascular Surgery And Treatment Of Aortic Coarctation; Updates On Vascular Malformations And Their Treatment

Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

# WEDNESDAY PROGRAMS

Program C: (Sessions 23-30) 6:40 A.M. – 3:56 P.M. Progress In Lower Extremity Occlusive Disease And Its Treatment (Sessions 31 and 32) 3:56 P.M. - 5:31 PM New Developments In Medical Treatments And New Drugs; Progress In Antiatherogenic, Antihypertensive And Cardiac Treatments: Cardiac Effects Of COVID - 19 Location: LECTURE HALL 1 - BONNET CREEK BALLROOM **Program D:** (Sessions 33-42) 7:00 A.M. – 6:10 P.M. Management Of Endoleaks; More Topics Related To Thoracic And Abdomial Aortic Diseases And Their Treatment; Treatment Of Complex AAAs; Treatment Of Iliac Aneurysms; Iliac Branched Devices And Miscellaneous Topics Related To Reimbursement, Outpatient Labs, the FDA And The SVS VQI Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

# THURSDAY PROGRAMS

**Program E**: (Sessions 43-50) 7:00 A.M. – 5:25 P.M. Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAA; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

Program F: (Sessions 51-59) 7:00 A.M. - 5:20 P.M. .

New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

Program G: (Sessions 60-69) 8:00 A.M. – 5:50 P.M. Superficial Venous Disease Course Leaders: Jose I. Almeida, MD, Lowell S. Kabnick, MD, Thomas W. Wakefield, MD and Steve Elias, MD Location: LECTURE HALL 3 - WALDORF ASTORIA GRAND BALLROOM A Program H: (Sessions 70-72) 7:45 A.M. – 12:10 P.M. *Cerebrovascular Disease And Its Treatment*Course Leader: Allan L. Brook, MD
Location: LECTURE HALL 4 - FLORIDIAN BALLROOM, SALON H

# FRIDAY PROGRAMS

## **Program I**: (Sessions 73-80) 7:00 A.M. – 4:50 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), Carotid Clot And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

**Program J**: (Sessions 81-88) 7:20 A.M. – 5:30 P.M.

New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Recorded Live Cases: Complex Endovascular Cases From The Mayo Clinic; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

Program K: (Sessions 89-97) 7:30 A.M. – 4:45 P.M. Deep Venous Disease Course Leaders: Jose I. Almeida, MD, Lowell S. Kabnick, MD, Thomas W. Wakefield, MD, and Steve Elias, MD Location: LECTURE HALL 3 - WALDORF ASTORIA GRAND BALLROOM A

# SATURDAY PROGRAMS

**Program L**: (Sessions 98-102) 7:00 A.M. – 1:05 P.M. Topics Too Important To Miss In The Treatment Of Lower Extremity, Aortic Or Carotid Disease, COVID-19 Updates Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

Program M: (Sessions 103-106) 8:00 A.M. – 3:25 P.M.
Improving Outcomes In Hemodialysis Access
Course Leaders: Larry A. Scher, MD, Anton N. Sidawy, MD,
and Haimanot (Monnie) Wasse, MD, MPH
Location: LECTURE HALL 2 - FLORIDIAN CREEK BALLROOM



VEITHSYMPOSIUM Connecting The Vascular Community



# SYMPOSIUM CHAIRMAN Frank J. Veith, MD

SYMPOSIUM CO-CHAIRMEN Enrico Ascher, MD Kenneth Ouriel, MD, MBA Sean P. Lyden, MD

SYMPOSIUM MANAGING DIRECTOR Jacqueline M. Simpson, BBA

ASSOCIATE PROGRAM DIRECTOR Mark A. Adelman, MD

**SYMPOSIUM ASSOCIATE DIRECTOR** Steven J. Feld, MSW

# **ADVISORY COMMITTEE**

Ali F. AbuRahma, MD Mark A. Adelman, MD Keith D. Calligaro, MD Nicholas J.W. Cheshire, MD Timur P. Sarac, MD Jacqueline M. Simpson, BBA Carol Veith, RN, BA, MA

# SCIENTIFIC COMMITTEE

Ali F. AbuRahma, MD Mark A. Adelman, MD Martin J. Austermann, MD Jean-Pierre Becquemin, MD Giancarlo Biamino, MD, PhD Keith D. Calligaro, MD Nicholas J.W. Cheshire, MD Roberto Chiesa, MD Daniel G. Clair, MD Jacob Cynamon, MD Sebastian E. Debus, MD, PhD Ellen D. Dillavou, MD Hans-Henning Eckstein, MD, PhD Peter Gloviczki, MD Roger M. Greenhalgh, MD Alison Halliday, MS, FRCS Krassi Ivancev, MD, PhD Sriram S. Iyer, MD Manju Kalra, MBBS Mario L. Lachat, MD Christos D. Liapis, MD Evan C. Lipsitz, MD, MBA Germano Melissano, MD Frans L. Moll, MD Samuel R. Money, MD, MBA Christoph A. Nienaber, MD, PhD Juan C. Parodi, MD Vicente Riambau, MD, PhD Jean-Baptiste Ricco, MD, PhD Caron B. Rockman, MD Plinio Rossi, MD Timur P. Sarac, MD Dierk Scheinert, MD Carlo Setacci, MD Cynthia K. Shortell, MD Sherif A.H. Sultan, MD Giovanni B. Torsello, MD Eric L.G. Verhoeven, MD, PhD Wayne W. Zhang, MD







# COMPONENT MEETING LEADERS

Jose I. Almeida, MD, RPVI, RVT George L. Berdejo, BA, RVT Allan L. Brook, MD Jacob Cynamon, MD Krassi Ivancev, MD, PhD Michael R. Jaff, DO Lowell S. Kabnick, MD, RPhS Natalie A. Marks, MD, RPVI, RVT Larry A. Scher, MD Anton N. Sidawy, MD, MPH Robert L. Vogelzang, MD Thomas W. Wakefield, MD Haimanot (Monnie) Wasse, MD, MPH Wayne F. Yakes, MD

# ASSOCIATE FACULTY PODIUM PRESENTATIONS COMMITTEE

Enrico Ascher, MD Sherif A.H. Sultan, MD, PhD Wayne W. Zhang, MD Zhong Chen, MD Anahita Dua, MD, MS Maria Frankovicova, MD, PhD Jan M.M. Heyligers, MD, PhD Paulo Eduardo Ocke Reis, MD, PhD Fuxian Zhang, MD Yeuhong Zheng, MD Steven M. Kawczak, PhD

# CENTER FOR CONTINUING MEDICAL EDUCATION

Steven M. Kawczak, PhD

# ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants\* in support of this activity from: Abbott Artio Medical **Boston Scientific Corporation** Cardiovascular Systems, Inc. Cook Medical, LLC Cordis CryoLife, Inc. Endologix, Inc. Gore & Associates Inari Medical LimFlow, Inc. Medtronic Merit Medical Systems, Inc. Penumbra, Inc. Philips Image Guided Therapy **Reflow Medical** Shockwave Medical Silk Road Medical **Terumo Aortic** 

# (PLEASE VISIT WWW.VEITHSYMPOSIUM.ORG FOR A FULL AND UPDATED LISTING OF THESE ACTIVITIES.)

TUESDAY, NOVEMBER 16, 2021

**BD** Lunch Symposium: Real-World PAD Strategies for Complex Lesions 12:00 P.M. – 1:30 P.M. **Location**: BD Pavilion, Floridian Ballroom - Salon F (This is a Non-CME activity.)

### CARDIOVASCULAR SYSTEMS, INC. (CSI)

Lunch Symposium: Battling Complex CLI with CSI - Learn How to Approach and Treat Advanced Disease 12:00 P.M. – 1:00 P.M. **Location**: Floridian Ballroom – Salon G (This is a Non-CME activity.)

### CLEVELAND CLINIC AND THE ACADEMY FOR CONTINUED HEALTHCARE LEARNING (ACHL)

Dinner Symposium on DOACs in PAD Post-Revascularization 6:00 P.M. – 8:00 P.M. Location: Floridian Ballroom - Salon H This CME activity is sponsored by the Cleveland Clinic Center for Continuing Education & The Academy for Continued Healthcare Learning (ACHL). This activity has been approved for AMA PRA Category 1 Credit<sup>™</sup>.

### ENDOLOGIX

Luncheon: A Lunch & Learn on EVAR Management in Challenging Aortic Anatomies 12:00 P.M. – 1:00 P.M. Location: Endologix Pavilion, Floridian Ballroom - Salon I (This is a Non-CME activity.)

### **ENDOLOGIX** (continued)

Virtual Reality Opportunity! 1:30 P.M. - 5:00 P.M. **Register here**: <u>https://bit.ly/VRforEVAR</u>

### **GORE & ASSOCIATES**

Lunch Symposium: Advancing the Quadruple Aim Through Physician and Supply Chain Collaboration 12:00 P.M. – 1:00 P.M. **Location**: Gore Pavilion, Bonnet Creek Ballroom - Salons II & III (This is a Non-CME activity.)

Medical Mastery Series 9:00 A.M. - 5:00 P.M. **Location**: Floridian Ballroom - Salon L

#### JANSSEN PHARMACEUTICALS, INC.

Lunch Symposium: Clinical Insights in PAD: Reducing the Risk of Major Thrombotic Vascular Events 12:00 P.M. – 1:00 P.M. **Location**: Floridian Ballroom – Salon H (This is a Non-CME activity.)

#### PENUMBRA

Reception: Latest Innovation in PE Treatment and Workflow with Penumbra and RapidAI<sup>®</sup> 6:00 P.M. - 7:00 P.M. Location: Penumbra Pavillion, Floridian Ballroom - Salon J

## WEDNESDAY, NOVEMBER 17, 2021

### 3M

Lunch Symposium: Reducing Hospital Readmissions in Vascular Surgery by Optimizing Surgical Outcome: Strategies for Success 12:00 P.M. - 1:00 PM Location: Floridian Ballroom – Salon G (This is a non-CME activity.)

COOK MEDICAL Lunch and Lively Debate: PAD 12:00 P.M. - 1:00 PM Location: Cook Medical Pavilion, Bonnet Creek Ballroom Salons IX & XII (This is a non-CME activity.)

ENDOLOGIX Virtual Reality Opportunity! 1:30 P.M. - 5:00 P.M. Register here: <u>https://bit.ly/VRforEVAR</u>

GORE & ASSOCIATES

Lunch Symposium: The GORE<sup>®</sup> VIABAHN<sup>®</sup> Family of Covered Stents: Durable Treatment for Peripheral Arterial Diseases 12:00 P.M. – 1:00 P.M. **Location**: Gore Pavilion, Bonnet Creek Ballroom - Salons II & III (This is a Non-CME activity.)

Medical Mastery Series 9:00 A.M. - 5:00 P.M. **Location**: Floridian Ballroom - Salon L

### **INARI MEDICAL**

Luncheon Program 12:00 P.M. – 1:00 P.M. **Location**: Floridian Ballroom – Salon H (This is a Non-CME activity.)

#### MEDTRONIC

Lunch Symposium: Hot Topics in PAD Intervention. SFA/BTK Roundtable: New Innovations, Evidence, Tools & Techniques for Your Practice 12:00 P.M. – 1:00 P.M. Location: Medtronic Pavilion, Bonnet Creek Ballroom – Salon V & VI

### PENUMBRA

Afternoon Symposium: Current Management Strategies for Complex Aneurysms and Vessel Sacrifice 3:00 P.M. – 4:00 P.M. **Location**: Penumbra Pavillion, Floridian Ballroom - Salon J

### **TERUMO INTERVENTIONAL SYSTEMS**

Breakfast Symposium: Advancements in the Endovascular Treatment of Peripheral Artery Disease and Critical Limb Ischemia Wednesday, November 17, 2021 6:30 A.M. - 7:30 A.M. Location: Floridian Ballroom - Salon H

# THURSDAY, NOVEMBER 18, 2021

COOK MEDICAL Lunch and Lively Debate: AORTIC 12:00 P.M. – 1:00 P.M. Location: Cook Medical Pavilion, Bonnet Creek Ballroom - Salons IX & XII

### ENDOLOGIX

Virtual Reality Opportunity! 1:30 P.M. - 5:00 P.M. **Register here**: <u>https://bit.ly/VRforEVAR</u>

### **GORE & ASSOCIATES**

Lunch Symposium: Beyond Durability: Compelling Insights and Remaining Questions from Five Years of Follow Up 12:00 P.M. – 1:00 P.M Location: Gore Pavilion, Bonnet Creek Ballroom – Salons II & III

## **GORE & ASSOCIATES (continued)**

Medical Mastery Series 9:00 A.M. - 5:00 P.M. **Location**: Floridian Ballroom - Salon L

### MEDTRONIC

Lunch Symposium: Valiant Captivia Clinical Experience Roundtable: Long-term Durability in Challenging Cases of the Descending Thoracic Aorta 12:00 P.M. – 1:00 P.M. Location: Medtronic Pavilion, Bonnet Creek Ballroom – Salon V & VI

### PENUMBRA

Morning Symposium: Lightning Computer-Aided Mechanical Aspiration for VTE 8:00 A.M. - 9:00 A.M. Location: Penumbra Pavillion, Floridian Ballroom - Salon J

Lunch Symposium: My Preferred Approach to Type II Endoleak Management 12:00 P.M. – 1:00 P.M. Location: Penumbra Pavillion, Floridian Ballroom - Salon J

# FRIDAY, NOVEMBER 19, 2021

### BD

Lunch Symposium: Creating Hemodialysis Access Utilizing BD's Innovative ESKD Solutions – A Discussion on WavelinQ<sup>™</sup> EndoAVF System and Pristine<sup>™</sup> Long-Term Hemodialysis Catheter 12:00 P.M. – 1:30 P.M. Location: BD Pavilion, Floridian Ballroom - Salon F

# COOK MEDICAL

Webinar: Venous Self-Expanding Stents: A Discussion Around Newly Presented Data and Achieving Optimal Outcomes 12:00 P.M. – 1:00 P.M. Location: Cook Medical Pavilion, Bonnet Creek Ballroom - Salons IX & XII

#### **GORE & ASSOCIATES**

Medical Mastery Series 9:00 A.M. - 5:00 P.M. **Location**: Floridian Ballroom - Salon L

SATURDAY, NOVEMBER 20, 2021

#### **GORE & ASSOCIATES**

Lunch Symposium: From Fistula-First to Patient-First: Data-Driven Decision Making in Vascular Access Creation 12:00 P.M. – 1:00 P.M. Location: Gore Pavilion, Bonnet Creek Ballroom – Salons II & III

# NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered at the meeting and for further reference in the web-based library, a long-term permanent resource.

In addition, by having numerous short (4.5-7 minutes) talks followed by panel discussions and capturing the entire meeting on the webbased library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

# FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 900 fastpaced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

# **OBJECTIVES**

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors

# TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists, Cardiac Surgeons and all others interested in the management of vascular disease.

# ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS

# Wednesday, November 17, 2021

**Location:** Waldorf Astoria Grand Ballroom B (Lecture Hall 5) In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our website. Please visit www.veithsymposium.org for additional information about the Associate Faculty Global Podium Presentations component of VEITHsymposium.

# **COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:**

# CEREBROVASCULAR

Thursday, November 18, 2021 **Location:** Lecture Hall 4 (Floridian Ballroom)

# HEMODIALYSIS ACCESS

Saturday, November 20, 2021 **Location:** Lecture Hall 2 (Floridian Ballroom)

# **ACCREDITATION STATEMENT**

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical

Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 43 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

# **ABS MAINTENANCE OF CERTIFICATION**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

# **CME CERTIFICATES AND COURSE EVALUATION FORMS**

CME certificates will be available online at www.veithsymposium.org. An e-mail with a unique password and instructions on how to obtain the certificate and complete a brief, course evaluation will be sent to all registered attendees after the meeting. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by **February 28, 2022.** 

# FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation

Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

# ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to admin@veithsymposium.org.

# VIRTUAL TEXTBOOK OF VASCULAR DISEASE MANAGEMENT - VINTAGE NOVEMBER 2021

The entire program with almost all the talks, slides, audio and videos fully synchronized - and the panels, will be available in a Virtual Textbook of Vascular Disease Management, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Virtual Textbook, please visit www.veithondemand. com or call (800) 987-9314, ext. 300.

# **ONLINE ACCESS TO ABSTRACTS**

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium website at www. veithsymposium.org after the meeting. Abstracts will be available on the website for one full year.

# **VEITHsymposium NON-CME ACTIVITIES**

# VENOUS VENOUS VENOUS<sup>®</sup>WORKSHOP AT VEITHsymposium - REAL LIFE CHALLENGES Wednesday, November 17, 2021 1:00 P.M. - 6:00 P.M. Location: Waldorf Astoria Golf Pavilion

The focus of the workshop is to help with the development of skills to clinically make better decisions when treating patients with venous disease. We will explore real life complex and challenging cases to better understand how to optimally manage venous disease. Case presentations and discussions with experts will be used to explore topics that relate to challenges of the management of superficial venous disease, and both deep acute and deep chronic venous disease.

The VEITHsymposium Venous Workshop will use the following methods to highlight key teaching points in venous disease management:

- Video Case Presentations
- Hands-On experience providing participants a forum to test products and ask questions regarding the products and their uses
- Faculty led discussions on challenging real life situations in the management of venous disease
- Panel discussion to elicit expert contributions on best practices in vein management

Visit www.veithsymposium.org for details. (This is non-CME activity.)

# VEITHsymposium NON-CME ACTIVITIES (CONT'D)



# Management of Complex CLTI Scenarios: From Access to Success

Presented by: Miguel Montero-Baker, MD - HENDOLAT Thursday, November 18, 2021• 1:00 P.M. - 2:00 P.M. Location: Floridian Ballroom - Salon H

Hendolat, the leading platform for digital education in Latin America, is joining forces with the VEITHsymposium to put together a futuristic approach to the delivery of medical proctorship. We are exploring novel ways to deliver medical education adapting ourselves to the complexities of the current state of health affairs around the world.We are pleased to deliver a hybrid program consisting of talks, edited live cases, and virtual reality technology.

# Fellows' Career Development Program

Friday, November 19, 2021• 8:00 A.M. - 5:00 P.M. **Location:** Waldorf Astoria Grand Ballroom B (Lecture Hall 5)

This is an Interactive Symposium for Vascular Surgery and Interventional Radiology Fellows and Residents preparing to enter the job market! The Program is open to:

- Graduating Fellows & Residents in Vascular Surgery & Interventional Radiology
   Attending Vascular Specialists seeking new opportunity
- Potential Employers of Vascular Specialists 
   Wound Care Specialists
- Vascular Career Recruiters and Potential Employers

Complimentary Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc. for finishing (graduating in June 2022) Vascular Surgery and Interventional Radiology Fellows in the US and Canada. An Educational Grant from Medtronic provides travel and lodging for Finishing Vascular Surgery and Interventional Radiology Fellows and Residents in the US. An interactive reception with potential employers will be held at the end of the program. Please visit **www.veithsymposium.org** for updates, and to view/print the agenda.

# **TUESDAY, NOVEMBER 16, 2021**

6:00 A.M. General Registration – Bonnet Creek Ballroom - North Foyer
6:00 A.M. Faculty Registration – Bonnet Creek Ballroom - Salon I
6:15 A.M. Continental Breakfast – Bonnet Creek and Floridian Ballrooms -North, West, Center and South Foyers

# **PROGRAM A**

(Sessions 1-8) 6:45 A.M. – 3:21 P.M. PROGRESS IN TRANSCATHETER HEART VALVES AND THORACIC AND ABDOMINAL AORTIC DISEASE; MANAGEMENT OF PULMONARY EMBOLISM LOCATION: LECTURE HALL 1 - BONNET CREEK BALLROOM

6:44 - 6:50	Opening Remarks
	Frank J. Veith, MD

### SESSION 1 (LECTURE HALL 1 - Bonnet Creek Ballroom) PROGRESS IN TRANSCATHETER VALVE REPLACEMENT, AND TREATMENT OF ASCENDING AORTIC DISEASE

Moderators:	Hazim J. Safi, MD
	Christoph A. Nienaber, MD, PhD

#### TRANSCATHETER HEART VALVES

- 6:50-6:55 The Future Of TAVR Martin B. Leon, MD (Power Point Presentation With Synched Audio)
- 6:56 7:01 Update On Current State Of Transcatheter Aortic Valve Replacement (TAVR): A Cardiac Surgeon's View: What Is The Role Of Surgery In Aortic Valve Disease Treatment Ali B. Khoynezhad, MD, PhD

#### THE ASCENDING AORTA

7:02 – 7:07 Progress In Endovascular Graft Treatment Of Ascending Aortic Lesions

Rodney A. White, MD

7:08-7:13	Progress In Endovascular Combined Devices For Repairing Lesions
	Of The Ascending Aorta And The Aortic Valve: The Endo-Bentall
	Concept
	Ali B. Khoynezhad, MD, PhD

- 7:14 7:19 Update On Endovascular Treatment Of Ascending Aortic Lesions: What Is Here And What Is On The Horizon Rodney A. White, MD Christoph A. Nienaber, MD, PhD
- 7:20 7:25 Endovascular Treatment Of Type A Aortic Dissections (TAADs): What Is Here And What Is Coming Ali Azizzadeh, MD

Panel Discussion Will Be Combined With Session 2 at 7:56 A.M.

### SESSION 2 (LECTURE HALL 1 - Bonnet Creek Ballroom) PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS

Moderators:	Alan B. Lumsden, MD
	Anthony L. Estrera, MD
7:26 – 7:31	Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results Ourania Preventza, MD Joseph S. Coselli, MD
7:32 – 7:37	Current Status Of Complete Hybrid Arch Repair With Elephant Trunk And FET: What does the Future Hold Anthony L. Estrera, MD
7:38 – 7:43	Endovascular Arch Repair With Cook 2- Or 3-Branched Device For Lesions Involving The Entire Aortic Arch: Indications, Contraindications And Results Stephan Haulon, MD (Power Point Presentation With Synched Audio)

7:44 – 7:49	Update On Relay Branch For Arch Lesion Endovascular Repairs: Advantages, Limitations And Results Vicente Riambau, MD, PhD Ciro Ferrer, MD Martin Czerny, MD (Power Point Presentation With Synched Audio)
7:50 – 7:55	Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations Michael D. Dake, MD (Power Point Presentation With Synched Audio)
7:56 – 8:08	Combined Panel Discussion (Sessions 1 and 2)
SESSION 3 PROGRESS IN	(LECTURE HALL 1 - Bonnet Creek Ballroom) THE ENDOVASCULAR TREATMENT OF AORTIC

# DISSECTIONS: REPORTING STANDARDS, CLASSIFICATION SYSTEMS, STABILISE, AND MORE

Moderators:	James H. Black, III, MD
	Joseph V. Lombardi, MD
8:08 - 8:13	New SVS-STS Aortic Dissection Reporting Standards And Classification System: How Are They Different And Better Joseph V. Lombardi, MD
8:14 – 8:19	Update On The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: How It Works, Precautions And Results Jean-Marc Alsac, MD, PhD (Power Point Presentation With Synched Audio)
8:20 – 8:25	Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: Indications, Technique And Results

Christoph A. Nienaber, MD, PhD

8:26 – 8:31	DEBATE: Fenestrated And Branched Endovascular Grafts (F/B/EVAR) Are Usually The Best Treatment For Post-Dissection Thoraco-Abdominal Aneurysms (TAAAs) Gustavo S. Oderich, MD
8:32 – 8:37	<b>DEBATE:</b> There Will Always Be A Need For Open Repair For Post-Dissection TAAAs: In What Circumstances Hazim J. Safi, MD Anthony L. Estrera, MD
8:38 - 8:43	Distal Stent-Graft Induced New Re-Entry Tears (SINEs) With TEVAR Treatment Of TBADs: Prevention By Avoiding Oversizing And Ballooning And Using Tapered Endografts Ludovic Canaud, MD, PhD
8:44- 8:49	When Is TEVAR The Best Treatment For Marfan Syndrome And Its Complications James H. Black, III, MD
8:50 - 8:56	Panel Discussion
	(LECTURE HALL 1 - Bonnet Creek Ballroom) EVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC ASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)
Moderators:	Hazim J. Safi, MD Ali B. Khoynezhad, MD, PhD
8:56 – 9:01	Long-Term Durability Of Open Repair Of Type I-IV TAAAs Remains Excellent: When Should It Be The First Line Treatment And When Should A Hybrid (Endo + Open) Down-Staging Approach Be Used To Improve Outcomes: How To Do The Latter Mark Conrad, MD, MMSc Richard P. Cambria, MD

9:02 – 9:07	Lessons Learned From The STABLE I And II Trials: What Are The Advantages And Limitations Of A Distal Bare Stent Combined With A Proximal Covered Stent Joseph V. Lombardi, MD
9:08 – 9:13	Why Is F/B/EVAR The Best Treatment For Post TBAD TAAAs: Challenges And Results Eric L.G. Verhoeven, MD, PhD
9:14 – 9:19	Gore TAMBE Endovascular Graft Device For TAAA Repair: How Does It Work: Results To Date, Advantages And Limitations Mark A. Farber, MD
9:20 - 9:25	How To Predict TAAA Patients Who Should Not Have An Endovascular Repair And How To Minimize Mortality: Age And Mural Thrombus Matter Patrick W. Kelly, MD
9:26 – 9:31	Improved Aortic Remodeling With TEVAR And A Distal Bare Metal Stent In Acute Complicated TBAD Christoph A. Nienaber, MD, PhD
9:32 – 9:37	Embolization Strategies To Achieve False Lumen Thrombosis With False Lumen TAAAs After TEVAR For TBADs Carlos H. Timaran, MD
9:38 – 9:43	High Failure Rate Of Best Medical Treatment For Intramural Hematoma Mandates Increased Use Of TEVAR: Does This Help Outcomes Jean M. Panneton, MD
9:44 – 9:54	Panel Discussion
9:54 – 10:20	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 5 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY AND TREATMENT, EVAR AND EVAS (ENDOVASCULAR ANEURYSM SEALING)

## Tilo Kölbel, MD, PhD *Moderators*: Kenneth Ouriel, MD, MBA Current Pros And Cons Of The Nellix EVAS Endograft For AAA 10:20-10:25 Repair: First Update Of The EVAS2 IDE Trial Of The Modified Improved Nellix Endograft Jeffrey P. Carpenter, MD Failing EVARs Are An Emerging Epidemic: Etiology And How 10:26-10:31 Best To Avoid And Treat The Problem Murray L. Shames, MD Diabetes And AAAs: Facts, Clues And Potential Treatment 10:32-10:37 Opportunities Ronald L. Dalman, MD How Does Metformin Work To Slow AAA Growth At The Cellular 10:38-10:43 Level: Could It Be Effective Treatment For Small AAAs: Is It The Reason For Decreased AAA Incidence In Diabetes Kak Khee Yeung, MD, PhD *Moderators*: Mark A. Adelman, MD Michel Makaroun, MD How Should AAA Sac Behavior After EVAR Be Used To Assess 10:44-10:49 Treatment Success And Patient Prognosis Jean-Pierre Becquemin, MD Impact Of AAA Sac Size On EVAR Outcomes Short And Long-10:50-10:55

Term: Large Size Is Associated With Failure: What To Do About It Carlos H. Timaran, MD

10:56-11:01	Decreased AAA Sac Diameter After EVAR Is Associated With Good Outcomes While Sac Stability Is Not Andres Schanzer, MD
11:02-11:12	Panel Discussion
Moderators:	Tilo Kölbel, MD, PhD Michel Makaroun, MD
11:13-11:18	Should Saccular AAAs Be Fixed At A Smaller Diameter Than Fusiform AAAs: How Should AAA Diameter Be Measured To Include The Normal Aorta Or Not Frans L. Moll, MD, PhD (Power Point Presentation With Synched Audio)
11:19-11:24	In Patients Suitable For EVAR Or Open Repair, Adverse Neck Anatomy (Short, Wide, Angulated) Is Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: From The DREAM RCT: How Should This Influence Treatment Jan D. Blankensteijn, MD
11:25-11:30	Why AAA Diameter Is Often Not Enough To Make A Decision Regarding Threshold For Repair Or Re-Treatment After EVAR: What Other Parameters Should Enter Into The Decision S. Rao Vallabhaneni, MD
11:31-11:36	Improved AAA Sac Diameter Surveillance After EVAR Using A Home Smart Phone Ultrasound System: Device Description And Why It Will Improve Outcomes Ian Loftus, MD Roger M. Greenhalgh, MD
11:37-11:42	Key New Developments In Long-Term Evaluation Of EVAR For AAA Treatment Jason T. Lee, MD

11:43-11:48 Long-Term EVAR Outcomes Have Improved Over Time Whereas Open Repair Outcomes Have Remained Stable: A VQI Propensity Study Explains Differing Results Of RCTs And Shows Late Survival Advantage Of EVAR Marc L. Schermerhorn, MD

- 11:49-11:59 Panel Discussion
- 12:00- 1:00 Lunch Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

### SESSION 6 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE ABOUT AAAs, EVAR AND THE PUBLISHED UK NICE AAA GUIDELINES AND THEIR IMPACT ON AAA TREATMENT IN THE UK AND ELSEWHERE

Moderators:	Matt M. Thompson, MD
	Jon S. Matsumura, MD
	Frank J. Veith, MD

- 1:00 1:05 The Scientific Rationale Underlying The AAA NICE Guidelines: A View From A Writing Committee Member Alun H. Davies, MA, DM, DSc
- 1:06 1:11 Long-Term Results Of The OVER RCT: Pertinence To NICE AAA Guidelines: How Operator Training And Experience Influence \ EVAR Outcomes Jon S. Matsumura, MD
- 1:12 1:17 Impact Of NICE Guidelines On AAA Practice In The UK: Decreased Use Of EVAR Is NOT Justified By Recent Data Showing That EVAR Has Better 10-Year Survival Than Open Repair Ian Loftus, MD
- 1:18 1:23 Are The NICE AAA Guidelines The End Of EVAR In The UK: Why The Guidelines Are Wrong And Can They Be Fixed Richard G.J. Gibbs, FRCS Michael P. Jenkins, MBBS, BSc, MS

1:24 – 1:29	What Is Wrong With The NICE AAA Guidelines: Do They Still Limit The Use Of EVAR As In The Draft Guidelines Bijan Modarai, PhD
1:30 – 1:35	Update On What Has Happened With The NICE Guidelines In The UK And Elsewhere: Where Do They Stand In November 2021 Sherif A.H. Sultan, MD, PhD
1:36 – 1:41	Impact Of UK NICE AAA Guidelines On Other Countries Served By The European ESVS Guidelines Anders Wanhainen, MD, PhD
1:42 – 1:47	What Has Been The Impact Of The UK NICE AAA Guidelines In Germany And Elsewhere – Despite Their Flaws Dittmar Böckler, MD
1:47 – 1:52	Panel Discussion
DISSECTIONS WITH TEVAR	(LECTURE HALL 1 - Bonnet Creek Ballroom) EVELOPMENTS IN THE TREATMENT OF AORTIC AND THORACIC PATHOLOGY; STROKE PREVENTION
<i>Moderators</i> :	Mark A. Farber, MD

10aerators:	Mark A. Farder, MD
	Thomas C. Bower, MD

1:52 – 1:57 Update On Stroke Reduction Strategies With TEVAR: How To Decrease Particulate And Gas Emboli: What Is The STEP 2 Study Telling Us Tilo Kölbel, MD, PhD

Stephan Haulon, MD

1:58 – 2:03 Advances In Stroke Prevention From TEVAR: How To Decrease Gas And Particulate Emboli: When Should These Methods Be Used

Richard G.J. Gibbs, FRCS

- 2:04 2:09 Update On Value Of Embolic Brain Protection Devices For Proximal TEVAR And TAVR Procedures: When Are They Mandatory Jeffrey P. Carpenter, MD
- 2:10 2:15 Material Properties Of The Aortic Arch Can Predict Bird Beaking And Type 1A Endoleaks With TEVAR: Will Conformable Endografts With Proximal Adjustable Angle Control Eliminate The Problem

Thomas L. Forbes, MD

2:16 – 2:22 Panel Discussion

## SESSION 8 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NATURAL HISTORY; NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TBADs

- *Moderators*: William D. Jordan Jr., MD Thomas L. Forbes, MD
- 2:22 2:28 Long-Term Outcomes Of Medically Managed Acute TBADs: How Were Patients Selected For This Treatment Thomas C. Bower, MD

### MEGA DEBATE ON TREATMENT OF ACUTE UNCOMPLICATED TBADs

- 2:29 2:34 DEBATE: Many Uncomplicated Acute TBADs Never Need Invasive Interventions And Are Better Treated Medically; How To Select Such Patients Rachel E. Clough, MD, PhD (Power Point Presentation With Synched Audio)
   2:35 – 2:40 DEBATE: With Uncomplicated Acute TBADs, The Case For
- 2:35 2:40 **DEBATE:** With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset And Then Limiting Aortic Coverage With TEVAR Mark A. Farber, MD

2:41 – 2:46	DEBATE: With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients William D. Jordan Jr., MD Brad Leshnower, MD
2:47 – 2:52	<b>DEBATE</b> : Early Intervention For Acute TBADs (7-30 Days After Onset) With TEVAR For Acute TBADs Prevents Abdominal Extension Of False Lumen And TAAA Formation Rodney A. White, MD
2:53 – 2:58	Ideal Timing And Patient Selection Of TEVAR In Acute Uncomplicated TBAD Patients: When Is Medical Treatment Indicated Ali Azizzadeh, MD
2:59 - 3:03	[SS] Impact Of Cocaine Abuse On The Course Of Acute TBADs And Their Treatment: What Is The Mechanism Frank R. Arko, MD
3:03 - 3:08	Techniques For And Advantages Of Rerouting A Misplaced TEVAR Which Is Leading To A Growing False Lumen And Malperfusion In Acute TBAD Patients David M. Williams, MD
3:09 - 3:14	Re-Entry Specific Endovascular Therapy (RESET), i.e., TEVAR Plus Dealing With Re-Entry Tears Improves Outcomes: How To Do It Jean M. Panneton, MD
3:15 - 3:21	Panel Discussion

### **SESSIONS 9-10**

# MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE TEAM APPROACH

Course Leader: Michael R. Jaff, DO

## SESSION 9 (LECTURE HALL 1 – Bonnet Creek Ballroom) MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1

Moderator:	Michael R. Jaff, DO
3:22 - 3:25	Introduction To The Symposium Frank J. Veith, MD
3:25 - 3:29	Welcome And Introduction Michael R. Jaff, DO
3:29 - 3:36	The Easy And Hard Parts About Running A PERT Program: Lessons Learned Ziv J. Haskal, MD
3:36 - 3:46	The Basics Of Pulmonary Embolism: What Is The Role Of The History, Exam, Biomarkers Raghu Kolluri, MD
3:46 - 3:54	Do We Need An Echo To Manage Acute Submassive PE David M. Dudzinski, MD
3:54 - 4:01	Advanced Imaging For PE: What Is The Optimal Strategy For The Diagnosis Of Acute And Chronic PE Brian B. Ghoshhajra, MD, MBA
4:01 – 4:11	Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember Ido Weinberg, MD, MD, MSc
4:11 – 4:19	Testing For Cancer And Other Hypercoagulable States In PE Rachel Rosovsky, MD, MPH
4:19 – 4:26	The First Opportunity – The Emergency Physician Algorithm For Acute PE Management D. Mark Courtney, MD

4:26 - 4:33	Ultrasound-Assisted Pharmacomechanical Thrombectomy: Does This Really Work Kush R. Desai, MD
4:33 - 4:40	Mechanical Thrombectomy: The Indigo System Robert A. Lookstein, MD, MHCDL
4:40 - 4:50	What Strategy Is Best For Acute PE Intervention Patrick Troy, MD
4:50 – 4:57	Step-By-Step Technical Tips For Pharmacomechanical Intervention For PE Gary M. Ansel, MD
4:57 – 5:04	Percutaneous Mechanical Thrombectomy: The Flowtriever System: Where Does This Fit Mitchell D. Weinberg, MD
SESSION 10 (LECTURE HALL 1 – Bonnet Creek Ballroom) MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2	
<i>Moderator</i> : 5:04 – 5:11	Michael R. Jaff, DO Low-Dose Systemic Lytics: Is This An Effective Strategy For Acute PE Treatment Mohsen Sharifi, MD
5:11 – 5:18	Vortex Strategy For Massive PE Christopher J. Kwolek, MD, MBA
5:18 – 5:26	ECMO And Surgical Thromboembolectomy For Massive PE: When, How, And Why Mark G. Davies, MD

5:26 – 5:36 Putting It All Together: What Is The Modern Algorithm For Management Of Massive And Submassive PE Ido Weinberg, MD, MSc

5:36 - 5:43	Vena Cava Filters In PE Treatment: Do We Need To Do This, And If So, When Kush R. Desai, MD
5:43 – 5:50	Balloon Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream Kenneth Rosenfield, MD
5:50 – 5:58	The Team Approach To PE Management: The National PERT Consortium William B. Keeling, MD
5:58 - 6:15	Challenging Cases And "PERT" Decisions Moderator: Michael R. Jaff, DO Panelists: Mark G. Davies, MD Kush R. Desai, MD Ziv J. Haskal, MD William B. Keeling, MD Christopher J. Kwolek, MD, MBA Kenneth Rosenfield, MD Mohsen Sharifi, DO Ido Weinberg, MD

End Of Program A

# **PROGRAM B**

(Sessions 11-22) 6:50 A.M. - 6:10 P.M.

Progress In Vascular Robotics, Guidance Systems, Simulation And Laparoscopy; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; Hot New Topics In Lower Extremity Occlusive Disease Treatment; New Technology, New Concepts And Artificial Intelligence (AI); Vascular Surgery Recognition, Identity And Independence; Updates On Open And Hybrid Vascular Surgery And Treatment Of Aortic Coarctation; Updates On Vascular Malformations And Their Treatment

Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

6:44 - 6:49	Opening Remarks
	Enrico Ascher, MD

### SESSION 11 (LECTURE HALL 2 - Floridian Ballroom) PROGRESS IN VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY AND SIMULATION

Moderators:	Willem Wisselink, MD
	Sean P. Lyden, MD

6:50 – 6:55	Update On Endovascular Robotics:	They Have A Promising Future
	Joseph J. Ricotta II, MD, MS	

- 6:56 7:01 Robotic Decompression Of The Median Arcuate Ligament Michael J. Singh, MD
- 7:02 7:07 Laparoscopic Assisted Aortofemoral Bypasses For Juxtarenal Aortic Occlusions: Why It Is The Best Treatment Method Joseph S. Giglia, MD
- 7:08 7:13 Laparoscopic Robotic Assisted Aortic Surgery: Is It Worthwhile And Cost Effective In The Endovascular Era: Based On A 7-Year Experience In 87 Patients Pierre-Olivier Thiney, MD

- 7:14 7:19 Present Status And Future Potential Of Radiation Free Guidewire And Catheter Guidance: The Fiber Optic RealShape (FORS) From Philips: What Are Microbots And How Do They Work Barry T. Katzen, MD
- 7:20 7:25 Update On The 3D Radiation Free Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: How Does It Work, Advantages And Limitations Matthew J. Eagleton, MD

7:26 – 7:32 Panel Discussion

# SESSION 12 (LECTURE HALL 2 - Floridian Ballroom) NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT; DIFFERING VIEWS ON TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND CAROTID SCREENING

Moderators:	Ali F. AbuRahma, MD
	Allan L. Brook, MD
	Frank J. Veith, MD

- 7:32 7:37 Variations In Carotid Treatment Within Countries And Between Countries In Europe, The US And Australia Is Great Despite All The RCTs: What Are The Implications Maarit Venermo, MD, PhD
- 7:38 7:43 What Vascular Surgeons And Vascular Specialists Need To Know About What Can Be Learned From MRI And MRA Studies Of The Head And Neck Allan L. Brook, MD
- 7:44 7:49 Update On Isolated Carotid Webs As A Cause Of Cryptogenic Stroke: How To Diagnose And Treat Clayton J. Brinster, MD W. Charles Sternbergh III, MD

# DIFFERING VIEWS ON TREATMENT OF ACS

7:50 – 7:55	<ul> <li>DEBATE: ALL Asymptomatic Carotid Stenosis (ACS) Patients Are</li> <li>Best Treated Medically: Invasive Treatment Causes More Harm</li> <li>Than Good</li> <li>Anne L. Abbott, MD, PhD</li> <li>(Power Point Presentation With Synched Audio)</li> </ul>
7:56 – 8:01	<b>DEBATE</b> : Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated Bruce A. Perler, MD
8:02 – 8:07	DEBATE: Both Views Are Wrong: About 5-10% Of ACS Patients Should Be Treated Invasively And Benefit From Such Treatment: Why Are Too Many ACS Patients Getting CEA Or CAS Kosmas I. Paraskevas, MD
	DIFFERING VIEWS ON CAROTID SCREENING
8:08 - 8:13	<b>DEBATE</b> : The Case For Widespread Carotid Screening George S. Lavenson, MD
8:14 – 8:19	<b>DEBATE</b> : The Case Against Carotid Screening: It Leads To Unneeded And Possibly Harmful Treatment Anne L. Abbott, MD, PhD (Power Point Presentation With Synched Audio)
8:20 – 8:25	<b>DEBATE</b> : Lifeline Proprietary Carotid Screening: Who Profits: Is It A Good Thing Or A Hoax And A Scam: What Can It Tell Us About The Prevalence Of ACS James F. Meschia, MD Thomas G. Brott, MD
8:26 - 8:32	Panel Discussion

## SESSION 13 (LECTURE HALL 2 - Floridian Ballroom) MORE ABOUT CAROTID AND VERTEBRAL DISEASE: UPDATE ON INVASIVE TREATMENT FOR ACUTE STROKES

Moderators:	Allan L. Brook, MD
	Klaus D. Mathias, MD
8:32 - 8:37	Endovascular Treatment Of Carotid Artery Aneurysms Of Etiologies: Technical Aspects Klaus D. Mathias, MD
8:38 – 8:43	When After Thrombolysis Treatment From A Stroke Should Carotid Endarterectomy (CEA) Be Performed And What Is The Best Timing For Those CEAs: Delay Has Consequences Maarit Venermo, MD, PhD
8:44 – 8:49	Why Vascular Surgeons Should Become Involved In Intracranial Endovascular Treatments For Acute Strokes: How To Learn These Procedures And Benefit Patients Laura Capoccia, MD
8:50 – 8:55	What Is New With Endovascular Intracranial Techniques For Arterial Clot Removal For Acute Strokes: New Methods; When And How Can The Time Window For Success Be Increased Adnan H. Siddiqui, MD, PhD L. Nelson Hopkins, MD
8:56 – 9:01	Update And New Developments In Intracranial Endovascular Treatment For Acute Strokes: Should Other Specialists Learn How To Do It And The Ways To Learn Adnan H. Siddiqui, MD, PhD L. Nelson Hopkins, MD
9:02 – 9:07	Improvements In The Treatment Of Acute Strokes: Why A Dedicated Stroke Center Matters: What And Who Must Be Involved: Yes, It Does Matter In Better Patient Outcomes
	Hernan A. Bazan, MD

9:08 – 9:14 Panel Discussion

9:14 – 9:24 Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

### SESSION 14 (LECTURE HALL 2 - Floridian Ballroom) PROGRESS IN THE TREATMENT OF AORTIC AND AORTO-ILIAC OCCLUSIVE DISEASE

- Moderators: Keith D. Calligaro, MD Daniel G. Clair, MD Wayne W. Zhang, MD
- 9:24 9:29 Current Concepts And Techniques For Treating External Iliac Artery Endofibrosis In Committed Athletes: What Works And Doesn't Work: Is There A Role For Endovascular Treatment Kenneth J. Cherry, MD
- 9:30 9:35 Iliac Stenosis In Professional Cyclists: How To Diagnose And Treat: ABIs Don't Help Gabriel Szendro, MD (Power Point Presentation With Synched Audio)
- 9:36 9:41 Value Of VBX Balloon Expandable Covered Stents In Treating Complex Aorto-Iliac Occlusive Disease: Advantages And Limitations

Ehrin Armstrong, MD (Power Point Presentation With Synched Audio)

#### COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB)PROCEDURE

9:42 – 9:47 5-Year Outcomes Of The CERAB Procedure With Covered Stents For Complex Aorto-Iliac Occlusive Disease: Why It's Better Than Kissing Stents And Which Covered Stent Works Best Michel M.P. Reijnen, MD, PhD Peter C.J. Goverde, MD, PhD

9:48 – 9:53	CERAB Procedure Versus Kissing Stents For Complex Aorto-Iliac Occlusive Diseases: Advantages And Disadvantages Of Each: CERAB Requires More Time And Radiation Maria Antonella Ruffino, MD
9:54 – 9:59	Covered Endovascular Reconstruction Of The Aortic Bifurcation (CERAB) Technique: Multicentre UK Experience Hany Zayed, MD
10:00-10:05	Value Of Shockwave Intravascular Lithotripsy For Calcified Aorto- Iliac Occlusive Disease Treatment Andrew Holden, MBChB (Power Point Presentation With Synched Audio)
10:06-10:12	Panel Discussion
10:12-10:17	Treatment Of Isolated Aortic Stenosis Without Iliac Disease: When Stents; When Stent-Grafts; When Open Bypass Sigrid Nikol, MD
10:18-10:23	<b>DEBATE</b> : How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go David Minion, MD
10:24-10:29	DEBATE: Not So: Open Surgery Is the Best Way To Treat Flush Juxtarenal Aortic Occlusions Safely: Technical Tips On How To Do It Thomas C. Bower, MD
10:30-10:35	<b>DEBATE</b> : Both Wrong: Hybrid Repairs Are Best For Complex Aorto-Iliac Occlusive Disease: Technical Tips On How To Do It Yamume Tshomba, MD
10:36-10:42	Panel Discussion

## SESSION 15 (LECTURE HALL 2 - Floridian Ballroom) HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE

Moderators:	<i>Neal S. Cayne, MD</i> Palma M. Shaw, MD
10:42-10:47	Key Steps For Success With Radial Artery Access For Remote Visceral, Renal Or Lower Extremity Lesion Treatment Marcelo Guimaraes, MD, MBA
10:48-10:53	<b>DEBATE:</b> CO2 As A Contrast Agent Is Valuable For Lower Extremity Angiography And Treatments If Used Appropriately Palma M. Shaw, MD
10:54-10:59	<b>DEBATE:</b> Not So: CO2 As A Lower Extremity Contrast Agent Is Unnecessary And Has Downsides Ali Amin, MD, RVT
11:00-11:05	Value Of Tack Optimized Balloon Angioplasty In Lower Extremity Interventions: When Should They Be Used And When Not (Tacks From Intact Vascular) Lawrence A. Garcia, MD
11:06-11:11	Heel Ulceration And Ischemic Gangrene Involving The Achilles Tendon Should Not Be An Indication For A BTK Amputation: How To Save Such A Limb Mark G. Davies, MD
11:12-11:17	Popliteal Artery-To-Distal Bypass For Limb Salvage; Status In 2021: Technical Tips And Value: When Is It Better Than Endovascular Treatments Francesco Spinelli, MD
11:18-11:24	Panel Discussion

# SESSION 16 (LECTURE HALL 2 – Floridian Ballroom) MORE HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND CHRONIC LIMB THREATENING ISCHEMIA (CLTI) (4 3/4-MINUTE TALKS)

Moderators:	Enrico Ascher, MD Peter A. Schneider, MD
11:24-11:29	Value Of External Duplex Ultrasound And Other Technical Factors In Optimizing BTK DCB Angioplasty Francesco Liistro, MD
11:29-11:34	How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): Why It Is Important Jos C. van den Berg, MD, PhD
11:34-11:39	Patterns Of Calcification In BTK Arteries: How They Influence Endovascular Treatments Jihad A. Mustapha, MD
11:39-11:44	How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries Enrico Ascher, MD Frank J. Veith, MD
11:44-11:49	Challenge Of Getting Endovascular Revascularization To Achieve Healing Of Ischemic Wounds: Value Of A Wound Center In A Limb Salvage Program Robert B. McLafferty, MD, MBA
11:49-11:54	Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Value And Limitations Ignacio Escotto, MD (Power Point Presentation With Synched Audio)
11:54-12:00	Panel Discussion

12:00- 1:00	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
	(LECTURE HALL 2 - Floridian Ballroom) PTS, MACHINE LEARNING AND NTELLIGENCE (AI)
Moderators:	Barry T. Katzen, MD
111040141013.	Gustavo S. Oderich, MD
	Frank J. Veith, MD
1:00 – 1:05	What Is The Bright Future Of AI And Robotic Technology In Vascular Surgery Willem Wisselink, MD
1:06 – 1:11	Unconventional Renal Allograft Landing Sites (Venous Anastomoses) In The Presence Of Near Total Caval Thrombosis Robert A. Montgomery, MD, DPhil
1:12 – 1:17	How Vascular Treatment Will Intersect With Other New Technologies: Wearable Trackers, AI, And Tissue Engineering David H. Deaton, MD
1:18 – 1:23	How 3D And 4D Machine Learning Is Changing Vascular Surgery Matthew T. Menard, MD
1:24 – 1:29	How Can AI Be Used To Predict Endoleaks And AAA Growth: Will It Have Clinical Value Kak Khee Yeung, MD, PhD
1:30 – 1:35	Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease Ravi K. Veeraswamy, MD

 1:36 – 1:41 Totally Radiation Free Deployment Of A Complex AAA Endograft Using An Intraoperative Positioning System (IOPS From Centerline) And Positional Markers On Graft Components As Well As Catheters And Wires To Enable Accurate 3D Guidance: It Is Analogous To Precise GPS Targeting Gustavo S. Oderich, MD

1:42 – 1:54 Panel Discussion

## SESSION 18 (LECTURE HALL 2 - Floridian Ballroom) VASCULAR SURGERY'S NUMBERS, IDENTITY, RECOGNITION, INDEPENDENT SPECIALTY STATUS; HOW TO INCREASE OUR NUMBERS TO MEET FUTURE NEEDS FOR OUR SERVICES

Moderators:	Bruce A. Perler, MD, MBA
	Ronald L. Dalman, MD

- 1:54 1:59 Updated Workforce Model Predicts A Shortage Of Vascular Surgeons For The Next 20 Years: What Should Vascular Surgery And The American Board of Surgery (ABS) Do About It Bhagwan Satiani, MD, MBA K. Craig Kent, MD
- 2:00 2:05 What Makes Vascular Surgery Different, Why Are There Insufficient Numbers Of Vascular Surgeons: How Can We Expand Our Numbers Evan C. Lipsitz, MD, MBA
- 2:06 2:11 The Clouded Identity Of Vascular Surgery Amongst Other Doctors And The Public: Why Is It So And What Can Be Done About It James C. Stanley, MD Frank J. Veith, MD
- 2:12 2:17 Why US News & World Report Cannot And Does Not Rank Vascular Surgery Programs: Vascular Surgery Needs To Be An Independent ABMS Approved Specialty: Why Isn't It James H. Black, III, MD

2:18 - 2:23	The American Board Of Vascular Surgery Or ABVS: Its Time Is Now
	Alan M. Dietzek, MD, RPVI
2:24 – 2:29	The SVS Executive Committee: What Is Its Function And How Has It Not Promoted Vascular Surgery And Thereby Failed To Serve Its Membership's Interests Benjamin W. Starnes, MD
2:30 – 2:35	What Will Happen If Vascular Surgery Does Not Become A Separate Specialty: How Have Our Vascular Societies Failed Vascular Surgeons David H. Deaton, MD
2:36 - 2:41	Why Vascular Surgery Must Be An Independent Specialty: It Needs Independent Departments So As To Not Be Exploited By Other Department Chairs Patrick J. Geraghty, MD
2:42 – 2:47	The Key To More Vascular Surgeons Is Better Exposure To Medical Students: We Are A Hidden Specialty Because Of Our Subordinate Specialty Status Which Also Limits Our Training Programs Jerry Goldstone, MD
2:48 – 2:53	Vascular Surgery Training Program's Update For 0+5 And 5+2 Programs: Do We Need More Applicants Or More Programs Or Both: How Can We Get There Murray L. Shames, MD
2:54 – 2:59	Is Getting A Vascular Surgery Training Position Becoming Less Competitive For 0+5 Residencies; For 5+2 Fellowships Peter L. Faries, MD
3:00 - 3:05	Leadership Roles Vascular Surgeons And Vascular Specialists Should Seek: Why They Are Important And How To Get There Without Abandoning Your Original Specialty Christopher J. Kwolek, MD, MBA

3:06 - 3:18	Panel Discussion And Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 19 PROGRESS IN DISEASE	(LECTURE HALL 2 - Floridian Ballroom) THE TREATMENT OF VISCERAL AND RENAL ARTERY
Moderators:	James C. Stanley, MD Alan M. Dietzek, MD, RPVI
3:18 - 3:23	<b>DEBATE:</b> All Visceral And Renal Artery Aneurysms Can Be Treated Endovascularly Robert A. Lookstein, MD, MHCDL
3:24 - 3:29	DEBATE: Open Treatment Of Visceral And Renal Artery Aneurysms Is Sometimes Best: When Is This Timur P. Sarac, MD
3:30 - 3:35	Technical Tips For Percutaneous Endovascular Treatment Of Visceral And Renal Artery Aneurysms Jacob Cynamon, MD
3:36 - 3:41	Update On New SVS Practice Guidelines For Treating Visceral Artery Aneurysms; When Endo; When Open Rabih A. Chaer, MD
3:42 - 3:47	Current Optimal Treatment Of Pancreatico-Duodenal Aneurysms With And Without Celiac Axis Occlusion: When Endo; When Open: Why They Are Both Challenging Benjamin M. Jackson, MD Ronald M. Fairman, MD
3:48 - 3:53	At What Size Do Renal Artery Aneurysms Need To Be Treated Invasively: A New Vascular Consortium Study Shows They Are
	Only Dangerous When >3 cm In Diameter Peter F. Lawrence, MD

- 3:54 3:59 Optimal Current Treatment Of Renal Artery Aneurysms: When Endo; When Open; Technical Tips Fred A. Weaver, MD, MMM
- 4:00 4:06 Panel Discussion

## SESSION 20 (LECTURE HALL 2 - Floridian Ballroom) UPDATE ON OPEN VASCULAR SURGICAL AND HYBRID PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS

Moderators:	Enrico Ascher, MD
	Jerry Goldstone, MD

#### **OPEN AND HYBRID VASCULAR SURGERY**

4:06 – 4:11	Minimal Incision For Retroperitoneal Aorto-Bifemoral Bypass: Technical Tips And Limitations Robert M. Proczka, MD, PhD
4:12 - 4:17	Duplex Surveillance Should Be Used After All Aorto-Bifemoral

- 4:12 4:17 Duplex Surveillance Should Be Used After All Aorto-Bifemoral Bypasses: It Improves Outcomes Keith D. Calligaro, MD
- 4:18 4:23 Thoraco-Bifemoral Bypass: A Good Option After All Endo And Open Standard Approaches Have Failed: Technical Tips Manju Kalra, MBBS
- 4:24 4:29 Long-Term Survival Results After Type II TAAA Endovascular Repair: When Is The Procedure Contraindicated Matthew J. Eagleton, MD
- 4:30 4:35 Technical Tips For Aortic And Inferior Vena Cava Resections During Cancer Operations Benjamin M. Jackson, MD

## UPDATE ON COARCTATION TREATMENT

4:36 – 4:41	Endovascular Techniques Are The Best Treatment For Aortic
	Coarctations: When Bare Stents; When Covered Stents;
	Precautions
	Zvonimir Krajcer, MD

- 4:42 4:47 Value Of BeGraft (From Bentley), A Balloon Expandable Covered Stent In Treating Aortic Coarctations: Can It Treat All Cases Elchanan Bruckheimer, MBBS (Power Point Presentation With Synched Audio)
- 4:48 4:53 Long-Term Outcomes Of Stent-Graft Treatment Of Aortic Coarctations Frank R. Arko, MD
- 4:54 5:00 Panel Discussion

# SESSIONS 21-22 CURRENT STRATEGIES IN THE DIAGNOSIS AND CURATIVE TREATMENT OF VASCULAR MALFORMATIONS

# SESSION 21 (LECTURE HALL 2 – Floridian Ballroom) ETHANOL ENDOVASCULAR CURATIVE TREATMENT OF VASCULAR MALFORMATIONS – PART 1

- Moderators: Krassi Ivancev, MD, PhD Robert L. Vogelzang, MD Wayne F. Yakes, MD
- 5:00 5:02 Welcome And Introduction Krassi Ivancev, MD, PhD
- 5:03 5:08 International Society for the Study of Vascular Anomalies (ISSVA) Classification System: How It Is Applied In My Practice Wayne F. Yakes, MD

5:09 – 5:17	The Yakes AVM Classification System: A Guide For Curative AVM Treatment As Documented In 100 Consecutive AVM Patients Krassi Ivancev, MD, PhD
5:18 – 5:26	A Step-By-Step Practicum For Ethanol Endovascular Treatment Of AVMs Applying The Yakes Classification System Robert L. Vogelzang, MD
5:27 – 5:34	A Step-By-Step Practicum For Ethanol Endovascular Treatment Of Venous Malformations Krassi Ivancev, MD, PhD
5:35 - 5:40	Panel Discussion
	(LECTURE HALL 2 – Floridian Ballroom) DOVASCULAR CURATIVE TREATMENT OF VASCULAR IONS – PART 2
Moderators:	<i>Krassi Ivancev, MD, PhD</i> Robert L. Vogelzang, MD Wayne F. Yakes, MD
5:41 – 5:48	Curative Ethanol Endovascular Treatment of Complex Head & Neck AVMs Wayne F. Yakes, MD
5:49 – 5:55	New Agents And Drugs For Vascular Malformation Management: Do They Offer Any Hope Robert L. Vogelzang, MD
5:56 – 6:03	Endovascular Ethanol Treatment Of Complex Low-Flow Venous And Lymphatic Malformations Wayne F. Yakes, MD
6:04 – 6:10	Problems! I've Got 'EmManaging The Tough Vascular Malformation Case Robert L. Vogelzang, MD
End of Progr	

# WEDNESDAY, NOVEMBER 17, 2021

6:00 A.M. General Registration – Bonnet Creek Ballroom - North Foyer
6:00 A.M. Faculty Registration – Bonnet Creek Ballroom - Salon I
6:15 A.M. Continental Breakfast – Bonnet Creek and Floridian Ballrooms - North, West, Center and South Foyers

# **PROGRAM C**

(Sessions 23-30) 6:40 A.M. – 3:56 P.M. Progress In Lower Extremity Occlusive Disease And Its Treatment; New Developments In Medical Treatments And New Drugs; Progress In Antiatherogenic, Antihypertensive And Cardiac Treatments: Cardiac Effects Of COVID-19 Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

## SESSION 23 (LECTURE HALL 1 - Bonnet Creek Ballroom) GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI

Moderators:	Enrico Ascher, MD
	Gary M. Ansel, MD

- 6:40 6:45 Do Diabetic Patients With CLTI And Substantial Foot Necrosis Have Time For An Endovascular First Strategy: Why Primary Open Bypass Treatment Is Better Katariina M. Noronen, MD, PhD
- 6:46 6:51 Key New Developments In Endovascular Treatments For CLTI Sahil A. Parikh, MD

## OPTIMAL TECHNIQUES FOR VESSEL PREP FOR ENDOVASCULAR TREATMENTS

6:52 – 6:57 Technical Tips For Vessel Prep Before DCBs And DESs: It Is Different And Not Simple Erwin Blessing, MD

- 6:58 7:03 Thirteen Technical Tips For Safe Radial Access For Renal/Visceral And Lower Extremity Interventions: How Far Distally In The Leg Can Lesions Be Treated Craig M. Walker, MD
- 7:04 7:09 What Are The Downsides To Trans-Radial Or Pedal Access Gary M. Ansel, MD

#### **TECHNICAL TIPS ON GUIDEWIRE CHOICE AND USAGE**

- 7:10 7:15 Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion And Getting A Resistant Balloon To Go Over The Wire Marco G. Manzi, MD
- 7:16 7:22 Panel Discussion

## SESSION 24 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE)

Moderators: Craig M. Walker, MD James F. McKinsey, MD

#### **PROGRESS IN ATHERECTOMY**

- 7:22 7:27 New Developments In Laser Atherectomy: What Makes It Different: When Is It Beneficial With Certainty George L. Adams, MD
- 7:28 7:33 Value Of Phoenix Atherectomy And Stellarex DCB For Infrapopliteal Lesions: Why IVUS Guidance Is Beneficial: 1-Year Results In CLTI Patients Michael K.W. Lichtenberg, MD Thomas Zeller, MD

Optical Coherence Tomography (OCT) Guided Atherectomy (Pantheris) For In Stent Restenosis (ISR): Why It Is More Effective Treatment: From The INSIGHT Trial Todd R. Vogel, MD, MPH
Current Role Of Atherectomy In Treating Lower Extremity CLTI: A Vascular Surgeon's View James F. McKinsey, MD
UPDATE ON THE SUPERA STENT
Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First Peter C.J. Goverde, MD (Power Point Presentation With Synched Audio)
Value And Technical Tips To Make The Supera Stent Work In Curved And Angulated Non-SFA Lesion Locations Rajiv Parakh, MBBS, MS
DRUG ELUTING STENTS FOR BTK LESIONS
10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations Robert A. Lookstein, MD, MHCDL
What Is The Future For Bioresorbable DESs To Treat BTK Lesions: Good Long-Term Results Including The DISAPPEAR Trial Justify A New Trial: The LIFE-BTK Trial With The Esprit Stent From Abbott Ramon L. Varcoe, MBBS, MS, PhD Sahil A. Parikh, MD Brian G. DeRubertis, MD

Steven Kum, MD

- 8:10 8:15 A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: The STAND Trial Robert E. Beasley, MD
- 8:16 8:22 Panel Discussion

# SESSION 25 (LECTURE HALL 1 - Bonnet Creek Ballroom) LOWER EXTREMITY TOPICS RELATED TO THE DRUG COATED DEVICES CAUSING INCREASED MORTALITY CONTROVERSY: DO PACLITAXEL COATED DEVICES CAUSE INCREASED MORTALITY (5 AND 4 ¾-MINUTE SHORT SUMMARY [SS] TALKS)

- Moderators: Kenneth Ouriel, MD, MBA Sahil A. Parikh, MD
- 8:22 8:27 Older And More Recent Meta-Analyses Reveal An Increased Mortality Signal In Patients Receiving Paclitaxel Coated Devices Compared To Uncoated Devices: A More Recent Study Reveals Increased Amputation Rates With Paclitaxel Coated Devices: What About Mortality

Konstantinos Katsanos, MSc, MD, PhD

- 8:28 8:33 Large Population Based German Multicenter Study Of Paclitaxel Coated BTK DCBs And DESs Indicates Decreased Mortality And Amputation Rates Compared To Uncoated Devices: Initial Thoughts About Katsanos' Recent Amputation Data Christian A. Behrendt, MD
- 8:34 8:39 Real World Big Data Patient-Level Evidence Confirms No Harm From Paclitaxel Coated Devices For Treating Fempop Disease: Update On Medicare Data From Over 150,000 Patients Eric A. Secemsky, MD, MSc Robert Yeh, MD

8:40 - 8:45	Mortality Rates After Paclitaxel Coated Device Use In Patients With Both Critical Limb Ischemia (CLI) And Claudication: Two
	Systematic Reviews And Meta-Analyses Of Randomized
	Controlled Trials Show NO Increased Mortality With Paclitaxel
	Coated Devices Up To 5 Years
	Ramon L. Varcoe, MBBS, MS, PhD
	Andrew Holden, MBChB
	Krystal Dinh, MD
	Peter A. Schneider, MD
	RELEVANT COMMENTS AS SHORT SUMMARY [SS] TOPICS (4 ¾-MINUTE TALKS)
8:46 – 8:51	[SS] The Paclitaxel Increased Mortality Effect Reported By Dr. Katsanos et al. Seems Not To Be Confirmed By Added Data: Initial Thought About Katsanos' Recent Meta-Analysis Showing Increased Amputation Rates With Paclitaxel Coated Devices Peter A. Schneider, MD
8:51 – 8:56	[SS] New Data On The Paclitaxel Mortality Controversy: Should You Continue Using These Devices Gary M. Ansel, MD
8:56 – 9:01	<ul> <li>[SS] VQI Data Do Not Support The Paclitaxel Increased Mortality</li> <li>Signal</li> <li>Daniel Bertges, MD</li> <li>Jack L. Cronenwett, MD</li> </ul>
9:01 – 9:08	Panel Discussion

SESSION 26 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs (5-MINUTE TALKS) *Moderators*: Joseph L. Mills, MD

Joseph L. Mills, MD John R. Laird, MD

## NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs

9:08 – 9:13	Cost Effectiveness Of Drug Eluting Technologies For Femoropopliteal Lesions: They Are Worth The Increased Device Costs Stefan Müller-Hülsbeck, MD (Power Point Presentation With Synched Audio)
9:14 – 9:19	Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Effective In Fempop Lesions: Final 5-Year Data From The ILLUMENATE RCTs Sean P. Lyden, MD
9:20 – 9:25	Pooled Data From The In.Pact RCT DCB Trials For SFA-Pop Lesions Show Safety And Efficacy For 5 Years Compared To POBA: Continued Use Is Justified Peter A. Schneider, MD John R. Laird, MD
9:26 – 9:31	New Findings From The DRASTICO Study Comparing DESs To DCBs For Fempop Lesions: 4-Year Results With TASC A/B Lesions Versus TASC C/D Lesions Francesco Liistro, MD
9:32 – 9:37	Update On The Randomized Head To Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 2-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages Dierk Scheinert, MD Sabine Steiner, MD (Power Point Presentation With Synched Audio)
9:38 – 9:43	Update On The Global RANGER II RCT Comparing Ranger DCBs With POBA Marianne Brodmann, MD

9:44 – 9:49 Panel Discussion

9:49 – 10:02 Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

Session 26 will continue after the Break.

# SESSION 26 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs (5-MINUTE TALKS)

Moderators:	Joseph L. Mills, MD
	John R. Laird, MD

- 10:02-10:07 New Information On The Safety And Effectiveness Of The Cook Zilver PTX DES Based On Global Trials Including A RCT: When Is It The Best Treatment Michael D. Dake, MD (Power Point Presentation With Synched Audio)
- 10:08-10:13 Update On Clinical Trials Of The Boston Scientific Eluvia DES William A. Gray, MD Stefan Müller-Hülsbeck, MD Thomas Zeller, MD

## NEW INFORMATION ON BTK DCBs AND DESs

 10:14-10:19 The Sirolimus DCB BTK Era Begins – Current Experience With \ The Selution DCB And Design Of The SELUTION SLR .014 BTK IDE Trial: Early Results From Singapore And Europe Patrick J. Geraghty, MD
 10:20-10:25 1-Year Results From The AcoArt II BTK DCB RCT Show Safety (No Increased Mortality) And Improved Patency Versus POBA Francesco Liistro, MD

Wei Guo, MD

- 10:26-10:31 Why BTK DCB Trials Do Not Show Uniformly Better Results: Technical Factors Matter Francesco Liistro, MD
- 10:32-10:37 Update On The SAVAL Trial With A Self-Expanding DES (From Boston Scientific) For BTK Occlusive Lesions Jihad A. Mustapha, MD Miguel F. Montero-Baker, MD

10:38-10:43 Panel Discussion

# SESSION 27 (LECTURE HALL 1 - Bonnet Creek Ballroom) PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: HOW TO SAVE THE "NO OPTION FOR TREATMENT" LIMB OR THE "DESERT FOOT" WITH NO PATENT TARGET ARTERIES

Moderators:	Daniel G. Clair, MD
	Marco G. Manzi, MD

 10:43-10:48 Contemporary Survival After Below-Knee Amputation (BKA), Above-Knee Amputation (AKA), Bilateral Amputations For Trauma; For Vascular Disease: It Is Worthwhile Saving Limbs Especially In Vascular Patients Philip P. Goodney, MD, MS

## VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES

10:49-10:54 Value Of Spliced Vein Grafts Versus PTFE Grafts For Bypasses:When A Single Autologous Vein Is InadequateJoseph L. Mills, MD

10:55-11:00	PTFE Tibial And Peroneal Artery Bypasses Can Save No Optic	
	Limbs Which Would Otherwise Require Amputation: They Can	
	Have Long-Term Patency And Limb Salvage And Are Worthwhile	
	Gregg S. Landis, MD	
	Richard F. Neville, MD	
	Hosan D. Dosluoglu, MD	
	Neal S. Cayne, MD	
	Mark A. Adelman, MD	
	Frank J. Veith, MD	

- 11:01-11:06 For Patients Facing Amputation With No Endo Options Or Useable Vein, PTFE Tibial Bypasses Are A Worthwhile Option R. Clement Darling III, MD
- 11:07-11:12 Current Outcomes With PTFE Bypasses To Infrapopliteal (Tibial) Targets: Is There Variability Between Surgeons And Institutions Matthew T. Menard, MD
- 11:13-11:18 Panel Discussion

## UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI

11:18-11:23	What Is The Real Prevalence Of No Option Anatomy Among The CLTI Population: What Is The Role For Foot Vein Arterialization: Impact Of The PROMISE I Trial With The LimFlow System Peter A. Schneider, MD
11:24-11:29	Role And Value Of Vein Arterialization: Best Way To Do It And Long-Term Results: From The Pioneer Pramook Mutirangura, FRCS (Power Point Presentation With Synched Audio)
11:30-11:35	Pathophysiology Of Venous Arterialization And Neo Angiogenesis For No Option CLTI: How To Predict When It Will Work And When It Won't Roberto Ferraresi, MD (Power Point Presentation With Synched Audio)

11:36-11:41	<ul> <li>2-Year Registry Results With Deep Vein Arterialization With The LimFlow Device For CLTI With Gangrene Shows Reasonable Limb</li> <li>Salvage And Wound Healing Daniela Branzan, MD Andrej Schmidt, MD</li> </ul>
11:42-11:47	How To Perform The LimFlow Procedure: Equipment Required And Technical Tips Miguel F. Montero-Baker, MD
11:48-11:53	Deep Vein Arterialization And Valve Lysis By Surgical Means For No Option Desert Feet With Gangrene: How To Do It And Results Richard F. Neville, MD
11:54-12:00	Panel Discussion
12:00- 1:00	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Fovers)

## SESSION 28 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN STENTS; PROSTHETIC GRAFTS; ENDOVASCULAR BYPASSES; STENT GRAFTS AND TREATMENT OF IN STENT RESTENOSIS (ISR)

- Moderators: Mark A. Adelman, MD Anahita Dua, MD, MS, MBA
- 1:00 1:05
   3-Year Results From The BioMimics 3D Swirling Flow Stent In The MIMICS-2 Study: Who Needs Paclitaxel Michael K.W. Lichtenberg, MD Peter A. Gaines, MD Timothy M. Sullivan, MD

#### **ARTERIAL PTFE BYPASSES**

1:06 – 1:11 RCT Comparing Heparin Bonded PTFE (Propaten) Grafts With Plain PTFE Grafts For BTK CLTI Bypasses: Is Heparin Bonding Helpful

> Yann Gouëffic, MD, PhD (Power Point Presentation With Synched Audio)

1:12 – 1:17 Hybrid Fluoroscopically Guided Improved Method For Restoring Patency To Occluded PTFE Bypasses: It's Less Invasive And More Effective

> Neal S. Cayne, MD Frank J. Veith, MD

#### **PERCUTANEOUS BYPASSES**

1:18 – 1:23 Percutaneous (PQ) Tranvenous Fempop PTFE Bypasse	
	Torus 2 Device: How It Works And Status Of The DETOUR And
	TORUS Trials In The US And Europe
	Sean P. Lyden, MD
	Daniel G. Clair, MD
	Ehrin Armstrong, MD
	Peter A. Schneider, MD
1:24 – 1:29	3-Year Results Of The Detour PQ Fempop Arterial Bypass Routed Through The Femoral Vein: Will It Make Open Bypass Obsolete Dainis K. Krievins, MD
1:30 – 1:35	A Novel Technique For PQ Fempop Bypass Routing The PTFE Bypass Through The Soft Tissue Of The Thigh: How To Do It And
	Early Results
	Pierre G. Sarradon, MD
	Jean-Pierre Becquemin, MD

#### **NEW INFORMATION ON STENT-GRAFTS**

1:36 – 1:41 2-Year Results Of The SUPER B RCT Shows That Viabahn Stent-Grafts Have Patency Rates As Good As Open Fempop PTFE Bypasses But Require More Reinterventions: How To Make Viabahns Work Best Michel M.P. Reijnen, MD, PhD

#### TREATMENT OF IN STENT RESTENOSIS (ISR)

1:62 – 1:47 Laser Atherectomy May Facilitate Endovascular Treatment Of ISR But Does Not Provide Long-Term Benefit: How Should ISR Be Treated

Russell H. Samson, MD

- 1:48 1:53 The Excimer Laser For Treating ISR: It Has A Role In Grossing And Debulking Difficult Lesions: Technical Tips Craig M. Walker, MD
- 1:54 2:00 Panel Discussion

## SESSION 29 (LECTURE HALL 1 - Bonnet Creek Ballroom) LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES

Moderators:	Mark K. Eskandari, MD
	Gregg S. Landis, MD

2:00 – 2:05 Update On The BEST-CLI RCT Comparing Endovascular And Open Treatment Of Lower Extremity Ischemia: Current Status, Challenges And What Will Be Its Value Matthew T. Menard, MD Alik Farber, MD, MBA Kenneth Rosenfield, MD

# METHODS FOR EVALUATING FOOT PERFUSION

2:06 – 2:11	Measuring Foot Perfusion After Endo Treatments For CLTI With Perfusion Angiography And Smart Software: Why It Is Important And How To Do It Jim Reekers, MD, PhD
2:12 – 2:17	Indocyanine Green Fluorescence (IGC-FL) Is A Good Way To Measure Foot Perfusion After Treatment: How It Explains Why The Angiosome Concept Is Important After Endo Treatments But Not After Bypasses Maarit Venermo, MD, PhD
2:18 – 2:23	How And Why To Measure Foot Perfusion During Endo Treatments: Hyperspectral Imaging, O <sub>2</sub> Sensors, Etc: When Is The Angiosome Concept Helpful; When Not Marianne Brodmann, MD
2:24 – 2:29	What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology, Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters Ido Weinberg, MD, MSc
2:30 – 2:35	Pedal Arch Patency Is Key To Predicting Limb Salvage With Endovascular Treatment For CLTI With Tissue Necrosis: How Is It Best Evaluated Hosan D. Dosluoglu, MD Linda M. Harris, MD
2:36 – 2:41	Foot Perfusion Measurements Show Why Open Bypasses Are Better Than Endovascular Treatments For CLTI Werner Lang, MD
2:42 – 2:48	Panel Discussion
2:48 - 3:08	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 30 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND ACUTE LIMB ISCHEMIA

Moderators:	Matthew T. Menard, MD
	Caitlin W. Hicks, MD, MS

## **INTERMITTENT CLAUDICATION (IC)**

 3:08 – 3:13 Overuse Of Vascular Interventions For IC Is A Measure Of Poor Care: How Is This Determined Caitlin W. Hicks, MD, MS James H. Black, III, MD

#### ACUTE LIMB ISCHEMIA (ALI) (See Also Session 59)

3:14 - 3:19	Update On Thrombosuction Devices For Treating ALI: Which
	Device In Which Circumstance: Advantages And Limitations
	Eric L.G. Verhoeven, MD, PhD
	Athanasios Katsargyris, MD

- 3:20 3:25 Computer Aided Mechanical Aspiration Thrombectomy (CMAT) Is Obviating The Need For Thrombolytics In ALI: Which Device Is Best When And Why Patrick E. Muck, MD
- 3:26 3:31 Aspiration Thrombectomy Devices And Techniques For ALI: Are Thrombolytics And Fogarty Balloon Catheters Obsolete Maria Antonella Ruffino, MD
- 3:32 3:37 Penumbra Indigo Clot Aspiration System To Treat ALI: Why Is It A Game Changer: Technical Tips For Usage James F. Benenati, MD
- 3:38 3:43 Value And Technical Tips For Using The Indigo Clot Removal System Before Treating ISR And Other Lesions With Balloon And Stents

Frank R. Arko, MD

- 3:44 3:49 How To Treat ALI Under Duplex Ultrasound Guidance: Advantages And Limitations Natalie A. Marks, MD, RPVI Enrico Ascher, MD
- 3:50 3:56 Panel Discussion

## SESSION 31 (LECTURE HALL 1 – Bonnet Creek Ballroom) ADVANCES IN MEDICAL TREATMENTS, NEW ANTIATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIS IN VASCULAR SURGERY PATIENTS

- *Moderators*: Ido Weinberg, MD, MSc Bhama Ramkhelawon, PhD
- 3:56 4:01 What Adequate And Ideal Lipid Levels Should We Strive For In PAD Patients: How To Get There Marianne Brodmann, MD
- 4:02 4:07 Risks And Consequences Of Perioperative Myocardial Infarctions (MIs) In Open Vascular Surgery Patients: What Can Be Done To Decrease MI Incidence And Their Morbidity And Mortality When They Occur

Peter Henke, MD

4:08 – 4:13 Update On LDL-C Lowering During A Lifetime: How Low To Strive For; How Young To Start If High; How Old To Continue Statins

J. David Spence, MD (Power Point Presentation With Synched Audio)

4:14 – 4:19 DEBATE: LDL-C Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful Sherif A.H. Sultan, MD, PhD

4:20 - 4:25	DEBATE: Not So: LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients' Risk Of MI And Death Ron Waksman, MD
4:26 - 4:31	Low Dose Rivaroxaban And Aspirin Improve Survival And Decrease Major Adverse Limb Events (MALE) After Endo And Open Treatments For PAD/CLTI: From The VOYAGER RCT Sebastian E. Debus, MD Marianne Brodmann, MD
4:32 - 4:37	How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials Anthony J. Comerota, MD
4:38 - 4:43	New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimbe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For Richard Bulbulia, MD, MA
4:44 - 4:50	Panel Discussion

SESSION 32 (LECTURE HALL 1 – Bonnet Creek Ballroom) CATHETER BASED TREATMENTS OF RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; MORTALITY RISK IN STROKE PATIENTS; VASCULAR AND CARDIAC COMPLICATIONS OF COVID-19 *Moderators*: Christopher K. Zarins, MD Michael R. Jaff, DO

# UPDATE ON RENAL DENERVATION FOR HYPERTENSION

4:50 – 4:55	Current Status Of Renal Denervation For Drug Resistant Hypertension: Why The Simplicity Spyral Radiofrequency Denervation System Is Different: Status Of The SPYRAL HTN- OFF MED RCT (Versus Sham) Sahil A. Parikh, MD
4:56 – 5:01	Preop Cardiac Evaluation With CT-Based Fractional Flow Reserve (FFR <sub>CT</sub> ) And Selective Coronary Revascularization Saves Lives In Patients Undergoing Procedures For CLTI And Carotid Disease Christopher K. Zarins, MD Dainis K. Krievins, MD
5:02 – 5:07	How And Why Do Thoracic Stent-Grafts For TEVAR Negatively Affect The Heart Frans L. Moll, MD, PhD (Power Point Presentation With Synched Audio)
5:08– 5:13	Permissive Transfusion Strategies Increase Mortality And Serious Adverse Events After Major Vascular And General Surgery Operative Interventions Panos Kougias, MD, MSc
5:14 – 5:19	Vascular Complications Of COVID-19 Infections: What Is Known And Unknown: How To Diagnose And Treat Michael E. Barfield, MD
5:20 – 5:25	Cardiac Complications Of COVID-19 Infections: What Is Their Genesis: Diagnosis And Treatment Roxana Mehran, MD (Power Point Presentation With Synched Audio)
5:26 - 5:31	Panel Discussion

End of Program C

## **PROGRAM D**

(Sessions 33-42) 7:00 A.M. – 6:10 P.M. Management Of Endoleaks; More Topics Related To Thoracic And Abdominal Aortic Diseases And Their Treatment; Treatment Of Complex AAAs; Treatment Of Iliac Aneurysms; Iliac Branched Devices And Miscellaneous Topics Related To Reimbursement, Outpatient Labs, the FDA And The SVS VQI. Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

# SESSION 33 (LECTURE HALL 2 - Floridian Ballroom) PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM

Moderators: Timur P. Sarac, MD Michel Makaroun, MD

#### TO TREAT OR NOT TO TREAT TYPE 2 ENDOLEAKS

 7:00 – 7:05 Most Type 2 Endoleaks Are Benign: The Case Can Be Made That By Treating Type 2 Endoleaks The Harm And Cost Of Such Treatment Outweighs The Benefits: When If Ever Should They Be Treated; AAA Sac Behavior Predicts Late Survival After EVAR Michel M.P. Reijnen, MD, PhD

#### **TREATING TYPE 1 ENDOLEAKS**

- 7:06 7:11 Type 1A Endoleaks After EVAR Are Predictable And Preventable: How To Do So Michael J. Singh, MD
- 7:12 7:17 When And How To Use Embolization Coils To Treat Type 1A Endoleaks Successfully: When Won't Coils Work: How To Diagnose Type 1A Endoleaks Accurately Sigrid Nikol, MD

7:18 – 7:23	How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR	
	(Ch/EVAR): How To Treat Them When They Occur: When Not	
	To Treat Them	
	Konstantinos P. Donas, MD	
	(Power Point Presentation With Synched Audio)	
7:24 – 7:29	Shape Memory Technology For AAA Sac Filling: How Does It	
	Work And Why It May Be A Better Form Of EVAR	

Andrew Holden, MBChB (Power Point Presentation With Synched Audio)

#### **ROLE OF INFLAMMATION**

- 7:30 7:35 The Role Of Inflammation In Causing Late Endoleaks: How To Evaluate It And How Should It Influence Treatment Furuzan Numan, MD
- 7:36 7:42 Panel Discussion

#### SESSION 34 (LECTURE HALL 2 - Floridian Ballroom) PREVENTION OF TYPE 2 ENDOLEAKS AFTER EVAR

Moderators:	Ross Milner, MD
	Adam Beck, MD

- 7:42 7:47 A RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: Confirmed By A Japanese RCT: When And How To Do It Dominique Fabre, MD Stephan Haulon, MD (Power Point Presentation With Synched Audio)
- 7:48 7:53 With A Large IMA (> 3mm), When Should It Be Embolized; When Should It Be Revascularized And Why Piotr M. Kasprzak, MD

# TREATMENT OF TYPE 2 ENDOLEAKS AFTER EVAR

7:54 – 7:59	How Duplex Ultrasound Velocities In Type 2 Endoleaks Determine Behavior And Help In Treatment: Technical Tips Ross Milner, MD
8:00 - 8:05	Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How Best To Do It Neal S. Cayne, MD
8:06 – 8:11	Transcaval Access To AAA Sacs For Treatment Of Type 2 Endoleaks After EVAR: When And How To Do It Adam Beck, MD
8:12 – 8:17	How To Best Leverage 3D Fusion Software (GE) To Get Into The Nidus And Treat Type 2 Endoleaks: Best Embolic Agent And Value Of Transcaval Access Mark W. Mewissen, MD, RVT
8:18 - 8:23	Transgraft Approach To Treat Type 2 Endoleaks: Indications, Equipment, Advantages And Precautions James F. McKinsey, MD
8:24 - 8:29	Laser Assisted Transgraft Onyx Embolization Of Type 2 Endoleaks: Indications, Equipment And Technique Zvonimir Krajcer, MD
8:30 - 8:35	With Type 2 Endoleaks And Sac Expansion Open Sacotomy And Branch Ligation Is The Best Treatment: Why And What Precautions Are Needed To Be Sure There Is Not Occult Type 1 Leak Zachary M. Arthurs, MD
8:36 - 8:48	Panel Discussion

# SESSION 35 (LECTURE HALL 2 – Floridian Ballroom) MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INTRAMURAL HEMATOMAS (IMHs) AND THEIR TREATMENT

Moderators:	Ramon Berguer, MD, PhD Paulo E. Ocke-Reis, MD, PhD
	raulo E. Ocke-Reis, MD, FIID
8:48 - 8:53	False Lumen Area >50% Of Total Aortic Cross-Section Area At The Tracheal Bifurcation At Time Of TEVAR For TBAD Is A Predictor Of Early Death: How To Decrease This Mortality Johnny Steuer, MD, PhD
8:54 – 8:59	Results From A Global Multicenter Registry On Candy Plug In Chronic TBAD Tilo Kölbel, MD, PhD
9:00 – 9:05	Staged Hybrid Single Lumen Reconstruction Is The Best Treatment For Complex Chronic TBAD With Visceral Segment Involvement Of The Aorta: How To Do It, Advantages And Results Sherif A.H. Sultan, MD, PhD
9:06 – 9:11	Reinterventions After TEVAR For TBADs: How To Decrease Them At The Index Procedure And How Planning Helps Bijan Modarai, PhD
9:12 – 9:17	Adjunctive Peripheral And Visceral Interventions During TEVAR For Complicated TBADs: Indications, Technical Tips And Results Mark K. Eskandari, MD
9:18 – 9:23	Update On Intramural Hematoma (IMH): Etiology, Natural History And Indications For TEVAR Frank J. Criado, MD
9:24 – 9:30	Panel Discussion
9:30 - 9:42	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 36 (LECTURE HALL 2 – Floridian Ballroom) MORE ADVANCES RELATED TO LESIONS INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS AND THEIR TREATMENT

Moderators:	Rodney A. White, MD Alan B. Lumsden, MD
9:42 – 9:47	Value Of Transcranial Doppler (TCD) For TEVAR And Endo Procedures Involving The Ascending Aorta And Aortic Arch Alan B. Lumsden, MD
9:48 – 9:53	Antegrade Stent-Graft Delivery For Treating Acute Type A Dissections: When Is It Advantageous And How To Do It Ourania Preventza, MD Joseph S. Coselli, MD
9:54 – 9:59	The Pulley Effect: Endovascular Instrumentation At The Aortic Bifurcation Generates Unexpected Forces That May Tear The Aorta Martin Malina, MD, PhD
10:00-10:05	For Precise TEVAR In The Aortic Arch Rapid Pacing And Caval Occlusion Are NOT Needed: Valsalva And PEEP By Anesthesiologist Do Just As Well And Are Simple: Technical Tips Nikolaos Tsilimparis, MD, PhD
10:06-10:11	Arch Lesion Repair With Single, Double Or 3-Branched Devices: When Is Each Best And Why Gustavo S. Oderich, MD
10:12-10:17	Laser Fenestration Option For TEVAR Involving The Great Arch Branches: When Is It Better Than Branched Endografts: Technique And Results Timothy A. Resch, MD, PhD
10:18-10:26	Panel Discussion

# SESSION 37 (LECTURE HALL 2 – Floridian Ballroom) OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; NEW DEVICES FOR THEIR TREATMENT

Moderators:	Giovanni B. Torsello, MD
	Gustavo S. Oderich, MD

#### **COMPLEX AAAs AND TAAAs**

- 10:27-10:32 Open Repair Is The Best Way To Treat Short Neck, No Neck And Pararenal AAAs: Why Is This So Laurent Chiche, MD
- 10:33-10:38 Comparative Morbidity And Mortality Outcomes Of Open, Hybrid And F/B/EVAR For Type II And III TAAAs Justify Greater Use Of F/B/EVAR For These Complex Lesions Gilbert R. Upchurch, MD Salvatore T. Scali, MD Dean Arnaoutakis, MD
- 10:39-10:44 New Techniques To Improve The Open Repair Of TAAAs Laurent Chiche, MD

#### **TOPICS RELATED TO INTERESTING NEW DEVICES**

10:45-10:50 A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Early Clinical Experience And Advantages Sebastian E. Debus, MD, PhD
10:51-10:56 A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Early Clinical Experience And Advantages Sebastian E. Debus, MD, PhD
10:57-11:02 Role Of Device Engineering On Sac Regression Seen With The TREO Endograft

Michael C. Stoner, MD

- 11:03-11:08 Update On The Colt Manifold Device For TAAAs, Complex AAAs, Failed EVARs And Failed EVAS Procedures: How Does It Work And Results Piotr Szopinski, MD, PhD
- 11:09-11:17 Panel Discussion

# SESSION 38 (LECTURE HALL 2 – Floridian Ballroom) PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS

Moderators: Thomas S. Maldonado, MD Rodney A. White, MD

#### TREATMENT OF ILIAC ANEURYSMS AND IBDs

- 11:18-11:23 **DEBATE:** How Best To Treat Iliac Aneurysms In 2021: There Is Not Much Of A Need For Open Surgery Stefan Müller-Hülsbeck, MD (Power Point Presentation With Synched Audio)
- 11:24-11:29 **DEBATE:** There Is A Role For Open Surgery In The Treatment Of Iliac Aneurysms: What Is It And Technical Tips Heron E. Rodriguez, MD
- 11:30-11:35 Long-Term Experience With Cook IBD For The Treatment Of Common Iliac Aneurysms: Advantages And Limitations Giovanni B. Torsello, MD
- 11:36-11:41 Update On The Gore IBE Excluder For Treating Iliac Aneurysms And Preserving Hypogastric Artery Flow: Advantages And Limitations: From The European ICEBERG Registry Michel M.P. Reijnen, MD, PhD
- 11:42-11:47 Advantages And Limitations Of The Jotec-Cryolite Iliac Branch Device For Treating Common And Internal Iliac Artery Aneurysms Lee H. Bouwman, MD, PhD, MSc

#### UPDATE ON MULTILAYER FLOW MODULATING (MLFM) BARE STENTS

- 11:48-11:53 MLFM Bare Stent (From Cardiatis) Is A Promising Treatment For Acute Aortic Dissections: What Is The Evidence In Support Rodney A. White, MD
- 11:54-12:00 Panel Discussion
- 12:00- 1:00 Lunch Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

# SESSION 39 (LECTURE HALL 2 – Floridian Ballroom) MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; LINK TO CANCER; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE

Moderators:	Thomas S. Maldonado, MD
	Fiona Rohlffs, MD

1:00 – 1:05 A Novel New Technology (Nectero) To Slow AAA Growth; How Does It Work And Early Clinical Results Venkatesh G. Ramaiah, MD

#### AAA NECK BEHAVIOR AFTER EVAR

- 1:06 1:11 Impact Of Oversizing And Level Of Fixation (Infra Versus Supra-Renal) On Aortic Neck Behavior: How Do These Variables Affect EVAR Outcomes: From A 10-Year Study Carlos Bechara, MD
- 1:12 1:17 Aortic Neck Dilatation Is Different After F/EVAR And EVAR: What Is The Reason And Why Is It Important For Outcomes Thomas S. Maldonado, MD

1:18 – 1:23	Major Aortic Neck Dilatation Occurs Equally After EVAR And Open Repair: From The DREAM RCT: This ONLY Occurs After EVAR With Self-Expanding Endografts Jan D. Blankensteijn, MD
1:24 – 1:29	Do AAA Necks Dilate After F/EVAR For Juxtarenal AAAs: What Are The Good Or Bad Consequences For Procedural Outcomes Benjamin W. Starnes, MD
1:30 – 1:35	<b>DEBATE:</b> Low Profile Devices For EVAR Are Failing: Their Future Is Questionable Hence J.M. Verhagen, MD, PhD
1:36 – 1:41	<b>DEBATE:</b> Not So: Ovation Stent-Graft (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft Mahmoud B. Malas, MD, MHS
1:42 – 1:47	Current Status Of The Link Between EVAR And Cancer: Is It Real And What Is Its Etiology Janet T. Powell, MD, PhD
1:48 – 1:53	Presenting AAAs As Ticking Time Bombs Or Unexploded Grenades Is Wrong-Headed, Inaccurate And Harmful Frank J. Criado, MD
1:54 – 2:00	Panel Discussion
SESSION 40 (LECTURE HALL 2 – Floridian Ballroom) MORE NEW DEVELOPMENTS IN AAAs: HOW DO THEIR NECK AND SAC SIZE AND THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR AND	

EVAS; OTHER RELATED AAA TOPICSModerators:Ali F. AbuRahma, MD

Janet T. Powell, MD, PhD

## AAA NECK AND SAC THROMBUS LOAD

2:00 – 2:05	<b>DEBATE:</b> Large Amount Of AAA Sac Thrombus Promotes Morbidity With And Without Rupture: What Is The Mechanism And How To Quantitate Thrombus Load David H. Deaton, MD
2:06 – 2:11	<b>DEBATE:</b> Large Flow Lumenal Space In AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective Hence J.M. Verhagen, MD, PhD
2:12 – 2:17	Graft Infolding: A Unique EVAR Complication: How To Prevent It And How To Treat It Ashraf Mansour, MD
2:18 - 2:23	Large AAA Necks (> 29 mm) Increase Migration And Leak Risks After EVAR With Self-Expanding Endografts Due To Neck Dilatation: Not So With Anatomically Adaptive (Polymer) Sealing Endografts (Ovation) Which Are Not Followed With Neck Dilatation Hence J.M. Verhagen, MD, PhD
2:24 - 2:29	Does Doxycycline Stabilize AAA Neck Diameter: From The NTACT Trial Jon S. Matsumura, MD
2:30 - 2:35	EVAS With Sac Filling Technology (Nellix) Has Lower Late Mortality Than EVAR With Other Endografts – Especially With Large AAAs: What Is The Mechanism Thought To Be Marc L. Schermerhorn, MD
2:36 - 2:42	Panel Discussion
2:42 – 2:56	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

# SESSION 41(LECTURE HALL 2 – Floridian Ballroom)HOT AORTIC TOPICS (4 ¾ AND 5--MINUTE FAST PACED TALKS)

Moderators:	Timothy A.M. Chuter, DM
	Luis A. Sanchez, MD
2:56 – 3:01	A Large Proportion Of EVARs Are Performed On Small AAAs: What Are The Implications And What Should Be Done About It Salvatore T. Scali, MD
3:01 – 3:06	Late Delayed Renal Artery Revascularization After Inadvertent Occlusion During Complex EVAR Is Worthwhile: Collaterals Keep The Kidney Viable Although No Urine Is Produced Nikolaos Tsilimparis, MD, PhD
3:06 - 3:11	How Can A Long-Term Aortic Risk (LEAR) Model Predict Mortality And Complication Risks And Guide Surveillance: Can The Model Be Made Device Specific Ian Loftus, MD Pete Holt, MD, PhD
3:12 - 3:17	Visceral Debranching With A Simple Aortic Endograft Is The Best Way To Treat AAAs In Good Risk Patients: How To Do It Safely Guillermo A. Escobar, MD
3:18 - 3:23	Update On Maintaining Euglycemia To Decrease Spinal Cord Ischemia With Complex AAA And TAAA Repairs Jade S. Hiramoto, MD
3:24- 3:29	Incidence And Etiology Of Cerebrovascular Injuries With Acute TBADs With And Without Treatment Loay S. Kabbani, MD
3:30 - 3:35	EVAR, F/EVAR And B/EVAR Results In Females: Are There Still Differences
	Eric L.G. Verhoeven, MD, PhD
	Athanasios Katsargyris, MD

3:36 - 3:41	Update On Performing EVAR With Only IVUS Guidance To
	Decrease Radiation: Technical Tips And 3-Year Results
	Jörg Tessarek, MD

 3:42 – 3:47 Risk Factors And Late Clinical Consequences Of AAA Neck Dilatation >6 Years After EVAR With Self-Expanding Endografts: Does The Neck Keep Dilating After The Spring Is Gone: What Are The Differences Between Excluder And Endurant Endografts Hence J.M. Verhagen, MD, PhD

3:48 – 3:58 Panel Discussion

#### SESSION 42 (LECTURE HALL 2 – Floridian Ballroom) MORE SHORT HOT NEW TOPICS RELATED TO AORTIC DISEASE AND ITS TREATMENT AND MISCELLANEOUS TOPICS

Moderators:	Luis A. Sanchez, MD
	Michael L. Marin, MD

- 3:58 4:03 Impact Of Iliac Aneurysms On The Treatment Of Complex AAAs Matthew J. Eagleton, MD
- 4:04 4:09 How To Treat AAAs With Large (>34 mm Diameter) Necks: When EVAR; When F/EVAR; When Open Rabih A. Chaer, MD
- 4:10 4:15 A New Gene Family In AAA Smooth Muscle Is Related To Aneurysm Diameter And Rupture: Could It Be A Screening Tool Kak Khee Yeung, MD, PhD
- 4:16 4:21 How Should Intramural Hematomas (IMHs) In The Ascending Aorta And Arch Be Treated Jennifer L. Perri, MD, MBA Timothy A.M. Chuter, DM

4:22 – 4:27	How To Safely Stent The Large Fenestration Of A ZFEN Endograft When It Is Crossed By Struts: Indications For Doing So And Late Results Luis A. Sanchez, MD	
	Luis A. Sanchez, MD	
4:28 – 4:33	The Sandwich-Periscope Technique For Left Subclavian Revascularization With Zone 2 TEVAR: It May Be The Best Way And How To Do It Sukgu Han, MD	
4:34 - 4:39	Comparison Of Endo And Open (Carotid-Subclavian Bypass) Treatments For Subclavian Artery Stenosis And Occlusions: Safety, Durability And Costs Ali F. AbuRahma, MD	
4:40 - 4:46	Panel Discussion	
MISCELLANEOUS TOPICS		
4:46 - 4:51	Propensity Score Matching Studies: How Do They Work And What Are Their Strengths And Weaknesses Charles C. Miller, PhD	
4:52 – 4:57	The Ever Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It's Happening And Where Is It Going Sean P. Roddy, MD Robert M. Zwolak, MD, PhD	
4:58 – 5:03	How Can Vascular Surgeons Identify High Risk, High Cost Patients And Help Health Care Systems Control Costs: How To Prevent Inappropriate Treatments In These Patients Lee Kirksey, MD	

5:04 – 5:09	What Obstacles And Blows Are Vascular Surgeons And Other Vascular Specialists Facing In 2021: Will Planned Increased Reimbursement For Office And Hospital Visits Cause Decreases In Procedural Reimbursements Sean P. Roddy, MD
5:10 – 5:15	What Vascular Injury Killed Martin Luther King, Jr. And Why He Might Have Survived Today Cynthia K. Shortell, MD
5:16 – 5:21	Historical Perspective Over The Last 25 Years On FDA Approvals Of EVAR Devices Submitted By Investigators And Industry: Lessons Learned To Guide Future Applications Kenneth Ouriel, MD, MBA Dorothy B. Abel, BSBME
5:22 – 5:27	Are The Quality, Safety And Effectiveness Of Generic Drugs Equating Those Of The Patented Original Drugs: How Is The FDA Assuring Equivalence; Should The FDA Do More Valerie M. Merkle, PhD
5:28 - 5:34	Panel Discussion
5:34 – 5:39	A Balanced View Of Atherectomy In Outpatient Facilities And OBLs In 2020: Is The Procedure Overused And Why Krishna Jain, MD
5:40 – 5:45	Inherent Conflicts Of Interest In OBLs: Why They Occur And Are Bad For Patients: How To Counteract Them O. William Brown, MD, JD
5:46 – 5:51	Why And How Do Outpatient Angio Suites And OBLs Fail Sam S. Ahn, MD, MBA
5:52 – 5:57	SVS VQI – From Quality Improvement To Disruptive Technology Jens Eldrup Jorgensen, MD Jack L. Cronenwett, MD

5:58 – 6:03 Improved Outcomes Of Type A Aortic Dissections With Use Of Bare Stents (Cardiatis And Ascyrus): They Decrease Malperfusion, Promote Aortic Remodeling And Prevent Strokes: How Do They Work Ralf R. Kolvenbach, M (Power Point Presentation With Synched Audio)

6:04 – 6:10 Panel Discussion

**End of Program D** 

# THURSDAY, NOVEMBER 18, 2021

6:00 A.M. General Registration – Bonnet Creek Ballroom - North Foyer
6:00 A.M. Faculty Registration – Bonnet Creek Ballroom – Salon I
6:30 A.M. Continental Breakfast – Bonnet Creek and Floridian Ballrooms - North, West, Center and South Foyers

## **PROGRAM E**

(Sessions 43-50) 7:00 A.M. – 5:25 P.M. Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAA; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

#### SESSION 43 (LECTURE HALL 1 - Bonnet Creek Ballroom) EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES OR CONCEPTS

Moderators:	Richard F. Neville, MD
	Frank J. Veith, MD
7:00 – 7:05	Combating Bias In Medical And Vascular Studies And Therapeutic Decision Making: Why It Is Such A Big Deal And What To Do About It Matthew T. Menard, MD
7:06 – 7:11	Update On Remote Monitoring Of Vascular Grafts: Where Is It At And Where Is It Going Richard F. Neville, MD
7:12 – 7:17	Value Of Digital Health In Vascular Disease Management: Virtual And Otherwise Tony S. Das, MD
7:18 – 7:23	Vascular Surgical Risks Of Shoulder Reconstructive Surgery: What Are They And How Should They Be Managed Jacques Busquet, MD

7:24 – 7:29	Measuring Aortic Diameters Is Inaccurate And Subjective: Even With Newer Imaging Technology, One Can Make The Diameter What You Want: What Are The Implications Janet T. Powell, MD, PhD
7:30 – 7:35	The Temporary Perfuse Dual Chamber Stent-Graft For Clamp Free Aortic Surgery, Drug Delivery And Other Uses: How Does It Work Bryan W. Tillman, MD, PhD
7:36 – 7:41	Non-Compliant Endografts For TEVAR Have A Detrimental Effect On Systolic Blood Pressure And Cardiac Function; Compliant Endografts Are The Remedy Juan C. Parodi, MD Sherif A.H. Sultan, MD, PhD (This presentation will be given by Dr. Sultan)
7:42 – 7:47	Update On Isolated Limb Perfusion To Enable Amputated Limb Reimplantation Zachary M. Arthurs, MD
7:48 – 7:59	Panel Discussion
	(LECTURE HALL 1 - Bonnet Creek Ballroom) FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND AFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED
Moderators:	James F. McKinsey, MD Timothy A.M. Chuter, DM
8:00 - 8:05	Lower Extremity Ischemic Complications After F/B/EVAR: Etiology And How To Avoid Them Thomas S. Maldonado, MD
8:06 – 8:11	F/B/EVAR Treatment Of FAILED EVAR: A Safer Better Way To Treat: How Has The Aortic Research Consortium Helped To Promote Solutions To This And Other Problems Andres Schanzer, MD

8:12 - 8:17	When Is Ch/EVAR Indicated And Equally Effective To F/EVAR For Juxta And Pararenal AAAs In Terms Of Outcomes And Cost: Why Are Opinions On Ch/EVAR So Divergent Konstantinos P. Donas, MD (Power Point Presentation With Synched Audio)
8:18 - 8:23	Fenestrated EVAR: Techniques And Outcomes With Physician Modification And Their Impact On A New IDE Pivotal Study Benjamin W. Starnes, MD
8:24 - 8:29	Mortality From Aneurysm Rupture While Waiting For A Customized F/B/EVAR Endograft: Strategy To Prevent: Are There Reasons For Open Repairs In A High Volume F/B/EVAR Center Eric L.G. Verhoeven, MD, PhD
8:30 - 8:35	Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective Mark A. Farber, MD
8:36 - 8:41	What Is The Best Bridging Covered Stent (Stent-Graft) For F/B/EVAR Based On An In Vitro Fatigue Testing Model And Other Considerations Martin J. Austermann, MD (Power Point Presentation With Synched Audio)
8:42 - 8:47	How To Safely And Effectively Treat TAAAs With Off-The-Shelf (OTS) Devices Including Chimney And Sandwich Stent-Grafts: The Docking Station Approach: How To Do It And Midterm Results Manish Mehta, MD, MPH
8:48 - 9:03	Panel Discussion
9:04– 9:38	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 45 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS

Moderators:	Mark A. Farber, MD Frank J. Veith, MD
9:38 – 9:43	Percutaneous Femoral And Axillary Access For Complex Endovascular AAA Repair: How To Do It Safely And To Safely Downsize Femoral Sheaths To Restore Lower Extremity Flow Darren B. Schneider, MD
9:44 – 9:49	Present Status Of Parallel Grafts For Complex AAAs And TAAAs: How To Do These Repairs Safely And Effectively: Results To Date Armando C. Lobato, MD, PhD
9:50 – 9:55	Value And Advantages Of Preloaded Wires And Catheters For F/B/EVAR: How Do They Work; Are There Pitfalls Mark A. Farber, MD
9:56 -10:01	<b>DEBATE:</b> The Case Against Ch/EVAR And Parallel Grafts For Complex AAA And TAAA Repairs: F/B/EVAR Is Much Better Adam Beck, MD
10:02-10:07	DEBATE: Nonsense! Ch/EVAR And Parallel Grafts If Done Right Are As Safe And Effective As F/B/EVAR And In Some Cases Better And Cheaper Edward Y. Woo, MD
10:08-10:13	F/EVAR Is Sometimes Justified In Patients >80: How About >90 Clark J. Zeebregts, MD, PhD
10:14-10:19	<b>DEBATE:</b> Increasing The Number Of Fenestrations In F/EVAR Beyond 2 Improves Outcomes Without Increasing Downsides Eric L.G. Verhoeven, MD, PhD

10:20-10:25 **DEBATE:** Not So! 2 Branch F/EVAR Is Sometimes Better And Has Fewer Complications And Downsides In Some Cases: Which Ones

Timothy A. Resch, MD, PhD

10:26-10:31 Advantages Of Steerable (Variable Curve) Sheaths For Complex AAA And TAAA Repairs And TBADs: Which One Is Best And Why: Pitfalls And How To Prevent Them W. Anthony Lee, MD

10:32 – 10:42 Panel Discussion

## SESSION 46 (LECTURE HALL 1 - Bonnet Creek Ballroom) A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; INNOVATIVE TECHNOLOGIES SUPPORTED BY THE DEFENSE DEPARTMENT

<i>Moderators</i> :	Joseph J. DuBose, MD
	Todd E. Rasmussen, MD
10:42-10:54	The Vietnam Battle Of Ia Drang (November 14-16, 1965): Why Was It Fought And Why Was It Significant (12-Minute Talk) Wayne F. Yakes, MD
10:55-11:01	Department of Defense Effort To Support Vascular Surgery Research And US National Preparedness For Mass Casualties Todd E. Rasmussen, MD
11:02-11:08	Update On Endovascular Resuscitation And Control Of Bleeding: What Is New And Different: What Is The EVTM Society Tal M. Hörer, MD, PhD
11:09-11:15	Update On Civilian REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta) For Treatment Of Hemorrhage And Trauma: What Is New And Different: When And Where Should It Be Used And By Whom Joseph J. DuBose, MD

11:16-11:22	Is REBOA A Panacea For Battlefield Hemorrhage Or Not Yet Ready
	For Prime Time Use
	Brandon Propper, MD
	Zachary M. Arthurs, MD
	Todd E. Rasmussen, MD
11:23-11:29	Current Advances In The Treatment Of Blast And High Velocity
	Gun Shot Injuries
	Paul W. White, MD
11:30-11:36	Undate On The Patriovable Pascue Stant Craft To Control Massive
11.30-11.30	Update On The Retrievable Rescue Stent Graft To Control Massive Aortic Or Caval Bleeding: How Does It Work And Present Status
	Bryan W. Tillman, MD, PhD
	Di yun vv. Thinnun, ivid, Thid
11:37-11:43	Major Amputation Prosthetics Can Be Fixed Into Bone: How Does
	Osteointegration Work And How Is Infection Avoided
	Zachary M. Arthurs, MD
	Todd E. Rasmussen, MD
11:44-11:50	Update On Tissue Engineered Biological Arterial Grafts
	(Humacyte): How Well Are They Working In Patients And In
	What Vascular Bed
	Jeffrey H. Lawson, MD, PhD
11:51-12:00	Panel Discussion
12:00- 1:00	Lunch Break – Visit Exhibits And Pavilions (North, West,
	Center and South Foyers)
SESSION 47	(LECTURE HALL 1 - Bonnet Creek Ballroom)
PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS	
Moderators:	Fiona Rohlffs, MD
	Timur P. Sarac, MD
	Frank J. Veith, MD

1:00 – 1:05	Value, Limitations And Technical Tips For Using The Nellix Endograft For Ruptured AAAs Tal M. Hörer, MD, PhD
1:06 – 1:11	The Incidence Of Ruptured AAAs Is Decreasing And So Is Their Mortality: Why Are These 2 Facts So Ross Milner, MD
1:12 – 1:17	Statins Decrease The Growth Rate And Rupture Risk Of AAAs As Well As The Perioperative Mortality: Who Should Receive Them, When And At What Dose Thomas L. Forbes, MD
1:18 – 1:23	Impact Of Weekends On Treatment Method (Endo Versus Open Repair) And Outcomes (Early And Late) Of Treatment For Ruptured AAAs Sebastian E. Debus, MD, PhD
1:24 – 1:29	Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: EVAR Wins In The End – Especially In Patients >80 Willem Wisselink, MD
1:30 – 1:35	Variation In Use Of EVAR Versus Open Repair For Ruptured AAAs Depends On Training And Bias Rather Than Data Logic Or Facts: EVAR Is Clearly The Best Treatment If It Can Be Done Martin Malina, MD, PhD
1:36 – 1:41	Emergency Treatment As Aortic Rupture From Chronic TBAD Using The Candy Plug Technique: Technical Tips And Results Daniela Branzan, MD
1:42 – 1:47	EVAR Is A Better Treatment For Ruptured AAAs Than Open Repair In Most Patients: The Mortality Benefit Of EVAR Is Increasing More Recently: Based On A Meta-Analysis George A. Antoniou, MD, PhD, MSc

1:48 – 1:53	<b>DEBATE:</b> With Ruptured Complex AAAs And TAAAs, Off-The- Shelf F/B/EVAR Is The Best Treatment Mark A. Farber, MD
1:54 – 1:59	<b>DEBATE:</b> Not So: With Ruptured Complex AAAs And TAAAs Parallel Grafts Are Simpler, More Effective And Less Costly Konstantinos P. Donas, MD (Power Point Presentation With Synched Audio)
2:00 - 2:06	Panel Discussion
	(LECTURE HALL 1 - Bonnet Creek Ballroom) EVELOPMENTS IN RUPTURED AAAs AND TAAAs; WHAT IS BE HAPPENING WITH AAA SCREENING Keith D. Calligaro, MD Manish Mehta, MD, MPH
	NEW DEVELOPMENTS IN AAA SCREENING
2:06 – 2:11	Why The Current US PSTF Guidelines For AAA Screening Are Insufficient: Many At Risk Patients Are Not Screened Malachi Sheahan, MD
2:12 – 2:17	Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed Marc L. Schermerhorn, MD
2:18 – 2:23	Flaws In AAA Screening In Finland Result In AAA Ruptures In Patients Too Young For Screening And Whose AAAs Are Too Small To Reach Threshold For Repair Maarit Venermo, MD, PhD
2:24 – 2:29	Why AAA Screening Should Be Expanded To More Females, Younger Men And Older Men Thomas F.X. O'Donnell, MD

## MORE ABOUT AAA RUPTURES AND THEIR TREATMENT

2:30 – 2:35	AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures Piotr Szopinski, MD, PhD
2:36 – 2:41	Update On Treating All (100%) Ruptured AAAs With EVAR: The Orebro And Zurich Experience Shows It Is The Best Treatment And Lowers The Turndown Rate Mario L. Lachat, MD David McGreavy, MD Thomas Larzon, MD, PhD
2:42 – 2:47	Update On Status Of Retrograde And Prograde In Site Fenestration For Arch Aneurysms And TAAAs: How To Do Them Jean M. Panneton, MD
2:48 – 2:53	Open Repair For AAAs Should Not Be Used In Patients >80 Unless Their AAA Is >6 cm And They Are At Risk Of Rupture Or Ruptured: These Restrictions Do Not Apply To EVAR Hence J.M. Verhagen, MD, PhD
2:54 – 2:59	When Should Ruptured AAA Patients Be Transferred: Should They Ever Be Denied Invasive Treatment Matthew W. Mell, MD, MS
3:00 - 3:10	Panel Discussion
3:10 - 3:30	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 49 EXCITING NEV TREATMENTS	(LECTURE HALL 1 - Bonnet Creek Ballroom) W OR UPDATED CONCEPTS, TECHNIQUES AND
Moderators:	Timur P. Sarac, MD

Reese A. Wain, MD

3:30 - 3:35	<ul> <li>The No Intervention Option For Treatment Is More Commonly</li> <li>Elected For Women Than Men With CLTI, AAAs, Ruptured AAAs</li> <li>And Thoracic Aneurysms: It Is Wrong Headed And Unfair</li> <li>Janet T. Powell, MD, PhD</li> </ul>
3:36 - 3:41	Transradial Approaches For Complex Lower Extremity Interventions: CTSOs, Iliac, Fempop And BTK Lesions Can Be Treated: How To Make Them Work And Precautions: Advantages
	Of The Terumo R <sub>2</sub> P System David O'Connor, MD (Power Point Presentation With Synched Audio)
3:42 - 3:47	Transcatheter Bariatric Embolotherapy: Early And Long-Term Results From A Randomized Study Nicholas Kipshidze, MD, PhD
3:48 - 3:53	The Spur Stent System (Reflow Medical): A Temporary Stent With Pins To Penetrate The Arterial Wall And Facilitate DCB Drug Delivery: How Does It Work And Results To Date Marianne Brodmann, MD Gunnar Tepe, MD Andrew Holden, MBChB Thomas Zeller, MD
3:54 - 3:59	The Serranator Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations And Prevents Dissections With PTA: Current Status: The PRELUDE BTK Trial Andrew Holden, MBChB (Power Point Presentation With Synched Audio)
4:00 – 4:05	What Is The OR Black Box System For Measuring Endovascular Operator Performance: How Does It Work And Should It Be In Every Hybrid Angio Suite Isabelle Van Herzeele, MD, PhD

4:06 – 4:11	Update On A Clampless Sutureless Technique For Performing Aorto-Iliac Anastomosis Using Endograft Connectors: The
	VORTEC Technique – Useful When Arterial Control And Suturing
	Is Impossible Mario L. Lachat, MD
4:12 - 4:17	Technical Tips For Safe Endovascular Treatment Of Hepatic Artery
	Stenosis After Liver Transplantation
	W. Charles Sternbergh III, MD
4:18 - 4:23	Current Status Of Left Gastric Embolization To Treat Obesity:
	Where Is It And What Will Its Role Be
	Robert E. Beasley, MD
4:24 - 4:29	The Many Possible Uses Of Femoral Veins For Arterial Procedures:
	How To Harvest Them Safely
	Timur P. Sarac, MD
4:30 - 4:38	Panel Discussion
SESSION 50	(LECTURE HALL 1 - Bonnet Creek Ballroom)
PROGRESS IN	RADIATION SAFETY AND MORE NEW CONCEPTS,
<b>DEVICES ANI</b>	<b>D TECHNIQUES</b>
Moderators	Robert A. Lookstein, MD, MHCDI

*Moderators*: Robert A. Lookstein, MD, MHCDL Glenn Jacobowitz, MD

## **PROGRESS IN RADIATION SAFETY**

4:38 - 4:43	Endovascular Team Radiation Safety Performance: How To Monitor It: It Is More Than Dose Measurement Isabelle Van Herzeele, MD, PhD
4:44 – 4:49	What Is New In Radiation Safety: ESVS Radiation Safety Guidelines And Why Chromosomal Aberrations In High Volume Endovascular Operators Matters Bijan Modarai, PhD

4:50 – 4:55 Simple Radiation Protection Techniques For All Interventionalists To Use

Ripal T. Gandhi, MD

## NEW CONCEPTS, ETC.

4:56 – 5:01	Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential Michael B. Silva, Jr., MD
5:02 – 5:07	Value Of Repetitive Digital Photo Documentation Of The Ischemic Foot: It Improves Decisions And Outcomes Martin Malina, MD, PhD
5:08 – 5:13	COVID-19 Virus Has Been Identified In Periaortic Fat: What Is Its Significance Kak Khee Yeung, MD, PhD
5:14 - 5:25	Panel Discussion

## End of Program E

## **PROGRAM F**

(Sessions 51-59) 7:00 A.M. – 5:30 P.M. New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels Location: LECTURE HALL 2 - FLORIDIAN BALLROOM

#### SESSION 51 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR (5-MINUTE TALKS)

Moderators:	Kim J. Hodgson, MD
	Rossi M. Silva, MD
	Enrico Ascher, MD

- 7:00 7:05 Treo Endograft (Terumo Aortic) For Standard Infrarenal EVAR: Approval In US And Japan Matthew J. Eagleton, MD
- 7:06 7:11 Real World Outcomes With The TREO Endograft (Terumo Aortic): Preliminary Results From The TIGER Registry Vicente Riambau, MD (Power Point Presentation With Synched Audio)
- 7:12 7:17 Status In The US Of The Gore Conformable Excluder With Variable Neck Angulation Control For AAAs With Imperfect Necks Robert Y. Rhee, MD
- 7:18 7:23 Status Of The Gore Conformable Excluder For EVAR In Europe: Results From The EXCEL And BSET Registries Marc R.H.M. van Sambeek, MD, PhD Colin D. Bicknell, MD

7:24 – 7:29	When Does The Gore Conformable Excluder For EVAR Really Make A Difference: How Does It Work
	Richard G.J. Gibbs, FRCS
	Michael P. Jenkins, MBBS, BSc, MS
7:30 – 7:35	Altura Endograft With Kissing Proximal Stents For Standard
	EVAR: Advantages And Limitations: From An Experience With
	150 Patients And Up To 5-Year Follow-Up
	Dainis K. Krievins, MD
7:36 - 7:41	Advantages And Limitations Of The Cook ZENITH Alpha
7.50 7.11	Endograft For EVAR: Based On European Multicenter Experience
	Philippe W.M. Cuypers, MD, PhD
	Marc R.H.M. van Sambeek, MD, PhD
7:42 - 7:47	How And Why Do The Endurant Endograft Results For EVAR In
	France Differ From The Global Results: What Are The Implications
	Jean-Pierre Becquemin, MD
7:48 - 7:53	AAA Repairs With The Endurant Endograft Outside The IFU Can
	Provide Acceptable Results In Some Patients: When Is This So And
	When Not
	Marc R.H.M. van Sambeek, MD, PhD
7:54 – 7:59	Update On The LEOPARD RCT Results Show That AFX
7.54 - 7.59	Endografts Compare Favorably To Standard Proximally Fixed
	Endografts For AAA Repair
	Christopher J. Kwolek, MD, MBA
8:00 - 8:12	Panel Discussion
SESSION 52	(LECTURE HALL 2 - Floridian Ballroom)
	OATED DEVICES FOR STANDARD EVAR, EVAS
	JLAR ANEURYSM SEALING) AND F/EVAR

Moderators:Jerry Goldstone, MDRamon Berguer, MD, PhD

8:12 - 8:17	<ul> <li>Alto Endograft (From Endologix) For Standard EVAR: This Latest</li> <li>Modification Of The Ovation Endograft Has More Proximal</li> <li>Polymer Sealing Rings: Results From The ELEVATE Trial And</li> <li>3-4-Year Results From The New Zealand Experience Show</li> </ul>
	Advantages Sean P. Lyden, MD Andrew Holden, MBChB
8:18 - 8:23	Combination Of Ovation Endograft And Bare Metal Renal Stent For Difficult AAA Neck Unsuitable For F/EVAR Gianmarco de Donato, MD
8:24 - 8:29	Experience With The Nellix Endograft In 120 Patients With Up To 10 Years Follow-Up: What Is The Devices' Future Dainis K. Krievins, MD
8:30 - 8:35	Update On Multicenter Results With F/EVAR Using The Fenestrated Anaconda Endograft: From The Global FACT Registry: Advantages And Limitations Clark J. Zeebregts, MD, PhD Michel M.P. Reijnen, MD, PhD
8:36 - 8:41	Update On The Incraft Endograft For Standard Infrarenal EVAR: Is Its Low Profile An Advantage Matteo Orrico, MD Nicola Mangialardi, MD (Power Point Presentation With Synched Audio)
8:42 - 8:47	Long-Term Outcomes Of The Cook pBranch OTS Device For F/EVAR: Advantages And Limitations Timothy A. Resch, MD, PhD
8:48 - 8:58	Panel Discussion
8:58 - 9:24	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 53 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH

Moderators:	Michel Makaroun, MD Rodney A. White, MD
9:24 – 9:29	Nexus OTS Endograft From Endospan For Treating Zone 1 Lesions Of The Aortic Arch: How Does It Work And 2-Year Clinical Results: Status In The US Ross Milner, MD Daniel G. Clair, MD Andrew Holden, MBChB
9:30 – 9:35	Outcomes Of The Custom Relay Ascending Aorta Endograft (Terumo Aortic): The European Experience Vicente Riambau, MD, PhD Afshin Assadian, MD Mo S. Hamady, MD (Power Point Presentation With Synched Audio)
9:36 – 9:41	Status In The US Of The RelayBranch Investigational Device For Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations Luis A. Sanchez, MD Eric E. Roselli, MD
9:42 – 9:47	Long-Term Safety And Durable Effectiveness Of Relay (Terumo Aortic) Scalloped Endograft For TEVAR Treatment Of Lesions In Or Near The Aortic Arch Mo S. Hamady, MBChB Jean-Marc Alsac, MD, PhD (Power Point Presentation With Synched Audio)
9:48 – 9:53	Status In The US Of The Gore Conformable CTAG Endograft With Variable Angulation Control In The Aortic Arch: How Does It Work And Advantages Jean Bismuth, MD

9:54 - 9:59	When And How To Use The Gore Conformable CTAG Endograft
	Optimally: Are There Downsides
	Sukgu Han, MD

- 10:00-10:05 Indications, Value And Limitations Of Single Branched TEVAR Devices For Revascularizing The Left Subclavian Artery: Are They Worth The Effort And Cost Gustavo S. Oderich, MD
- 10:06-10:15 Panel Discussion

#### SESSION 54 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED DEVICES FOR THORACIC AORTIC LESION REPAIRS (TEVAR) AND FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS (ALL TALKS ARE 4 ¾-MINUTES)

Moderators: Giovanni B. Torsello, MD James F. McKinsey, MD

#### **DEVICES FOR TEVAR**

10:15-10:20	Low Profile Devices For TEVAR: Advantages And Disadvantages Based On Long-Term Results Giovanni B. Torsello, MD
10:20-10:25	6-Year Experience With The Cook ZENITH Alpha Thoracic Endograft For TEVAR In 400 Patients: How To Achieve Long- Term Durably Good Results Germano Melissano, MD Roberto Chiesa, MD (Power Point Presentation With Synched Audio)
10:25-10:30	Long-Term Outcomes Of TEVAR For Repair Of Traumatic Aortic Injuries From The RESCUE U.S. IDE Clinical Trial Ali Azizzadeh, MD
10:30-10:35	Endoanchors To Improve Outcomes With TEVAR: They Can Help Distally As Well As Proximally Ross Milner, MD

10:35-10:40	Tips And Tricks Of Endoanchors Application After TEVAR (TESAR)
	Giovanni G.T. Tinelli, MD, PhD
	Yamume Tshomba, MD
10:40-10:46	Panel Discussion
10:46-10:51	The Relay Pro (Terumo Aortic) Endograft For TEVAR And Its Advantages In Treating TBADs: Why Is It Better Than The Older Relay Plus Device Edward Y. Woo, MD Steven D. Abramowitz, MD
10:51-10:56	Patient Specific Custom Designed Relay Pro Endografts (Terumo Aortic): How Do They Work And What Are Their Advantages In Various Circumstances David M. Williams, MD
10:56-11:01	Relay Endografts (Terumo Aortic) For TEVAR: Why Do They Provide Better Wall Apposition For Sealing Fadi Taher, MD Afshin Assadian, MD (Power Point Presentation With Synched Audio)
11:01-11:06	European Experience With The Gore CTAG Conformable Endograft For TEVAR With Variable Angulation Control Proximally: When And How Does It Improve Results Vicente Riambau, MD, PhD (Power Point Presentation With Synched Audio)
11:06-11:11	New Polymer Filled Low Profile Endograft Device With O-Ring Sealing: How Does It Work And Why Is It Better Piotr Szopinski, MD, PhD
11:11-11:17	Panel Discussion

## NEW OR IMPROVED ENDO DEVICES FOR TAAA REPAIRS

11:17-11:22	To Treat Complex TAAAs A Combination Of A Relay (Terumo) TEVAR And A Fenestrated Anaconda Is Best: How Are The SMA And Celiac Axis Revascularized Mo Hamady, MBChB
11:22-11:27	Status Of The Cook t-Branch OTS Endograft For TAAA Repairs: Advantages And Limitations Based On A Meta-Analysis Nikolaos Tsilimparis, MD, PhD
11:27-11:32	Comparison Of 3 OTS Endografts For Urgent TAAA Repairs: TAMBE (Gore) Versus E-nside (Jotec) Versus t-Branch (Cook): Advantages And Disadvantages Of Each Luca Bertoglio, MD Germano Melissano, MD Roberto Chiesa, MD (Power Point Presentation With Synched Audio)
11:32-11:37	Valiant Manifold OTS Endograft (Medtronic) Device For Repairing TAAAs: How Does It Work And Early Clinical Experience In The US Murray L. Shames, MD
11:37-11:42	Unitary Manifold Endograft System For Complex Type 4 TAAAs And Failed EVARs: How Does It Work And 2-Year Results Patrick W. Kelly, MD
11:42-11:47	Novel OTS Life Tech Endograft For TAAA Repair: How Does It Work And What Makes It Different Ralf R. Kolvenbach, MD (Power Point Presentation With Synched Audio)
11:48-12:00	Panel Discussion
12:00- 1:00	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 55 (LECTURE HALL 2 - Floridian Ballroom) NEW OR UPDATED INFORMATION ON BALLOON EXPANDABLE COVERED STENTS, LOWER EXTREMITY PROSTHETIC GRAFTS, BIORESORBABLE GRAFTS, PERIGRAFT SEROMA AND VALUE OF A PROSTHETIC PERIGRAFT SIROLIMUS PATCH [SEE ALSO SESSION 28] ALL TALKS ARE 5 MINUTES)

Moderators:	Ali F. AbuRahma, MD
	Patrick J. Lamparello, MD

#### **STENT-GRAFTS**

1:00 – 1:05	Why Are VBX Balloon Expandable Stent-Grafts (From Gore)
	Different And Better Than Other Covered Stents In Various
	Vascular Beds
	James F. McKinsey, MD

1:06 – 1:11 Safety Of MRI Early After Deployment Of Various Covered Stents Maria Antonella Ruffino, MD

#### **PROSTHETIC GRAFTS**

1:12 – 1:17	Final 3-Year Results Of The ZILVERPASS RCT Comparing
	Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat
	Long Fempop Lesions: Should Open Prosthetic Bypass Be
	Abandoned
	Michel J. Bosiers, MD
	Marc Bosiers, MD

- 1:18 1:23 The 3DH Spiral Flow Prosthetic Graft: Does It Prevent Neointimal Hyperplasia In Leg Bypasses Or A-V Access Hosam F. El Sayed, MD
- 1:24 1:29 Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: Are The Heparin Coated Grafts Worth The Cost David J. Dexter, MD

1:30 - 1:35	Bioabsorbable Arterial Grafts (Xeltis Grafts): How Do They Work And What Is Their Potential Frans L. Moll, MD, PhD (Power Point Presentation With Synched Audio)
1:36 – 1:41	Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology And What To Do About Them Jae S. Cho, MD

- 1:42 1:47 Update On External Sirolimus Patch Wrap-Around For PTFE Graft Anastomoses: Do They Decrease Neointimal Hyperplasia Sriram S. Iyer, MD
- 1:48 1:54 Panel Discussion

## SESSION 56 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, TACKS, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)

Moderators:	Kenneth Ouriel, MD, MBA
	Enrico Ascher, MD

#### ATHERECTOMY RELATED TOPICS

1:54 – 1:59	Complications Of Atherectomy: How To Prevent Some, How To Treat The Others Theodosios Bisdas, MD
2:00 – 2:05	Value And Limitations Of 355 nm Auryon B-Laser™ (From AngioDynamics): It Enables Safe Crossing Of Difficult Lesions Not Crossed With A Guidewire: How Does It Work And Clinical Results
	Luis R. Leon, Jr., MD, RVT
2:06 - 2:11	Orbital And Laser Atherectomy: Indications, Advantages And
	Precautions With Above Knee BTK De Novo Lesions And ISR
	Craig M. Walker, MD

2:12 – 2:17 Value Of Atherectomy And DCBs: Interim Results Of The REALITY Trial Brian G. DeRubertis, MD

#### **ANCILLARY TECHNIQUES**

- 2:18 2:23 Value of Wingman Catheter (Reflow Medical) For Crossing Difficult Lesions: How Does It Work And Results John R. Laird, MD
- 2:24 2:29 Value of New Dedicated Special Tools And Devices To Facilitate Trans-Radial Access For Lower Extremity Lesion Treatments: How Far Distally Can It Be Effective Ramon L. Varcoe, MBBS, MS, PhD

#### **NEW INFORMATION ON STENTS**

- 2:30 2:35 Advantages Of Supera (Vasculomimetic VMI) Stent For Complex Fempop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position Erwin Blessing, MD
- 2:36 2:41 Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 2-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery)

Brian G. DeRubertis, MD

- 2:42 2:52 Panel Discussion
- 2:52 3:18 Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 57 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ANGIOPLASTY BALLOONS

Moderators: John R. Laird, MD Kenneth Ouriel, MD, MBA

3:12 - 3:17	Chocolate Touch DCBs (From TriReme Medical): How Do They Work, Advantages And Updated Clinical Results Andrew Holden, MBChB (Power Point Presentation With Synched Audio)
3:18 – 3:23	Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: The Chocolate DCB Is One Way Jos C. van den Berg, MD, PhD
3:24 - 3:29	Update On The TANGO Trial Using The Bullfrog Balloon Device (Mercator Medical Systems) To Inject Sirolimus Drug Into Lesion Wall Before Angioplasty: How Does It Work And Results Ehrin Armstrong, MD (Power Point Presentation With Synched Audio)
3:30 - 3:35	The Importance Of Dissection In Angioplasty Treatment Of BTK Lesions: How To Prevent And Treat Such Dissections: The Value Of Tacks (From Intact Vascular): How Do They Work Andrew Holden, MBChB (Power Point Presentation With Synched Audio)
3:36 - 3:41	24-Month Results Of TOBA II BTK Trial Of The Tack Device To Decrease Dissections With Balloon Angioplasty Of BTK Lesions Show Safety And 94.7% Target Limb Salvage Patrick J. Geraghty, MD
3:42 - 3:49	Panel Discussion
	(LECTURE HALL 2 - Floridian Ballroom) ROVED DEVICES AND TECHNIQUES TO PREVENT OR LEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.

Moderators:William D. Jordan Jr., MDJean M. Panneton, MD

3:49 – 3:54	Prophylactic Endoanchors (Medtronic) With TEVAR For Complex Anatomy Improves Outcomes: Technical Tips For Their Use In TEVAR Jean M. Panneton, MD
3:55 – 4:00	New Developments From The ANCHOR Registry With Over 5 Years Of Follow-Up Show The Value Of Endoanchors When Used Prophylactically For Certain Indications Prevent Endoleaks And Migration: What Are Those Indications William D. Jordan Jr., MD
4:01 – 4:06	New Developments From The ANCHOR Registry With >5 Years Follow-Up Show That Endoanchors Can Be Used To Treat Endoleaks And Migration Effectively In Hostile Neck Anatomy: The Proof Jean-Paul de Vries, MD, PhD (Power Point Presentation With Synched Audio)
4:07 – 4:12	Vesteck – The Next Generation Of Endoanchor Technology: How Does It Work And Where Does It Stand David H. Deaton, MD
4:13 - 4:18	Balloon Optimized Molding For Better Deployment And Sealing Of Ovation Alto Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks and Migration David J. Minion, MD
4:19 - 4:25	Panel Discussion

## SESSION 59 (LECTURE HALL 2 - Floridian Ballroom) NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)

Moderators: James F. Benenati, MD Neal S. Cayne, MD

#### **CLOT REMOVING DEVICES**

4:25 – 4:30	Percutaneous Embolectomy Or Thrombectomy With The Indigo System (From Penumbra): What Makes It Different, Technical Tips, Results And Limitations David J. Dexter, MD
4:31 - 4:36	Newer Pharmaco-Mechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use Guillermo A. Escobar, MD
4:37 – 4:42	Catheter Based Vacuum Assisted Thrombectomy For Acute Limb Ischemia: How Does It Work: Advantages And Limitations: From A Multicenter Study: Key Findings From The INDIAN Trial Gianmarco de Donato, MD Carlo Setacci, MD
	VASCULAR OCCLUSIVE DEVICES

4:43 – 4:48	Technical Tips For Effective Coil Embolization: Importance Of Dense Packing; Coils With Fibers Versus Plain Metal Coils; Value And Indications For Different Coils James F. Benenati, MD
4:49 – 4:54	Constantino Pena, MD Why Ruby Coils, The Penumbra Occlusion Device (POD) And Decking Coils Have Different Uses And Why They Are Valueble

- Packing Coils Have Different Uses And Why They Are Valuable And Cost Effective For Different Lesions: Technical Tips For Optimizing Sean P. Lyden, MD
- 4:55 5:00 Caterpillar<sup>™</sup> Embolic Plug (From Bard): How Does It Work: Advantages And Clinical Results Andrew Holden, MBChB (Power Point Presentation With Synched Audio)

5:01 – 5:06	How To Treat Type 1A Endoleaks With Ruby Coils: When Will They Work; When Will They Not: Technical Tips Mazin Foteh, MD
5:07 – 5:12	How To Insert Large Vessel Embolization Devices (PODs) Through Low Profile Access Frank R. Arko, MD
5:13 – 5:18	Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting Juan C. Parodi, MD Sherif A.H. Sultan, MD, PhD (This presentation will be given by Dr. Sultan)
5:19 - 5:30	Panel Discussion

# End of Program F

#### **PROGRAM G**

(Sessions 60-69) 8:00 A.M. – 5:50 P.M. *Superficial Venous Disease* Course Leaders: Jose I. Almeida, MD, Lowell S. Kabnick, MD, Thomas W. Wakefield, MD and Steve Elias, MD **Location**: LECTURE HALL 3 - WALDORF ASTORIA GRAND BALLROOM A

#### SESSION 60 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) VENOUS CLINICAL EXAMINATION AND HEMODYNAMICS

- Moderators: Jose I. Almeida, MD, RPVI, RVT Lowell S. Kabnick, MD Thomas W. Wakefield, MD Steve Elias, MD
- 8:00 8:04 Introduction To Veins At VEITH Jose I. Almeida, MD, RPVI, RVT
- 8:05 8:10 AVF CEAP Revision 2020 Marc A. Passman, MD
- 8:11 8:16 CEAP, VCSS, HASTI: Their Significance And How To Utilize Lowell S. Kabnick, MD
- 8:17 8:22 Physiology Of Venous Return Brajesh K. Lal, MD
- 8:23 8:28 Status Of The Evidence For C2 Intervention Peter Gloviczki, MD
- 8:29 8:34 An Algorithm To Predict Disease Severity In C2 Patients Mikel Sadek, MD
- 8:35 8:40 Evidence Summary On The Pathophysiology Of Varicose Veins Thomas W. Wakefield, MD
- 8:41 8:46 CVD: A Clinical Approach Algorithm Seshadri Raju, MD

8:47 - 8:52	Non-Venous Causes Of The Swollen Extremity Andrea T. Obi, MD
8:53 – 8:58	Quality Of Life Tools Reflect Disease Severity, But They Can Be Improved Alun H. Davies, MA, DM, DSc
8:59 - 9:04	Panel Discussion
SESSION 61 VENOUS IMAC Moderators:	<b>(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A)</b> GING AND BIOLOGY Raghu Kolluri, MD Steve Elias, MD
9:05 – 9:10	1470mm Laser And Wound Care Trial Lorena Grillo, MD
9:11 – 9:16	Are They Venous Ulcers Raghu Kolluri, MD
9:17 – 9:22	Ambulatory Venous Pressure, Air Plethysmography, And The Role Of Calf Venous Pump In Chronic Venous Disease Seshadri Raju, MD
9:23 - 9:28	Does Deep Venous Reflux Matter With Superficial Ablation Peter Henke, MD
9:29 - 9:34	Value Of Coordinated Registry Network: Information Obtained Steve Elias, MD
9:35 - 9:40	Understanding Venous Physiology Helps Guide Therapy Fedor Lurie, MD
9:41 – 9:46	Panel Discussion

SESSION 62 SUPERFICIAL Moderators:	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) VEIN TREATMENT STRATEGIES AND TECHNIQUES Glenn Jacobowitz, MD
	Alun H. Davies, MA, DM, DSc
9:47 – 9:52	Results Of Randomized Controlled Trial MOCA Versus Cyanoacrylate Alun H. Davies, MA, DM, DSc
9:53 – 9:58	"Choosing Wisely" Items For Chemical Or Thermal Ablation In The Treatment Of The Incompetent Saphenous Veins And Recurrence Claudine Hamel-Desnos, MD

- 9:59 -10:04 What Drugs Do I Recommend For Symptomatic Venous Disease Jorge H. Ulloa, MD
- 10:05-10:10 Ablative Procedures And Cost Effectiveness Alun H. Davies, MA, DM, DSc
- 10:11-10:16 SVT Treatment During Pregnancy: Treatment Choices Ellen D. Dillavou, MD
- 10:17-10:22 Vein Histopathology: 5.5 Years After Cyanoacrylate Closure Jose I. Almeida, MD, RPVI, RVT
- 10:23-10:28 Saphenous Ablation On Anticoagulation: Is It Safe, Effective And Durable Glenn Jacobowitz, MD
- 10:29-10:34 Panel Discussion
- 10:35 10:50 Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 63 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) THERMAL AND NON-THERMAL ABLATION – PART 1

Moderators:	Lowell S. Kabnick, MD Kursat A. Bozkurt, MD
10:50-10:55	Decision Making In Saphenous Ablation: What To Use When Ellen D. Dillavou, MD
10:56-11:01	HIFU: Is It Ready For Prime Time Mark S. Whiteley, MD
11:02-11:07	Tips, Tricks And Limitations: HIFU Mark S. Whiteley, MD
11:08-11:13	Tips, Tricks And Limitations: Perforator Ablation Steve Elias, MD
11:14-11:19	Tips, Tricks And Limitations: Varithena Edward G. Mackay, MD
11:20-11:25	Tips, Tricks, And Limitations: Laser Truncal Ablation Lowell S. Kabnick, MD
11:26-11:31	Panel Discussion
<b>SESSION 64</b> <b>THERMAL AN</b> <i>Moderators</i> :	<b>(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A)</b> <b>D NON-THERMAL ABLATION – PART 2</b> Alan M. Dietzek, MD, RPVI Gutenburg Gurgel, MD, MSc
11:32-11:37	Tips, Tricks, And Limitations: Liquid Sclerotherapy Victor M. Canata, MD, PhD
11:38-11:43	Tips, Tricks And Limitations: Clarivein Steve Elias, MD

11:44-11:49	Tips, Tricks And Limitations: VenaSeal Alun H. Davies, MS, DM, DSc
11:50-11:55	Tips, Tricks And Limitations: Radiofrequency Ablation Alan M. Dietzek, MD, RPVI
11:56-12:01	Tips, Tricks And Limitations: Brazilian Phlebectomy Gutenburg A. Gurgel, MD, MSc
12:02-12:07	Tips, Tricks And Limitations: Phlebogrif Lorena Grillo, MD
12:08-12:13	Safety And Efficacy Of Endovenous Ablations InOctogenarians, Nonagenarians, And Centenarians Anil P. Hingorani, MD Enrico Ascher, MD
12:14-12:20	Panel Discussion
12:20 - 1:15	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 65 SPIDER VEINS TREATMENT	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) 5, TRUNCAL VEINS, TRIBUTARY VEINS, EXOTIC VEIN
Moderators:	Kathleen D. Gibson, MD Edward G. Mackay, MD
1:15 – 1:20	Foam Therapies (PCF Versus PEM): When To Use And Does It Make A Difference Edward G. Mackay, MD
1:21 – 1:26	Patient Preferences For Thermal Ablation Versus Non-Thermal, Non-Tumescent Varicose Vein Treatments: A Choice-Based Conjoint (CBS) Analysis
	Peter J. Pappas, MD

1:27 – 1:32	Randomized Controlled Study Of EVLA And Foam In the SSV- Fovelass Study: 3-Year Results Claudine Hamel-Desnos, MD
1:33 – 1:38	CLACS In Paraguay Results Of The Aesthetic Phlebology Trial Victor M. Canata, MD, PhD
1:39 – 1:44	Superficial Ablation Outcomes (5 Years) In 13,000 Patients Peter J. Pappas, MD
1:45 – 1:50	Labial Varices: Choices And How I Do It Ellen D. Dillavou, MD
1:51 – 1:56	Which Saphenous Vein Recanalization Should Be Treated Kathleen D. Gibson, MD
1:57 – 2:02	Is Combination Therapy Laser And Sclerotherapy More Efficacious For Telangiectatic Treatment Gutenberg A. Gurgel, MD, MSc
2:03 - 2:08	Concomitant Versus Staged Tributary Treatment Kathleen D. Gibson, MD
2:09 – 2:14	Panel Discussion
<b>SESSION 66</b> <b>VENOUS SO</b> <i>Moderators</i> :	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) CIETAL AND GOVERNANCE Kathleen J. Ozsvath, MD Harold J. Welch, MD
2:15 - 2:20	CMS And Commercial Policy Update On Non-Thermal Ablation Harold Welch, MD
2:21 – 2:26	The Future Of Venous Reimbursement In A Non-Fee For Service Environment Thomas F. O'Donnell, Jr., MD

2:27 – 2:32	Can We Use The Data From VQI VVR To Advocate For Coverage Of Venous Procedures Nicholas H. Osborne, MD, MS
2:33 – 2:38	Results Of Appropriateness Criteria (AVF) I Kathleen J. Ozsvath, MD
2:39 – 2:44	Results Of Appropriateness Criteria (AVF) II Kathleen J. Ozsvath, MD
2:45 – 2:50	Ground Zero On 9/11: What Did We Learn Mark A. Adelman, MD
2:51 – 2:56	Focused Practice Designation – Venous Disease Treatment Brajesh K. Lal, MD
2:57 - 3:02	From The AVF And SVS: EHIT Recommendations Lowell S. Kabnick, MD
3:03 - 3:12	Panel Discussion
SESSION 67 MORE SUPERI Moderators:	<b>(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A)</b> FICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES Jose I. Almeida, MD, RPVI, RVT Anil P. Hingorani, MD
3:13 - 3:18	Risk Factors For EHIT And Recanalization: An Analysis Of 10,000 Patients Anil P. Hingorani, MD
3:19 - 3:24	Ablation Outcomes In Obese Patients Peter J. Pappas, MD
3:25 - 3:30	Venolymphatic Edema And Its Treatment Options Raghu Kolluri, MD

3:31 - 3:36	Radiofrequency Ablation Increases The Incidence Of Endothermal Heat Induced Thrombosis Anil P. Hingorani, MD
3:37 – 3:42	Varithena® VLU Registry: The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence Raghu Kolluri, MD
3:43 - 3:48	Saphenous Incompetence With Post-Thrombotic Deep Veins Jose I. Almeida, MD, RVT, RPVI
3:49 - 3:54	European College Of Phlebology Guideline for Truncal Ablation Kursat A. Bozkurt MD
3:55 - 4:00	Varicose Veins Among Klippel Trenaunay Syndrome: What You Should Know About Byung-Boong (B.B.) Lee, MD
4:01 – 4:10	Panel Discussion
4:10 - 4:25	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 68 VENOUS CLIN STRATEGIES	(LECTURE HALL 3 - Waldorf Ballroom A) ICAL TRIALS; LYMPHATIC AND VEIN TREATMENT
Moderators:	Peter Gloviczki, MD Mark H. Meissner, MD
4:25 – 4:30	What Articles Are JVS-VL Looking For and How Can You Write A Paper That Will Be Accepted And Published Peter Gloviczki, MD
4:31 – 4:36	Unilateral, Bilateral, Staged Endovenous Ablation – VQI Data Nicholas H. Osborne, MD, MS

4:37 - 4:42	Is Saphenous Vein Stripping A Cost-Effective Treatment Lourdes Reina, MD
4:43 – 4:48	The Recalcitrant Ulcer: Our 52-Week Analysis Thomas F. O'Donnell, Jr., MD
4:49 – 4:54	Correlation Amongst Transabdominal/Transvaginal Duplex Versus Venography For Pelvic Venous Insufficiency And Leg Varicosities Lourdes Reina, MD
4:55 – 5:00	Treating Low And Moderate Severity Venous Disease Is Beneficial – Data From The VQI VVR Nicholas H. Osborne, MD, MS
5:01 – 5:06	What Venous Trials Do We Need Mark H. Meissner, MD
5:07 - 5:12	Panel Discussion
SESSION 69 LIPEDEMA, LY	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) MPHEDEMA, PHLEBOLYMPHEDEMA
	<b>(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A)</b> <b>MPHEDEMA, PHLEBOLYMPHEDEMA</b> Thomas F. O'Donnell, Jr., MD Steven M. Dean, DO
LIPEDEMA, LY	<b>MPHEDEMA, PHLEBOLYMPHEDEMA</b> Thomas F. O'Donnell, Jr., MD
<b>LIPEDEMA, LY</b> <i>Moderators</i> :	Thomas F. O'Donnell, Jr., MD Steven M. Dean, DO Diagnosis Of Lipedema And Treatment
<b>LIPEDEMA, LY</b> <i>Moderators</i> : 5:13 – 5:18	<ul> <li>MPHEDEMA, PHLEBOLYMPHEDEMA</li> <li>Thomas F. O'Donnell, Jr., MD</li> <li>Steven M. Dean, DO</li> <li>Diagnosis Of Lipedema And Treatment Steven M. Dean, DO</li> <li>Overview Of Lymphatic Anatomy, Physiology And Imaging Techniques</li> </ul>

- 5:37 5:42 Advanced Pneumatic Compression: Continued Improvement In Quality Of Life Thomas S. Maldonado, MD
- 5:43 5:50 Panel Discussion

# **End of Program G**

#### **PROGRAM H**

(Sessions 70-72) 7:45 A.M. – 12:10 P.M. *Cerebrovascular Disease And Its Treatment* Course Leader: Allan L. Brook, MD **Location**: LECTURE HALL 4 - FLORIDIAN BALLROOM, SALON H

#### SESSION 70 (LECTURE HALL 4 - Floridian Ballroom) STROKE 2021 INCLUDING COVID

- Moderators:Allan L. Brook, MDJoshua A. Hirsch, MD7:45-7:50Introduction
  - Allan L. Brook, MD
- 7:51 8:01 Lessons Learned On Patient Selection For Acute Stroke Treatment Michael D. Hill MD
- 8:02 8:12 Innovative And Novel Stroke Therapies That Are In The Pipeline Michael D. Hill MD
- 8:13 8:23 COVID-19 Overview Of What Happened Seon-Kyu Lee, MD, PhD
- 8:24 8:34 Long-Term Effects Of Stroke: COVID-19 Is Here To Stay Reade A. De Leacy, MBBS
- 8:35 8:45 How CSC/Organized Medicine Helped Prepare Us For The COVID Onslaught Ansaar T. Rai, MD
- 8:45 8:50 Collateral Physiologic Flow: Our Friends And Our Foes Allan L. Brook, MD
- 8:50 9:00 Panel Discussion
- 9:00 9:10 Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

# SESSION 71 (LECTURE HALL 4 - Floridian Ballroom) CAROTIDS AND REVASCULARIZATION

Moderators:	Evan C. Lipsitz, MD, MBA
	Joshua A. Hirsch, MD
9:11 – 9:21	Carotid Revascularization: Observations Of Change Over The Course Of A Career Adnan H. Siddiqui, MD L. Nelson Hopkins, MD (Power Point Presentation With Synched Audio)
9:22 – 9:33	Medical Management Of Carotid Disease Michael D. Hill, MD
9:33 - 9:43	TCAR: Technical Pearls: Why It's The Latest Trending Vascular Procedure Mahmoud B. Malas, MD, MHS
9:44 – 9:54	TCAR: Why Not Just Do An Endarterectomy Marc L. Schermerhorn, MD
9:55-10:05	Pooled Analysis With Greater Power From The CREST And ACT I Trials With Asymptomatic Patients Clarifies The CREST Conclusion: Sex Makes No Difference Between CEA And CAS While Oldest Age Group Demonstrates Worse Results With CAS Jon S. Matsumura, MD Bret M. Hanlon, MD
10:06-10:30	Panel Discussion
10:30-10:40	Break - Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 72 (LECTURE HALL 4 - Floridian Ballroom) INTRACRANIAL HEMORRHAGE

Moderators:	Allan L. Brook, MD Joshua A. Hirsch, MD
10:40-10:50	Hemicraniectomy: Why It Is Not A Lost Art, And Benefits Adam S. Arthur, MD
10:51-11:01	Devices Are The Next Generation Of Aneurysm Treatment Or Is It Prevention Ajay K. Wakhloo, MD, PhD
11:02-11:12	Intrasaccular Devices: Overview And Indications David J. Altschul, MD
11:13-11:23	Unruptured Aneurysms: Why Do We Treat These James Milburn, MD
11:24-11:34	Intracranial Hemorrhage: Open Or Closed Treatment-Decision Tree Brian L. Hoh, MD
11:35-11:45	Sub-Dural Hemorrhage Endovascular Therapy: Trials And Tribulations Adam S. Arthur, MD
11:46-11:56	Cerebrovascular Vascular Malformation Classification And Management Decisions Wayne F. Yakes, MD
11:57-12:10	Panel Discussion
12:11- 1:00	Lunch – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

# End of Program H

# FRIDAY, NOVEMBER 19, 2021

6:00 A.M. General Registration – Bonnet Creek Ballroom – North Foyer
6:00 A.M. Faculty Registration – Bonnet Creek Ballroom – Salon I
6:15 A.M. Continental Breakfast – Bonnet Creek Ballroom – North, West, Center and South Foyers

#### **PROGRAM I**

(Sessions 73-80) 7:00 A.M. - 4:45 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), Carotid Clot And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care Location: LECTURE HALL 1 - BONNET CREEK BALLROOM

#### SESSION 73 (LECTURE HALL 1 - Bonnet Creek Ballroom) PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS

Moderators:	Richard P. Cambria, MD Christian D. Etz, MD
7:00 – 7:05	A Multidisciplinary Approach To Prevent SCI During Endovascular TAAA Repairs Patrick W. Kelly, MD
7:06 – 7:11	Strategies To Minimize Paraplegia After TAAA Repairs: How A Biomarker Can Help Bijan Modarai, PhD Adam Beck, MD

7:12 – 7:17	Cerebrospinal Fluid (CSF) Drainage (To Decrease SCI) Is Not A Benign Procedure: Why: When Not And When To Use It Gustavo S. Oderich, MD (Power Point Presentation With Synched Audio)
7:18 – 7:23	SCI Is More Severe And Resolves Less When Routine CSF Drainage Is Used With TAAA Repairs: When Should It Be Used Selectively And With What Precautions Adam Beck, MD
7:24 – 7:29	Near Infrared Spectrometry (NIRS) Monitoring Is Helpful In Decreasing SCI With TAAA Repairs: How To Do It: Why Is There Controversy Carlos H. Timaran, MD
7:30 – 7:35	Current Strategies To Minimize SCI With TAAA Repairs, Endo And Open: Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Status Of PAPA-ARTIS RCT Christian D. Etz, MD, PhD
7:36 – 7:41	Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair Daniela Branzan, MD Christian D. Etz, MD, PhD Andrej Schmidt, MD
7:42 – 7:50	Panel Discussion

#### SESSION 74 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS WITH MESH COVERED STENTS AND TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION (TCAR)

Moderators:Frank J. Veith, MDKlaus D. Mathias, MD

# MESH COVERED STENTS

7:50 – 7:55	Long-Term Results Of Micromesh Stents Show Their Value In
	Carotid Artery Stenting (CAS): Are There Limitations: Do The
	Differences In The 3 Micromesh Stents Matter
	Max Amor, MD
	(Power Point Presentation With Synched Audio)
7:56 – 8:01	Advantages And Limitations Of Mesh Covered Stents In CAS: Are They Really Better
	Laura Capoccia, MD, PhD
8:02 - 8:07	7-Year Experience With Micromesh Stents For CAS: Are There Downsides (Thrombosis Or ISR): Technical Tips To Optimize
	Their Results
	Stefan Müller-Hülsbeck, MD
	(Power Point Presentation With Synched Audio)
8:08 - 8:13	New Multicenter Data Showing The Long-Term Value Of The
	C-Guard Micronet Mesh Covered Stent For CAS In High Risk
	Carotid Lesions (Thrombotic, Calcified And Symptomatic) From
	The Flow-Guard And Other Trials
	Piotr Musialek, MD, DPhil
	D. Christopher Metzger, MD

# TCAR RELATED TOPICS

Matched SVS VQI Study: 1-Year Results Show Equal Str Rates And Decreased Cranial Nerve Injuries With TCAR Also Confirmed By A Meta-Analysis Mahmoud B. Malas, MD, MHS	sity
Also Confirmed By A Meta-Analysis	ke/Death
	: Findings
Mahmoud B. Malas, MD, MHS	
Marc L. Schermerhorn, MD	

8:20 – 8:25	TCAR Versus Transfemoral CAS (TFCAS): A Propensity Matched SVS VQI Study Shows That TCAR Has Lower Stroke And Death Rates Than TFCAS Marc L. Schermerhorn, MD Mahmoud B. Malas, MD, MHS Vikram S. Kashyap, MD
8:26 – 8:31	Why I Am Uncertain That TCAR Will Have Better Outcomes Than TFCAS: What Does The CREST 2 Registry Show Thomas G. Brott, MD William A. Gray, MD Giancarlo Biamino, MD, PhD
8:32 - 8:37	<b>DEBATE:</b> For TFCAS Reversal Or Cessation Of Flow With The Gore Or MoMA Device Cerebral Embolic Protection Is No Better Than Filter Protection: Why Is This So Marc L. Schermerhorn, MD
8:38 - 8:43	DEBATE: Not So: In Some Specific Circumstances Reversal Or Cessation Of Flow Protection During TFCAS Is Better And Safer Than Filter Protection William A. Gray, MD Giancarlo Biamino, MD, PhD
8:44 - 8:49	Based On Data To Date When Should TCAR Replace CEA And When Should It Not: A Balanced View Vikram S. Kashyap, MD
8:50 – 8:55	TCAR Seems Better Than TFCAS And Equal To CEA: It Has A Bright Future: What Are Its Drawbacks Wesley S. Moore, MD
8:56 - 9:04	Panel Discussion
9:04 - 9:17	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

# SESSION 75(LECTURE HALL 1 - Bonnet Creek Ballroom)MORE CAROTID HOT TOPICS RELATED TO TCAR, MINI-INCISION CEA,SIGNIFICANCE OF DW MRI DEFECTS AND COGNITIVE FUNCTION

Moderators:	Enrico Ascher, MD
	Peter A. Schneider, MD
	John H. Furtek, BS, RT(r)
9:17 – 9:22	TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why It Should Be The Procedure Of Choice In Those Conditions Peter A. Schneider, MD
9:23 – 9:28	<b>DEBATE:</b> TCAR Is Not Hard To Learn: Results Are Unrelated To Operator Experience In ROADSTER 2 Trial Vikram S. Kashyap, MD
9:29 – 9:34	<b>DEBATE:</b> Not So: TCAR Has A Steeper Learning Curve Than Commonly Thought: Some Precautions To Prevent Adverse Events Michael B. Silva, Jr., MD Charles Thang, MD
9:35 - 9:40	Learning And Optimizing The TCAR Procedure Edward Y. Woo, MD Steven D. Abramowitz, MD
9:41 – 9:46	Complications Of TCAR: How To Avoid Them And Fix Those That Occur Thomas S. Maldonado, MD
9:47 – 9:52	Adjunctive EEG Can Help With TCAR And Decrease The Stroke Rate: When And How Todd R. Vogel, MD, MPH
9:53 – 9:58	Mini-Incision CEA Is Better And Less Costly Than TCAR Enrico Ascher, MD

9:59 -10:04 TCAR Can Be Performed Under Local Anesthesia With Outcomes Equal To TCAR Under General Anesthesia: From A VQI Study: How To Do It Safely Dipankar Mukherjee, MD

#### SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER CEA/CAS

- 10:05-10:10 **DEBATE:** How Size And Number Of Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Affect Cognitive Changes: They Really Do Matter Wei Zhou, MD
- 10:11-10:16 **DEBATE:** Silent DWI MRI Brain Lesions (Small Infarcts) After CEA/CAS Don't Matter Thomas G. Brott, MD
- 10:17-10:22 Why Asymptomatic Carotid Stenosis (ACS) Is Associated With Impaired Cognitive Function And Silent Infarcts: However, CEA And CAS For ACS Cause More Cognitive Impairment Than They Prevent

J. David Spence, MD (Power Point Presentation With Synched Audio)

10:23-10:30Panel Discussion

#### SESSION 76 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, MESH COVERED STENTS, MINI-INCISION CEA, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS

Moderators:	Michael B. Silva, Jr., MD
	Enrico Ascher, MD
	Frank J. Veith, MD

10:30-10:35 Comparative Cost Effectiveness: TCAR Versus CEA Versus TFCAS Mohammad H. Eslami, MD, MPH

10:36-10:41	Value Of Lithotripsy (Shockwave) For CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions
	Max Amor, MD
	(Power Point Presentation With Synched Audio)
10:42-10:47	Results From A Multicenter Italian Study Of The C-Guard Micromesh Stent For CAS: Advantages And Complications Gianmarco de Donato, MD
	Carlo Setacci, MD
	Francesco Speziale, MD
	Wassim Mansour, MD
	Pasqualino Sirignano, MD
10:48-10:53	OCT Proves CAS Is Rendered Safer Because Emboli Are Decreased By Mesh Covered Stents: The Evidence Francesco Setacci, MD Carlo Setacci, MD
10:54-10:59	Transcranial Doppler (TCD) Hits During TCAR: When Do They Occur And What Is Their Significance Cynthia K. Shortell, MD
11:00-11:05	TCAR Versus Minimal Incision CEA: Cost Effectiveness, Advantages And Limitations Of Both Robert M. Proczka, MD, PhD
11:06-11:12	Panel Discussion
TIMING	OF CAROTID INTERVENTIONS AFTER SYMPTOM ONSET

11:12-11:17 Optimal Timing Of Carotid Revascularization (CEA, TFCAS, TCAR) After Symptom Onset: Within 48 Hours Risk Is Increased For All Procedures; After 48 Hours Risk Is Less With CEA And TCAR Than With TFCAS: Based On Large National Database Study

Mahmoud B. Malas, MD, MHS

11:18-11:23	<ul> <li>DEBATE: It's Reasonable To Perform CEA Within 48 Hours After</li> <li>A Stroke's Symptoms Start: Under What Conditions And What</li> <li>Precautions Should Be Taken</li> <li>R. Clement Darling III, MD</li> </ul>
11:24-11:29	<b>DEBATE:</b> Patients With Moderate To Severe Strokes Do Poorly With Both CEA And CAS Done Within 48 Hours Of Symptom Onset: Both Procedures Should Be Avoided During This Period: How Long Should One Wait Hernan A. Bazan, MD
11:30-11:35	What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Asymptomatic): Can High Risk Plaques Be Made Low Risk And Can They Be Made Smaller: Are Some Plaques Resistant To Medical Treatment And Why J. David Spence, MD (Power Point Presentation With Synched Audio)
11:36-11:41	Technical Tips And Maneuvers To Make Treatment Of High Carotid Lesions Safe And Relatively Simple Richard J. Powell, MD
11:42-11:47	Getting Non-Compliant Carotid Patients To Comply With Best Medical Treatment By Showing Them Their Duplex Scans And Pictures Of Hemorrhagic And Ulcerated Plaques J. David Spence, MD (Power Point Presentation With Synched Audio)
11:48-12:00	Panel Discussion
12:00- 1:00	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 77 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTs; NEW INFORMATION ON TREATMENT OF TANDEM LESIONS, CAROTID ANEURYSMS AND STROKES DURING INTERVENTION

Moderators:Samuel R. Money, MD, MBAChristopher J. Kwolek, MD, MBA

#### **UPDATE ON CAROTID RCTs**

1:00 - 1:05	Optimal Management Of Extracranial Carotid Aneurysms In 2021: When Open; When Endo: Technical Tips And Results Samuel R. Money, MD, MBA
1:06 – 1:11	Update On ACST 2: CEA Versus CAS For ACS: What Is It Telling Us And When Will We Have All The Answers Richard Bulbulia, MA, MD Alison Halliday, MS, FRCS
1:12 – 1:17	Initial Results Of ACST 2 Trial Alison Halliday, MS, FRCS (Power Point Presentation With Synched Audio) Richard Bulbulia, MA, MD
1:18 – 1:23	Not So Fast! ACST 2 Has Flaws That Invalidate Its Conclusions: What Are They J. David Spence, MD (Power Point Presentation With Synched Audio)
1:24 – 1:29	Update On SPACE 2: CEA Versus Best Medical Treatment (BMT); CAS Versus BMT For ACS: Updated And Interesting Findings From A Stopped RCT H. Henning Eckstein, MD, PhD (Power Point Presentation With Synched Audio)
1:30 – 1:35	Update On CREST 2: CEA Versus BMT And CAS Versus BMT For ACS: Findings To Date And When Will We Have Final Results Brajesh K. Lal, MD

Thomas G. Brott, MD

1:36 – 1:41 Why Is BMT With Clopidogrel Different In The Arms Of CREST and CREST 2 And Why This Difference Could Invalidate The RCTs Results

Timothy M. Sullivan, MD

#### TANDEM CAROTID LESIONS

1:42 – 1:47 Tandem Lesions At The Carotid Bifurcation Plus The Common Carotid Or Innominate Arteries: Stroke And Mortality Risks Are Higher Than For Simple Bifurcation Lesions: How Best To Treat: Endo, Open, Staged, Hybrid W. Darrin Clouse, MD, RPVI Mark Conrad, MD, MMSc

1:48 – 1:53 CEA And Retrograde Stenting Of A Tandem Proximal Lesion: Technical Tips To Make It Safe And Effective Christopher J. Smolock, MD

1:53 – 2:02 Panel Discussion

#### SESSION 78 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE HOT CAROTID TOPICS: TREATMENT IN 2021 OF BIG CAROTID BODY TUMORS, OPTIMAL PLATELET AND PROTAMINE STRATEGIES; BENIGNANCY OF ACS

Moderators:	Cynthia K. Shortell, MD
	Ali F. AbuRahma, MD

- 2:02 2:07 Technical Tips For Treating Large Shamblin III Carotid Body Tumors Safely; From An Ecuadorian Team Which Treats Many Oscar L. Ojeda, MD
- 2:08 2:13 Value Of Protamine Use During CEA: How Should It Be Used And With What Precautions David H. Stone, MD (Power Point Presentation With Synched Audio)

2:14 – 2:19	CEA Can Be Performed Safely And Optimally Under General Anesthesia And Without Completion Duplex Or Angio Control: What Is Required To Do So And Are There Downsides To Duplex
	Or Angio Controls
	Ali F. AbuRahma, MD
2:20 – 2:25	Are Symptomatic And Asymptomatic Carotid Stenosis Really 2 Different Diseases As Some Suggest Thomas G. Brott, MD
2:26 – 2:31	Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA W. Darrin Clouse, MD Mark Conrad, MD, MMSc
2:32 – 2:37	Unnecessary Redundant Testing/Imaging Prior To CEA: What Is The Reason For This Needless Addition To Health Care Costs Reese A. Wain, MD
2:38 – 2:43	<b>DEBATE:</b> CAS Is The Best Treatment For Young Patients With A High Grade Asymptomatic Carotid Stenosis (ACS) William A. Gray, MD Giancarlo Biamino, MD, PhD
2:44 – 2:49	<b>DEBATE:</b> Not So: Young Patients With A High Grade ACS Should Not Be Treated By CAS Or CEA Anne L. Abbott, MD, PhD (Power Point Presentation With Synched Audio)
2:50 - 3:12	Panel Discussion
3:12 - 3:22	Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 79	(LECTURE HALL 1 – BONNET CREEK BALLROOM)
	ATED CONCEPTS FOR ENDOVASCULAR TREATMENTS
Moderators:	Sean P. Lyden, MD
111040141013.	Jacob Cynamon, MD
	Jacob Cynanion, with

3:22 - 3:27	Clinical Judgment Is Required In The Application Of Evidence Based Medicine: RCTs Can Have Flaws Leading To Misleading Conclusions
	J. David Spence, MD
	(Power Point Presentation With Synched Audio)
3:28 - 3:33	How Should Left Subclavian Artery Stenosis Be Treated In Patients Before Coronary Artery Bypass: Stent Versus Carotid Subclavian Bypass Versus Ignore But Don't Use The Left Internal Mammary Artery Jennifer L. Perri, MD, MBA
3:34 - 3:39	Progress In Open And Endovascular Treatment For Erectile Dysfunction: Diagnosis And Treatment Of Cavernous Leak And Other Pathology: A New Horizon Eric Allaire, MD, PhD
3:40 - 3:45	Embolic Treatment Of Hemorrhoids: How To Do It And How Well Does It Work Gloria Salazar, MD
3:46 - 3:51	Using Machine Learning To Improve Stroke Prediction In Carotid Stenosis Mathew D. Wooster, MD Ravi K. Veeraswamy, MD
3:52 - 3:58	Transfemoral Transcaval Liver Biopsy: A Better Way To Do It Jacob Cynamon, MD
3:58 - 4:04	Panel Discussion

#### SESSION 80 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE, ENDOVASCULAR SUTURING AND WOUND CARE

Moderators:	Kenneth Ouriel, MD, MBA
	Mark A. Adelman, MD

4:04 – 4:09	Update On Large Bore Percutaneous Access Closure Devices: Key New Devices And Developments: How To Prevent Failure And Complications
	Zvonimir Krajcer, MD (Power Point Presentation With Synched Audio)
4:10 – 4:15	Endovascular Suturing Devices At The Tip Of An 8-9 French Catheter To Close Large Bore Sheath Access From Inside: The NovelRad Device: How Does It Work And Present Status Elchanan Bruckheimer, MBBS (Power Point Presentation With Synched Audio)
	PROGRESS IN WOUND CARE
4:16 – 4:21	Optimal Treatment For Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg Hosam F. El Sayed, MD
4:22 – 4:27	New Developments In The Treatment Of Mixed Arterial And Venous Wounds And Ulcers Katherine A. Gallagher, MD
4:28 - 4:33	Value Of A Wound Care Center To A Vascular Practice: Who Should Staff It And How To Make It Revenue Positive Venita Chandra, MD
4:34 - 4:39	Best Treatment Strategies For Complex Infected Groin Wounds After Vascular Surgery: When To Do What: Wide Debridement, Antibiotics, Muscle Flap Reconstruction Or Graft Removal Jan-Willem Elshof, MD (Power Point Presentation With Synched Audio)
4:40 - 4:50	Panel Discussion

# End of Program I

# **PROGRAM J**

(Sessions 81-88) 7:20 A.M. - 5:30 P.M.

New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Recorded Live Cases: Complex Endovascular Cases From The Mayo Clinic; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of

Vascular Trauma

LOCATION: LECTURE HALL 2 - FLORIDIAN BALLROOM

#### SESSION 81 (LECTURE HALL 2 - Floridian Ballroom) POPLITEAL DISEASE TOPICS RELATED TO NEW GUIDELINES, ANEURYSM TREATMENT (PRIMARY AND REDO), ENTRAPMENTS AND ATHERECTOMY FOR OCCLUSIVE LESIONS

Moderators:Enrico Ascher, MDKeith D. Calligaro, MD

#### POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS

7:20 – 7:25	High Points Of New SVS Guidelines For The Treatment Of Popliteal Aneurysms: Roles Of Endo And Open Repairs Patrick J. Geraghty, MD Alik Farber, MD, MBA
	Allk Paroel, MD, MDA
7:26 – 7:31	<b>DEBATE:</b> Endovascular Repair Is The Best Option For Most Popliteal Aneurysms Requiring Repair: Recent Progress In The Procedure: When Is Open Repair Indicated Irwin V. Mohan, MBBS, MD (Power Point Presentation With Synched Audio)
7:32 – 7:37	<b>DEBATE:</b> Open Repair With Prosthetic Bypass Graft Is Better Than Endovascular Treatment For Popliteal Aneurysms Requiring Repair Laurent Chiche, MD

7:38 – 7:43	Update On Optimal Treatment For Popliteal Aneurysms: When Observation; When Endo Repair; When Open Repair And How Fred A. Weaver, MD, MMM		
7:44 – 7:49	What Are Complex Popliteal Aneurysms And How Should They Be Fixed: When Endo; When Open Jacques Busquet, MD		
7:50 – 7:56	Panel Discussion		
	POPLITEAL ENTRAPMENTS		
7:56 – 8:01	What's New In The Treatment Of Popliteal Entrapments Niten Singh, MD		
	POPLITEAL ARTERY INJURY		
8:02 - 8:07	Surgical Approach And Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation Charles J. Fox, MD		
	POPLITEAL ARTERY ATHERECTOMY		
8:08 - 8:13	Value Of Orbital Atherectomy For Popliteal Artery Occlusive Lesions: Indications, Results, Precaution Konstantinos P. Donas, MD (Power Point Presentation With Synched Audio)		
8:14 - 8:20	Panel Discussion		
SESSION 82 NEW DEVELO INFECTIONS	(LECTURE HALL 2 - Floridian Ballroom) PMENTS IN TREATING ARTERIAL (INCLUDING AORTIC)		
Moderators:	Keith D. Calligaro, MD		
	Peter F. Lawrence, MD		

8:20 - 8:25	Update On Deep Vein Use For Arterial Procedures: The NAIS Operation For Infections: Recent Technical Improvements Patrick A. Stone, MD
	TREATMENT OF MYCOTIC ANEURYSMS
8:26 - 8:31	Optimal Treatment Of Mycotic AAAs In 2021: Value Of And Precautions With EVAR: Is It Ever A Stand-Alone Treatment Timur P. Sarac, MD
8:32 - 8:37	Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques Guillermo A. Escobar, MD
8:38 - 8:43	Why Open Repair Is The Best Treatment For Mycotic AAAs: Is EVAR Ever Of Value Yamume Tshomba, MD
8:44 - 8:49	Best Treatment For Mycotic Aortic Aneurysms In The Thorax And Abdomen Based On Long-Term Results Samy S. Nitecki, MD
TREATMEN	T OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS

- 8:50 8:55 Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment, Outcomes Mohammad H. Eslami, MD, MPH
- 8:56 9:01 Optimal Techniques For Treating Aorto-Iliac Graft And Endograft Infections In 2021 Anders Wanhainen, MD, PhD

9:02 – 9:07	Semi-Conservative Therapy May Be Best For Some Aortic Graft Infections: What Is It And When Will Saving All Or Part Of An Infected Graft Work Zoran Rancic, MD, PhD
	(Power Point Presentation With Synched Audio)
9:08 – 9:13	Open Repair Of Suprarenal Aortic Graft Infections: Technical Tips And Long-Term Results Thomas C. Bower, MD Manju Kalra, MBBS
9:14 - 9:24	Panel Discussion

9:24 – 9:52 Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 83 (LECTURE HALL 2 - Floridian Ballroom) PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS WITH LESS RADIATION EXPOSURE OR CONTRAST TOXICITY

Moderators:	Matthew J. Eagleton, MD
	Carlos A. Timaran, MD

#### VASCULAR HOLOGRAPHY

9:52 – 9:57	How Will The Microsoft Hololens Look Through Patients' Bodies And Facilitate Endovascular Interventions: The ARCUS System Of Augmented Reality And Its Value In Vascular Surgery Jan M.M. Heyligers, MD, PhD (Power Point Presentation With Synched Audio)
9:58 -10:03	Real View Holographic Imaging: How Will It Help In Endovascular Treatments: Is It Available In The US Elchanan Bruckheimer, MBBS (Power Point Presentation With Synched Audio)

10:04-10:09	Holographic Guidance Of Endovascular Procedures:	What Is
	Possible And What Is Not	
	Claude Mialhe, MD	
	(Power Point Presentation With Synched Audio)	

#### DUPLEX AND INTRAVASCULAR ULTRASOUND

10:10-10:15 Duplex Ultrasound Guidance: How, Where And When Can It Replace Fluoroscopy For Endovascular Procedures: Advantages, Limitations, And Why Its Use Is Increasing Enrico Ascher, MD Natalie A. Marks, MD, RPVI, RVT

#### **IMPROVED IMAGING**

10:16-10:21	Dual Fluoroscopy With Live Image Digital Zooming: How Does It
	Work And Why Does It Decrease Radiation During Complex AAA
	Repairs: What Is Its Cost
	Carlos H. Timaran, MD

10:22-10:27 Cydar Medical System's Evolution To Facilitate Fusion With All Digital Fluoroscopes: How The System Uses AI To Improve EVAR Planning, Guidance And Deployment Jan M.M. Heyligers, MD, PhD (Power Point Presentation With Synched Audio)

#### 10:28-10:33 The Cydar System Deformation Tool For Improving Image Fusion Accuracy: How Does It Work And Why Does It Help Cynthia K. Shortell, MD

10:34-10:39 The Cydar System's Value In Standard And Complex EVAR Venkatesh G. Ramaiah, MD

#### 10:40-10:50 Panel Discussion

#### SESSION 84 (LECTURE HALL 2 - Floridian Ballroom) CHALLENGING RECORDED LIVE CASES FROM THE MAYO CLINIC AND THE UNIVERSITY OF TEXAS, HOUSTON

Moderators:	Bernardo C. Mendes, MD
	Gustavo S. Oderich, MD
10:50-11:00	Case 1: 45 Female With Loeys-Dietz Syndrome And Multiple Aortic Repairs
	Guilherme B. Lima, MD
11:00-11:04	Panel Discussion
11:04-11:14	Case 2: 83-Year-Old Man With Ascending Aortic Pseudoaneurysm Bernardo C. Mendes, MD
11:14-11:18	Panel Discussion
11:18-11:28	Case 3: 79 Female With Large Visceral Patch Aneurysm Following Open TAAA Repair Naveed U. Saqib, MD
11:28-11:32	Panel Discussion
11:32-11:42	Case 4: 72-Year-Old Woman With Chronic Mesenteric Ischemia And Extent III TAAA Bernardo C. Mendes, MD
11:42-11:46	Panel Discussion
11:46-11:56	Case 5: 71 Male With Aortic Arch Graft Pseudoaneurysm Guilherme B. Lima, MD
11:56-12:00	Panel Discussion
12:00-1:15	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 85 (LECTURE HALL 2 - Floridian Ballroom) ONE PRESENTATION FROM MÜNSTER, GERMANY ON LOWER EXTREMITY STENTS

- *Moderators*: Mark A. Adelman, MD Giovanni B. Torsello, MD
- 1:15 1:21 One Year Results Of The EMINENT RCT Comparing The Eluvia DES Versus Bare Metal Stents Giovanni B. Torsello, MD
- 1:22 1:25 Discussion

#### SESSION 86 (LECTURE HALL 2 - Floridian Ballroom) NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)

- Moderators: Robert W. Thompson, MD Mark A. Adelman, MD
- 1:26 1:31New Developments In The Treatment Of Neurogenic TOSs: What<br/>Preop Factors Correlate With Good Outcomes; With Bad<br/>Outcomes

Karl A. Illig, MD

1:32 – 1:37 Supraclavicular Approach To Arterial And Neurogenic TOSs (Video Presentation) Ramesh K. Tripathi, MD (Power Point Presentation With Synched Audio)

#### **VENOUS TOSs**

- 1:38 1:43Venous TOSs: Lessons Learned After Treating >1000 Cases<br/>Robert W. Thompson, MD
- 1:44 1:49 Spectrum Of Treatment Options For Venous TOS: What Are The Outcomes And How Do They Differ Jason T. Lee, MD

- 1:50 1:55 Venography And Balloon Angioplasty For Neurogenic Thoracic Outlet Syndrome: A New Diagnostic And Therapeutic Approach Sam S. Ahn, MD, MBA
- 1:56 2:03 Technical Tips For Optimal Surgical Treatment For Venous TOS Robert W. Thompson, MD
- 2:04 2:14 Panel Discussion
- 2:14 2:30 Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

#### SESSION 87 (LECTURE HALL 2 - Floridian Ballroom) NEW DEVELOPMENTS IN MEDICAL AND DRUG TREATMENTS: BEST ANTIPLATELET REGIMENS; UPDATE ON RARE VASCULAR DISEASES

*Moderators*: Caron B. Rockman, MD James H. Black, III, MD

#### ANTIPLATELET REGIMENS

2:30 – 2:35	Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs David H. Stone, MD (Power Point Presentation With Synched Audio)
2:36 – 2:41	Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE Peter Henke, MD
2:42 – 2:47	Most Effective Antiplatelet After Lower Extremity Interventional Treatments For CLTI – POBA, DCBs, Stents, Etc. Maciej L. Dryjski, MD, PhD
2:48 – 2:53	Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem Karthik Kasirajan, MD

## **NEW DEVELOPMENTS IN LIPID MANAGEMENT – STATINS**

2:54 – 2:59	Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Shockingly These Treatments Are Underutilized – Especially In Women: Why Is This So Christian A. Behrendt, MD
3:00 - 3:05	Value Of Statins In AAA Patients After Repair: Long-Term Impact On Mortality Adam Beck, MD
3:06 - 3:11	The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help Caron B. Rockman, MD Jeffrey S. Berger, MD, MS
3:12 - 3:18	Panel Discussion
3:18 - 3:23	Elevated Neutrophil To Lymphocyte Ratio Predicts Poor Outcomes And Mortality After Elective EVAR And CEA: What Is The Mechanism Jae S. Cho, MD
3:24 - 3:29	The Justification For Carotid Screening Is To Promote Medical Treatment To Decrease Stroke And MI Risks, Not To Push Patients To Have Unnecessary Invasive Procedures Kosmas I. Paraskevas, MD
3:30 - 3:35	Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: Doing These Things Should Be A Lifetime Goal Richard Bulbulia, MA, MD

3:36 – 3:41 How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well James H. Black, III, MD

3:42 – 3:48 Panel Discussion

#### SESSION 88 (LECTURE HALL 2 - Floridian Ballroom) ADVANCES IN THE ENDO AND OPEN TREATMENT OF VASCULAR TRAUMA Moderators: Timur P. Sarac, MD

Moaerators:	Timur P. Sarac, MD
	Todd E. Rasmussen, MD
3:48 – 3:53	Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions Gilbert R. Upchurch, MD
3:54 – 3:59	Value Of REBOA For Pending And Actual Cardiac Arrest: What Is Partial And Intermittent REBOA And How Is It Helpful Tal M. Hörer, MD, PhD
4:00 – 4:05	Transexamic Acid – An Antifibrinolytic Drug: Does It Reduce Mortality With Mild To Moderate Traumatic Brain Injuries: Based On A RCT Todd E. Rasmussen, MD
4:06 – 4:11	Why One Should Have A Stock On Hand Of Balloon-Expandable And Self-Expandable Covered Stents To Deal With Emergencies From Iatrogenic And Other Traumatic Vascular Injuries: What Should Be In The Stock Maria Antonella Ruffino, MD
4:12 – 4:17	Radial Access Techniques And Technology For Embolotherapy To Treat Vascular Trauma: Indications And Results Jonathan J. Morrison, MD, FRCS
	JUIIAIIIAII J. WUITISUII, WID, FRUS

4:18 - 4:23	For Major Venous Injuries: Repair Versus Ligation – Which Is Currently Best When Samy S. Nitecki, MD
4:24 – 4:29	Update On Best Current Management Of Pediatric Vascular Injuries: When Conservative; When Open; When Endo And Precautions Michael C. Dalsing, MD
4:30 - 4:38	Panel Discussion
	<b>BLUNT THORACIC AORTIC INJURY (BTAI)</b>
4:38 - 4:43	Endovascular Repairs Of Traumatic Aortic Injuries – Civilian And Military: Technology, Technical Tips And Results James W. Dennis, MD
4:44 - 4:49	When Can Minor BTAI Be Treated By Observation Without TEVAR: What Precautions Are Necessary Elina Quiroga, MD, MPH
4:50 – 4:55	<b>DEBATE:</b> Are We Overtreating BTAI – Especially Lesser Injuries Joseph J. DuBose, MD
5:56 – 5:01	<b>DEBATE:</b> Why Many Patients With Lesser Degrees Of BTAI Require TEVAR Ali Azizzadeh, MD
5:02 – 5:07	Why Rapid And Complete Aortic Healing After TEVAR For BTAI Should Influence The Length And Diameter Of The Endograft Used: Oversizing And Length Of Seal Zone Can Be Minimized: Technical Tips Shang Loh, MD
5:08 - 5:13	How To Manage Heparin In TEVAR For BTAI When Head Or
	Other Injuries Are Also Present: Some, None Or Just Sheath Flushing
	Charles J. Fox, MD

- 5:14 5:19 With BTAI Requiring TEVAR, When Can The Left Subclavian Artery Be Covered And When Not: Tips On Endograft Sizing Elina Quiroga, MD, MPH
- 5:20 5:30 Panel Discussion

# **End of Program J**

#### **PROGRAM K**

(Sessions 89-97) 7:20 A.M. – 4:45 P.M. *Deep Venous Disease* Course Leaders: Jose I. Almeida, MD, Lowell S. Kabnick, MD, Thomas W. Wakefield, MD, and Steve Elias, MD **Location**: LECTURE HALL 3 - WALDORF ASTORIA GRAND BALLROOM A

#### SESSION 89 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) PELVIC VENOUS DISORDERS, FEMORO-ILIOCAVAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION

Moderators:	Jose I. Almeida, MD, RPVI, RVT Lowell S. Kabnick, MD Thomas W. Wakefield, MD Steve Elias, MD
7:30 – 7:35	Venographic Techniques To Identify Pelvic Anatomy And Escape Points Mark H. Meissner, MD
7:36 – 7:41	Iliocaval Duplex Ultrasound With Image Optimization Jan M. Sloves, RVT
7:42 – 7:47	We Need Dedicated Venous Stents For Nutcracker Syndrome And We Need Them Now Peter Gloviczki, MD
7:48 – 7:53	Open Surgery For Nutcracker: Techniques And Results Cynthia K. Shortell, MD
7:54 – 7:59	Ovarian Vein Embolization: Which Patient Benefits And Reimbursement Kathleen D. Gibson, MD
8:00 - 8:05	Panel Discussion

# SESSION 90 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) CHRONIC VENOUS OBSTRUCTION

Moderators:	Jose I. Almeida, MD, RPVI, RVT Patrick E. Muck, MD
8:06 – 8:11	CAVA Trial Lessons Learned About Post Thrombotic Syndrome Cees H. A. Wittens, MD, PhD
8:12 – 8:17	Utilizing The Radiofrequency Power Wire To Vaporize A Channel Through Chronic Iliocaval Venous Obstructions (CICVO) Patrick E. Muck, MD
8:18 - 8:23	Recanalizing Occluded Venous Stents Jose I. Almeida, MD, RPVI, RVT
8:24 - 8:29	Contralateral Limb Improvement After Unilateral Iliac Vein Stenting: Argument Against Simultaneous Bilateral Stenting Seshadri Raju, MD
8:30 - 8:35	Panel Discussion
SESSION 91 FEMORO-ILIO VENOUS HYPI	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) CAVAL INTERVENTIONAL STRATEGIES TO REDUCE ERTENSION
Moderators:	Ellen D. Dillavou, MD
	Rabih A. Chaer, MD
8:36 – 8:41	Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux Natalie A. Marks, MD, RPVI, RVT
8:42 - 8:47	Best Anticoagulation After Deep Venous Stenting Ellen D. Dillavou, MD
8:48 - 8:53	Reinterventions Following Vein Stent Placements – Lessons Learned From 166 Cases

Windsor Ting, MD

8:54 – 8:59 Outcomes And Predictors Of Failure Of Iliac Vein Stenting Rabih A. Chaer, MD

#### 9:00 – 9:05 Panel Discussion

## SESSION 92 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) HYBRID TECHNIQUES, STENT PROBLEMS, POST-IMPLANTATION

- *Moderators*: Erin H. Murphy, MD Cees H.A. Wittens, MD, PhD
- 9:06 9:11 Techniques For Endovenectomy And Concomitant Ilio Stenting With And Without Adjuvant Arteriovenous Fistula Creation Steven D. Abramowitz, MD
- 9:12 9:17 Endovascular Remote Endovenectomy For Chronic Venous Disease Using The Inari CloTriever Steven D. Abramowitz, MD
- 9:18 9:23 Technical Properties Of Nitinol Erin H. Murphy, MD
- 9:24 9:29 Biopsy Of Venous In-Stent Stenosis: Histopathology And Treatment David M. Williams, MD
- 9:30 9:35 Utilizing Indigo System To Extract Thrombus Prior To ISR Ballooning And Stenting: Our Institution's Experience Frank R. Arko, MD
- 9:36 9:41 CAVA Trial: Long-Term Follow Up Cees H. A. Wittens, MD, PhD
- 9:42 9:47 Panel Discussion
- 9:48-10:28 Break Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## SESSION 93 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) STRATEGIES FOR CORRECTING SEVERE DEEP VENOUS REFLUX AND/ OR OBSTRUCTION, WOUNDS, MEDICINES, AND NEW HORIZONS FOR VENOUS DISEASE MANAGEMENT

Moderators:	Peter F. Lawrence, MD
	William A. Marston, MD
10:29-10:34	Management Options Of Infrainguinal Disease: Indications And
	Options
	Steve Elias, MD
10:35-10:40	A Look At ABRE Stent Occlusions From The IDE Trial: Key
	Takeaways
	Erin H. Murphy, MD
10:41-10:46	The Economic Impact Of Infections In Venous Leg Ulcer Patients
	Thomas F. O'Donnell, Jr., MD
10:47-10:52	What Is The Standard Of Care For Venous Wounds
	William A. Marston, MD
10:53-10:58	Treatment Of Superficial And Perforator Reflux And Deep Venous
	Stenosis Improves Healing Of Chronic Venous Leg Ulcers
	Peter F. Lawrence, MD
10:59-11:04	Panel Discussion
SESSION 94	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) NT TRIALS AND CONCEPTS
Moderators:	Lowell S. Kabnick, MD
111040141013.	Seshadri Raju, MD
11:05-11:10	Aspect Ratio Of Iliac Stenosis: Does It Matter
	Seshadri Raju, MD
11:11-11:16	What Is Aspect Ratio And What Does The Clinical Data Reveal
	Lowell S. Kabnick, MD

11:17-11:22	Virtus Trial - 3-Year Update William A. Marston, MD
11:23-11:28	What Can The Arnsberg Registry Tell Us Michael K. W. Lichtenberg, MD
11:29-11:34	ABRE 24-Month Study Data Erin H. Murphy, MD
11:35-11:40	Zilver Vena Stent Trial Anthony J. Comerota, MD
11:41-11:46	Vernacular 36-Month Study Data Michael K.W. Lichtenberg, MD
11:47-11:52	Deep Venous Imaging Strategies To Minimize Stenting Complications Steve Elias, MD
11:52-1200	Panel Discussion
12:00-12:45	Lunch Break – Visit Exhibits And Pavilions (North, West, Center and South Foyers)
SESSION 95 MORE ILIOFE	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) MORAL FLOW AND PELVIC ISSUES
Moderators:	Paul J. Gagne, MD Peter J. Pappas, MD
12:46-12:51	Deep Venous Reconstruction: Is It Safe And Profitable In An OB Paul J. Gagne, MD
12:52-12:57	Which Is More Important: Pelvic Venous Insufficiency Or Iliac Vein Obstruction Peter J. Pappas, MD

- 12:58- 1:03 Male Pelvic Congestion And Varicose Veins: How Much Of A Problem Mark S. Whiteley, MS
- 1:04 1:09 A Novel Technique And Outcomes For Iliocaval Extravascular Reconstruction (TIER) For Iliocaval Agenesis Steven D. Abramowitz, MD
- 1:10 1:15 Panel Discussion

## SESSION 96 (LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A) STRATEGIES FOR THROMBOEMBOLIC EVENTS IN THE VENOUS SYSTEM

*Moderators*: Michael K.W. Lichtenberg, MD Brian G. DeRubertis, MD

#### **VTE INTERVENTIONAL**

1:16 – 1:21	Thrombolysis For Acute DVT: Utilization And Guidance From Current Clinical Trials Brian G. DeRubertis, MD
1:22 – 1:27	Venous Aneurysms: Should They Be Treated Peter F. Lawrence, MD
1:28 – 1:33	DVT Removal Without Thrombolytics – Mechanical Thrombectomy Is Now The Standard Of Care For Both Upper And Lower Extremity DVT Patrick E. Muck, MD
1:34 – 1:39	P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With Aspirex Michael K.W. Lichtenberg, MD
1:40 - 1:45	Panel Discussion

1:46 – 2:21 Break - Visit Exhibits And Pavilions (North, West, Center and South Foyers)

## **CENTRAL VENOUS THROMBOSIS; COVID-19; VTE MEDICAL**

Moderators:	Steve Elias, MD Mikel Sadek, MD
2:22 – 2:27	COVID-19 Treatment Of Venous Thrombosis In Hospitalized Patients Mikel Sadek, MD
2:28 – 2:33	COVID-19 Outpatient Experience With Anticoagulation Steve Elias, MD
2:34 - 2:39	Closed Plication Is A Safe And Effective Method For Treating Popliteal Venous Aneurysm Thomas W. Wakefield, MD
2:40 - 2:45	Mesenteric Vein Thrombosis: What Is The Best Strategy Mark G. Davies, MD
2:46 – 2:51	DOAC Revolution – Which Drug For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD
2:52 – 2:57	Update In Experimental DVT Pathogenesis And Resolution Peter Henke, MD
2:58 - 3:03	Inflammation And Venous Thrombosis: An Evidence Summary Thomas W. Wakefield, MD
3:04 - 3:09	Pediatric DVT: An Evidence Summary Dawn M. Coleman, MD
3:10 – 3:15	Using The Femoral Vein As A Tunneling Conduit For An Arterial Bypass: Venous Outcomes In PQ Bypass Mark A. Adelman, MD

3:16 – 3:21	Duration Of Anticoagulation Rachel Rosovsky, MD, MPH
3:22 – 3:27	Should All Patients With Acute VTE Be Treated With A Statin: When And Dose
3:28 - 3:33	Anthony J. Comerota, MD Update On Reversal Agents For The DOACs Timothy K. Liem, MD
3:34 - 3:39	Role Of Thrombophilia Testing Rachel Rosovsky, MD, MPH
3:40 - 3:45	Panel Discussion
SESSION 97	(LECTURE HALL 3 - Waldorf Astoria Grand Ballroom A)

## DEEP VEIN VALVE TECHNOLOGIES, CAVAL INTERRUPTION

Moderators:	Mikel Sadek, MD
	Jorge H. Ulloa, MD

#### **DEEP VALVE PROGRESS**

3:46 - 3:51	US Experience Of The BlueLeaf®Endovenous Valve Formation: Update William A. Marston, MD
3:52 – 3:57	Safety And Efficacy Report On The Venovalve (First In Man) IDE Feasibility Study Jorge H. Ulloa, MD
3:58 – 4:03	The Need For A Deep Venous Valve For Severe CVI Patients With DVT Mikel Sadek, MD
4:04 - 4:09	Implantable Bicuspid Valve: Early Preclinical Results Paul J. Gagne, MD

## **CAVAL INTERRUPTION**

Moderators:	Timothy K. Liem, MD, MBA
	Jose I. Almeida, MD, RPVI, RVT
4:16 – 4:21	Thrombosed IVC Filter: How To Recanalize The Cava And Manage The Filter Thomas J. Almeida, MD, RPVI, RVT
4:22 - 4:227	IVC Management In Pregnant Patients Joann Lohr, MD
4:28 - 4:33	Surgical Removal Of IVC Filters: Perforation Or Infiltration Timothy K. Liem, MD, MBA
4:34 - 4:39	Why Temporary Filters Are Not Removed: Clinical Predictors In 1,000 Consecutive Cases Heron E. Rodriguez, MD
4:40 - 4:45	Panel Discussion

# End of Program K

# SATURDAY, NOVEMBER 20, 2021

6:15 A.M. General Registration – Bonnet Creek Ballroom – North Foyer
6:00 A.M. Faculty Registration – Bonnet Creek Ballroom – Salon I
6:30 A.M. Continental Breakfast – Bonnet Creek Ballroom – North Foyer

## **PROGRAM L**

(Sessions 98-102) 7:00 A.M. – 1:05 P.M. Topics Too Important To Miss In The Treatment Of Lower Extremity, Aortic Or Carotid Disease, COVID-19 Updates Location: LECTURE HALL 1 - Bonnet Creek Ballroom

## SESSION 98 (LECTURE HALL 1 - Bonnet Creek Ballroom) LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 <sup>3</sup>/<sub>4</sub>-MINUTE TALKS)

Moderators:	Keith D. Calligaro, MD
	Frank J. Veith, MD
	Michael H. Wholey, MD, MBA
7:00 - 7:05	Optimal Vessel Prep Is Key To Successful BTK And Tibial
	Angioplasty (PTA): How To Do It
	Peter A. Schneider, MD
7:05 – 7:10	Why Endovascular Treatments Should Be The First Choice For
	Common Femoral Artery (CFA) Occlusive Lesions
	Niten Singh, MD
7:10 – 7:15	What Is The Real Complication Rate With Retrograde Tibial And
	Pedal Access: How To Minimize These Complications
	Michael H. Wholey, MD, MBA
7:15 – 7:20	<b>DEBATE:</b> An Endo First Approach Is Best For Treating CLTI In
	All Patients: Is There Any Role For Open Bypasses
	Christopher J. Abularrage, MD

7:20 – 7:25	DEBATE: Not So: Open Bypass Should Be The First Treatment For Some CLTI Patients: When Is This So And In What Percentage Of CLTI Patients Karan Garg, MD
7:25 – 7:30	Panel Discussion
7:30 – 7:35	Value Of Atherectomy And Other Technologies In Heavily Calcified Infrapopliteal Lesions For CLTI: Which Lesions To Treat And What Do We Know About Their Impact Venita Chandra, MD
7:35 – 7:40	Are Isolated Pedal Interventions For CLTI Worthwhile Mark G. Davies, MD
7:40 – 7:45	<b>DEBATE:</b> Multivessel Tibial Revascularization Does Not Improve Limb Salvage In CLTI Patients: From A VQI Study Venita Chandra, MD
7:45 – 7:50	DEBATE: Not So: In Some Circumstances Multivessel Tibial Revascularization Does Improve Outcomes In CLTI Patients: Which Circumstances Brian G. DeRubertis, MD (Power Point Presentation With Synched Audio)
7:50 – 7:55	Technical Tips For Open Tibial And Pedal Artery Exposures In Virginal And Redo Situations William P. Robinson, MD
7:55 – 8:00	When Are Oral Antibiotics Without Excision Of Infected Bone Adequate Treatment For Osteomyelitis In The Foot Wayne J. Caputo, DPM
8:10 - 8:10	Panel Discussion

## SESSION 99 (LECTURE HALL 1 - Bonnet Creek Ballroom) MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)

Moderators:	Ali F. AbuRahma, MD Enrico Ascher, MD
8:10 – 8:15	Dangers And Pitfalls Of Retrograde Lower Extremity Access Distal To The Common Femoral Artery Venita Chandra, MD
8:16 – 8:21	Impact Of A Dedicated Limb Preservation/Limb Salvage Service On Amputation Rates: Must It Include An Open Bypass Surgery Component Niten Singh, MD
8:22 – 8:27	Importance Of Functional And Ambulatory Status In Decision Making In CLTI Patients: Why Limbs Should Be Saved In Patients Who Are Not Ambulatory Vincent I. Rowe, MD
8:28 - 8:33	Open Versus Endo Revascularizations In Dialysis Patients With CLTI: What Is The Role Of Each Rabih A. Chaer, MD
8:34 - 8:39	What Is The Best Vessel Prep For Endo Treatments Of Heavily Calcified Lesions: Technical Tips And Precautions Theodosios Bisdas, MD
8:40 - 8:45	Real World Outcomes With Zilver PTX DESs For Complex Fempop Disease: Why Do They Differ From Trial Results Ali F. AbuRahma, MD
8:46 - 8:54	Panel Discussion
8:55 – 9:00	Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access Natalie A. Marks, MD, RPVI, RVT

9:01 – 9:06	Effect Of Short-Term Complications Of Lower Extremity Revascularizations On Long-Term Outcomes And Patient Survival Joseph L. Mills, MD (Power Point Presentation With Synched Audio)
9:07 – 9:12	Endovascular Diagnosis And Control Of Hemorrhage After Fempop Open Operations: It Is A Better Way And How To Do It Francesco Setacci, MD Carlo Setacci, MD (Power Point Presentation With Synched Audio)
9:13 – 9:18	Longer Procedure Times Are Predictive Of Worse Outcomes With Endovascular Treatments Of Lower Extremity Occlusive Lesions Alan M. Dietzek, MD, RPVI
9:19 – 9:24	Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Value And Limitations Ignacio Escotto, MD (Power Point Presentation With Synched Audio)
9:25 – 9:30	Panel Discussion
9:30 - 9:35	Break – Visit Exhibits And Pavilions (North, and West Foyers)
SESSION 100 (LECTURE HALL 1 - Bonnet Creek Ballroom) NEW DEVELOPMENTS IN COVID-19 TREATMENTS AND THE EFFECTS OF COVID-19 ON THE VASCULAR SYSTEM (5-MINUTE TALKS)	
Moderators:	Mark A. Adelman, MD Ronald L. Dalman, MD
9:35 – 9:40	Patients With AAAs Who Had COVID-19 May Need More Frequent Surveillance Ronald L. Dalman, MD
9:41 – 9:46	What Will Be The Post-Pandemic Steady State Of Novel Infection And Acquired Immunity: Is "Herd Immunity" A Realistic Concept Clayton J. Brinster, MD

9:47 – 9:52	Impact Of COVID-19 On The Extra- And Intracranial Circulation: How Effective Are Endovascular Treatments Allan L. Brook, MD	
9:53 – 9:58	Current Treatment Paradigms For Symptomatic COVID-19 \ Infection: What Works, What Doesn't, What's Available And What's In The Pipeline Clayton J. Brinster, MD	
9:59 -10:04	Endovascular Management Of COVID-19 Induced Acute Limb Ischemia: When Is It Effective And When Not Karthik Kasirajan, MD	
10:05-10:10	Do Current Vaccines Or Previous Infection Protect Against New Variants Of COVID-19: Will Vaccine Boosters Be Required – For Whom And How Often Clayton J. Brinster, MD	
10:11-10:20	Panel Discussion	
SESSION 101 AORTIC TOPIC Moderators:	<b>(LECTURE HALL 1 - Bonnet Creek Ballroom)</b> CS TOO IMPORTANT TO MISS (5-MINUTE TALKS) James F. McKinsey, MD Kenneth Ouriel, MD, MBA	
10:20-10:25	Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And F/EVAR David J. Minion, MD	
10:26-10:31	Top 10 Clinical Trials That Are Needed In AAA Disease Ronald L. Dalman, MD	
SPINE EXPOSURE SURGERY		
10:32-10:39	Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (7-Minute Presentation) Jeffrey Jim, MD, MPHS	

10:40-10:47	Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (7-Minute Presentation) William P. Robinson, MD
10:48-10:53	EVAR Outside The IFUs Of Commercial Devices Is Sometimes Justified And Does Not Negatively Impact On Midterm Outcomes: When Is This So George A. Antoniou, MD, PhD, MSc
10:54-11:00	Panel Discussion
11:00-11:05	How To Avoid Axillary Artery Complications After Large Sheath Use In Complex AAA Repairs Michael C. Stoner, MD
11:06-11:11	Late Complications Of F/B/EVAR In An Experience Of >1000 Cases Eric L.G. Verhoeven, MD, PhD Athanasios Katsargyris, MD
11:12-11:17	With F/EVAR Intraoperative Endoleaks Do Not Predict Midterm Failure Michael J. Singh, MD
11:18-11:23	Left Subclavian Revascularization With TEVAR: Technical Tips And Tools To Make In Situ Fenestration Easy Wayne W. Zhang, MD
11:24-11:29	Variable Curve Directional Sheaths Will Eliminate The Need For Upper Extremity Access With F/B/EVAR: Which Sheath Is Best And Pitfalls James F. McKinsey, MD
11:30-11:35	How Can Computer Modeling Help To Improve The Treatment Of TBADs Ross Milner, MD

11:36-11:42 Panel Discussion

## SESSION 102 (LECTURE HALL 1 - Bonnet Creek Ballroom) AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS 5-MINUTE TALKS)

Moderators: Sean P. Lyden, MD Enrico Ascher, MD Frank J. Veith, MD

## **AORTIC TOPICS**

Edward Steven I	). Abramowitz, MD
Bypass For Re Why And Ho	xillary Bypass Is Better Than Carotid-Subclavian evascularizing Subclavian Arteries With TEVAR: w To Do It Criado, MD
Carotid-Subc	ft Subclavian Chimney Graft Better Than A avian Bypass For Preserving Subclavian Artery Flow ent Darling III, MD
Associated W	nity Access For Complex Endo AAA Repairs Is ith A High Rate Of Stroke: From A VQI Study Schermerhorn, MD
Endovascular	e Vast Majority Of Failed EVARs Can Be Treated ly rre Becquemin, MD
Open Conver	ot So: Many Failed EVARs Are Best Repaired By sion Makaroun, MD

12:18-12:23	AAAs With Large Diameter Necks (>34 mm) Do Poorly With EVAR: How Should Such Patients Be Treated Matt M. Thompson, MD	
12:24-12:29	Value Of 3D Flow Models To Analyze The Cause Of Failure After F/EVAR And TEVAR Maciej L. Dryjski, MD, PhD	
12:30-12:35	Panel Discussion	
CAROTID TOPICS		
12:35-12:40	How To Use The Silk Road TCAR Device In The Treatment Of Tandem Carotid Lesions: Technical Tips And Results Michael C. Stoner, MD	
12:41-12:46	Radiation And Carotid Stenosis: What Is The Relationship And How Is Radiation Stenosis Best Treated When Asymptomatic And When Symptomatic Cynthia K. Shortell, MD	
12:47-12:52	Mini-Incision CEA With Standard Or Eversion Techniques: How To Do It Safely: It's Better Than Transfemoral CAS Or TCAR Alan M. Dietzek, MD	
12:53-12:58	TCAR With Flow Reversal Versus Transcervical CAS With Distal Protection: TCAR's Benefit Is Not Just Due To Its Avoidance Of Having To Traverse The Aortic Arch Mahmoud B. Malas, MD, MHS (Power Point Presentation With Synched Audio)	
12:59- 1:05	Panel Discussion Lunch Available	

## **End of Program L**

VEITHsymposium continues in the Floridian Ballroom with Sessions on Hemodialysis Access.

#### **PROGRAM M:**

(Sessions 103-106) 8:00 A.M. – 3:25 P.M. Improving Outcomes In Hemodialysis Access Course Leaders: Larry A. Scher, MD; Anton N. Sidawy, MD, Haimanot (Monnie) Wasse, MD, MPH Location: LECTURE HALL 2 - Floridian Creek Ballroom

8:00 – 8:05 Introduction Anton N. Sidawy, MD, MPH Larry A. Scher, MD

#### SESSION 103 (LECTURE HALL 2 – Floridian Ballroom) IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

- Moderators: Larry A. Scher, MD Anton N. Sidawy, MD, MPH
- 8:06 8:13 What Vascular Access Issues Are Important To Patients Dori R. Schatell, MS
- 8:14 8:21 Where Should Patients And Physicians Get Information About Hemodialysis Access Ellen D. Dillavou, MD
- 8:22 8:29 Amplifi<sup>™</sup> Vein Dilation System: First In Human Study Surendra Shenoy, MD
- 8:30 8:37 Update On The Use Of Fist Assist To Maximize Creation And Maturation Of Autogenous AV Fistula Tej M. Singh, MD, MBA
- 8:38 8:45 Surgical Management Of The Mega Fistula John R. Ross, Sr., MD
- 8:46 8:53 Cardiovascular Implantable Electronic Devices In Hemodialysis Patients: Prevalence And Strategies For Management Theodore F. Saad, MD

8:54 - 9:04	Panel Discussion
9:05 – 9:12	Body Image, Sexuality And Hemodialysis Access Dori R. Schatell, MS
9:13 – 9:20	Options For Management Of Deep AV Fistulas William Jennings, MD
9:21 – 9:28	Managing The Pulsatile AV Access: How To Prolong Access Life Surendra Shenoy, MD, PhD
9:29 – 9:36	Use Of Drug Eluting Balloons And Stents: What Does The Data Tell Us Theodore F. Saad, MD
9:37 – 9:44	LIMA Steal Syndrome After Ipsilateral AV Fistula: Is It Real Jeffrey E. Indes, MD (Power Point Presentation With Synched Audio)
9:45 – 9:52	Early Banding For High Flow AV Fistulas Moro Salifu, MD
9:53 -10:03	Panel Discussion
10:04-10:25	Break – Visit Exhibits And Pavilions (North, West and Center Foyers)
SESSION 104 MORE IMPOR TALKS)	(LECTURE HALL 2 – Floridian Ballroom) TANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE
Moderators:	Haimanot (Monnie) Wasse, MD, MPH Evan C. Lipsitz, MD, MBA
10:26-10:33	Performance Of Vascular Access Procedures During A Global Pandemic
	Haimanot (Monnie) Wasse, MD, MPH

10:34-10:41	Surgeon's Perspective On Management Of Acute Kidney Injury During The COVID-19 Pandemic Clifford M. Sales, MD, MBA	
10:42-10:49	How Has COVID-19 Impacted Medicare Reimbursement Evan C. Lipsitz, MD, MBA	
10:50-10:57	Does A High Bifurcation Brachial Artery Affect Outcomes For AV Fistulas And Grafts John S. Futchko, MD	
10:58-11:05	Accelerating Technology Development During A Pandemic To Bring More People With Kidney Failure Home Prabir Roy-Chaudhury, MD, PhD (Power Point Presentation With Synched Audio)	
11:06-11:16	Panel Discussion	
Moderators:	John E. Aruny, MD Clifford M. Sales, MD, MBA	
THE USE OF ULTRASOUND IN CONTEMPORARY DIALYSIS ACCESS PRACTICE		
11:17-11:24	Preoperative Vessel Mapping: Did KDOQI Really Make This Optional Surendra Shenoy, MD, PhD	
11:25-11:32	Economic And Clinical Impact Of Changes In Reimbursement For Predialysis Duplex Planning Jason K. Wagner, MD	
11:33-11:40	Incorporating Point Of Care Ultrasound Into The Practice Of Nephrology Vandana Niyyar, MD	
11:41-11:48	Use Of IVUS For Evaluation And Sizing Of Central Vein Stenosis John E. Aruny, MD	

11:49-12:00 Panel Discussion

12:00- 1:00 Lunch Break – Visit Exhibits And Pavilions (North, West and Center Foyers)

### SESSION 105 (LECTURE HALL 2 - Floridian Ballroom) POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS (7-10-MINUTE TALKS)

- Moderators: Larry A. Scher, MD Anton N. Sidawy, MD
- 1:00 1:07 Creating AV Fistulas For Children In Guatemala William Jennings, MD
- 1:08 1:15 How Will Government Initiatives Move Patients From Dialysis Centers To Home Dialysis Sean D. Kalloo, MD
- 1:16 1:23 Implementing The Results Of A Randomized Trial Comparing Early Cannulation Grafts To Catheters Into Practice David Kingsmore, MD
- 1:24 1:31 How Artificial Kidneys And Miniaturized Dialysis Could Save Millions Of Lives Buddy D. Ratner, PhD
- 1:32 1:46 Panel Discussion

## SESSION 106 (LECTURE HALL 2 – Floridian Ballroom) NEW TECHNOLOGIES AND OTHER IMPORTANT CLINICAL ISSUES IN AV ACCESS (7-MINUTE TALKS

- Moderators:Haimanot (Monnie) Wasse, MD, MPHEllen D. Dillavou, MD
- 1:47 1:54 Use Of External Support Devices To Improve AV Fistula Maturation Ellen D. Dillavou, MD

1:55 – 2:02	Use Of Pharmacologic Adjuncts To Improve AV Fistula Maturation Alan Dardik, MD, Ph
2:03 – 2:10	<b>DEBATE:</b> Will EndoAV Fistulas Ever Become The Gold Standard: EndoAV Fistula Is Better Than Surgery Neghae Mawla, MD
2:11 – 2:18	<b>DEBATE:</b> Will EndoAV Fistulas Ever Become The Gold Standard: Surgery Is Still The Gold Standard John R. Ross, Sr., MD
2:19 – 2:26	Cannulation Issues With Endovascular Fistulas Deborah Brouwer-Maier, RN, CNN
2:27 – 2:34	A Non-Biologic Vascular Prosthesis That Heals And Integrates: Application For Dialysis Blood Access And Small Diameter Sites Buddy D. Ratner, PhD
2:35 - 2:42	What Is The Best Option For Cephalic Arch Stenosis Mark G. Davies, MD
2:43 - 2:50	Management Of The Abandoned HeRO Device Stephen E. Hohmann, MD
2:51 – 2:58	HeRO Graft With ARtegraft Attachment For Hemodialysis Access: What Are The Outcomes Jesse Garcia, MD
2:59 – 3:06	WRHAPSODY™ Endovascular Stent Graft (Merit Medical) For Treatment Of Hemodialysis Access Outflow Stenosis James A. Gilbert, MD
3:07 - 3:25	Panel Discussion

# End of Program M